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Summary 
Chronic kidney disease (CKD) is associated with increased cardiovascular risk in 
comparison with the general population. This can be observed even in the early stages of 
CKD, and rises in proportion to the degree of renal impairment. Not only is cardiovascular 
disease (CVD) more prevalent in CKD, but its nature differs too, with an excess of morbidity 
and mortality associated with congestive cardiac failure, arrhythmia and sudden death, as 
well as the accelerated atherosclerosis which is also observed. Conventional cardiovascular 
risk factors such as hypertension, dyslipidaemia, obesity, glycaemia and smoking, are highly 
prevalent amongst patients with CKD, although in many of these examples the interaction 
between risk factor and disease differs from that which exists in normal renal function. 
Nevertheless, the extent of CVD cannot be fully explained by these conventional risk factors, 
and non-conventional factors specific to CKD are now recognised to contribute to the burden 
of CVD.  
Oxidative stress is a state characterised by excessive production of reactive oxygen species 
(ROS) and other radical species, a reduction in the capacity of antioxidant systems, and 
disturbance in normal redox homeostasis with depletion of protective vascular signalling 
molecules such as nitric oxide (NO). This results in oxidative damage to macromolecules 
such as lipids, proteins and DNA which can alter their functionality. Moreover, many 
enzymes are sensitive to redox regulation such that oxidative modification to cysteine thiol 
groups results in activation of signalling cascades which result in adverse cardiovascular 
effects such as vascular and endothelial dysfunction.  
Endothelial dysfunction and oxidative stress are present in association with many 
conventional cardiovascular risk factors, and can be observed even prior to the development 
of overt, clinical, vascular pathology, suggesting that these phenomena represent the earliest 
stages of CVD. 
In the presence of CKD, there is increased ROS production due to upregulated NADPH 
oxidase (NOX), increase in a circulating asymmetric dimethylarginine (ADMA), uncoupling 
of endothelial nitric oxide synthase (eNOS) as well as other mechanisms. There is also 
depletion in exogenous antioxidants such as ascorbic acid and tocopherol, and a reduction 
in activity of endogenous antioxidant systems regulated by the master gene regulator Nrf-2. 
In previous studies, circulating markers of oxidative stress have been shown to be increased 
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in CKD, together with a reduction in endothelial function in a stepwise fashion relating to 
the severity of renal impairment.  
Not only is CVD linked to oxidative stress, but the progression of CKD itself is also in part 
dependent on redox sensitive mechanisms. For example, administration of the ROS 
scavenger tempol attenuates renal injury and reduces renal fibrosis seen on biopsy in a mouse 
model of CKD, whilst conversely, supplementation with the NOS inhibitor L-NAME causes 
proteinuria and renal impairment. Previous human studies examining the effect of 
antioxidant administration on vascular and renal function have been conflicting however. 
The work contained in this thesis therefore examines the effect of antioxidant administration 
on vascular and endothelial function in CKD.  
Firstly, 30 patients with CKD stages 3 – 5, and 20 matched hypertensive controls were 
recruited. Participants with CKD had lower ascorbic acid, higher TAP and ADMA, together 
with higher augmentation index and pulse wave velocity. There was no difference in baseline 
flow mediated dilatation (FMD) between groups. Intravenous ascorbic acid increased TAP 
and O2
-, and reduced central BP and augmentation index in both groups, and lowered ADMA 
in the CKD group only. No effect on FMD was observed  
The effects of ascorbic acid on kidney function was then investigated, however this was 
hindered by the inherent drawbacks of existing methods of non-invasively measuring kidney 
function. Arterial spin labelling MRI is an emerging imaging technique which allows 
measurement of renal perfusion without administration of an exogenous contrast agent. The 
technique relies upon application of an inversion pulse to blood within the vasculature 
proximal to the kidneys, which magnetically labels protons allowing measurement upon 
transit to the kidney. At the outset of this project local experience using ASL MRI was 
limited and there ensued a prolonged pre-clinical phase of testing with the aim of optimising 
imaging strategy. A study was then designed to investigate the repeatability of ASL MRI in 
a group of 12 healthy volunteers with normal renal function. The measured T1 longitudinal 
relaxation times and ASL MRI perfusion values were in keeping with those found in the 
literature; T1 time was 1376 ms in the cortex and 1491 ms in the whole kidney ROI, whilst 
perfusion was 321 mL/min/100g in the cortex, and 228 mL/min/100g in the whole kidney 
ROI. There was good reproducibility demonstrated on Bland Altman analysis, with a CVws 
was 9.2% for cortical perfusion and 7.1% for whole kidney perfusion.  
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Subsequently, in a study of 17 patients with CKD and 24 healthy volunteers, the effects of 
ascorbic acid on renal perfusion was investigated. Although no change in renal perfusion 
was found following ascorbic acid, it was found that ASL MRI demonstrated significant 
differences between those with normal renal function and participants with CKD stages 3 – 
5, with increased cortical and whole kidney T1, and reduced cortical and whole kidney 
perfusion. Interestingly, absolute perfusion showed a weak but significant correlation with 
progression of kidney disease over the preceding year. 
Ascorbic acid was therefore shown to have a significant effect on vascular biology both in 
CKD and in those with normal renal function, and to reduce ADMA only in patients with 
CKD. ASL MRI has shown promise as a non-invasive investigation of renal function and as 
a biomarker to identify individuals at high risk of progressive renal impairment. 
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1.1 Cardiovascular disease and chronic kidney disease 
1.1.1 Epidemiology of cardiovascular disease 
There is extensive evidence that patients with chronic kidney disease (CKD) are at a 
significantly elevated risk of cardiovascular disease (CVD). Data from the United Kingdom 
(UK) renal registry show that cardiovascular disease is the cause of death in 22% of patients 
requiring renal replacement therapy (RRT) (Pruthi R, 2013), and moreover, this risk is not 
limited to patients with end stage renal disease (ESRD) requiring haemodialysis (HD), but 
applies even in the earliest stages of renal impairment, with the risk of cardiovascular 
complications rising in proportion to the degree of renal impairment (Culleton et al., 1999). 
In fact, for the vast majority of patients with CKD, CVD proves a greater burden than 
progression of their renal disease: most patients with CKD will die of a cardiovascular cause 
before requiring renal replacement therapy. 
United States (US) registry data show an increased incidence of many manifestations of 
CVD in patients with CKD (US Renal Data System, 2011a). For example, the prevalence of 
atherosclerotic coronary artery disease was 42.9% in older CKD patients compared to 17.4% 
in the general population, and the prevalence of myocardial infarction was 10.3% compared 
to 2.3% (figure 1.1). 
1.1.2 Chronic kidney disease and cardiovascular risk 
There are a number of possible explanations for the increase in cardiovascular risk associated 
with CKD. Firstly, there are risk factors for CVD which are also common aetiological factors 
in CKD. Diabetes and hypertension (HTN) are the commonest causes of CKD in the 
developed world (US Renal Data System, 2011b) and also predispose to atherosclerotic 
coronary artery disease. CKD is also associated with advanced age and co-morbidity such 
that even when these cardiovascular risk factors are not implicated in the aetiology of CKD, 
such factors are highly prevalent. For example diabetes has a prevalence of 9.4%, and 
smoking of 14% in patients with CKD (Rao A, 2013). Patients with CKD have been 
notoriously undertreated in the past, with low prescribing rates of cardioprotective 
medications, and underutilisation of revascularisation (Herzog et al., 2007). Lastly, there 
may be specific aspects of CKD which endow cardiovascular risk due to circulating factors 
comprising the ‘uraemic milieu’.  
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Figure 1.1 The prevalence and nature of cardiovascular disease in CKD. 
Many manifestations of cardiovascular disease are increased in prevalence in CKD (A), in comparison 
with the general population. This risk is established early in CKD and rises in proportion to the degree 
of renal impairment (B). ASHD = Atherosclerotic heart disease, CHF = Congestive heart failure, VHD 
= Valvular heart disease, CVA = Cerebrovascular accident, TIA – transient ischaemic attack, PAD = 
Peripheral arterial disease, AFIB = Atrial fibrillation, SCA/VA = Sudden cardiac arrest/Ventricular 
arrhythmias. Adapted from US Renal Data System 2011a, and Go et al 2004.  
There is evidence to support the hypothesis that uraemia itself is an independent 
cardiovascular risk factor. Go et al, showed an increase in cardiovascular events, 
hospitalisation, and mortality occurring in proportion to severity of renal impairment, even 
after adjustment for diabetes, hypertension, dyslipidaemia, sociodemographic characteristics 
and the presence or absence of prior CVD (Go et al., 2004). The adjusted hazard ratio for 
CVD was 2.0 in patients with an estimated glomerular filtration rate (eGFR) between 15 and 
30 mL/min/1.73m2 and 3.4 with an eGFR below 15 mL/min/1.73m2. Similarly, Manjunath 
et al found a linear relationship between eGFR and incidence of atherosclerotic 
cardiovascular events after adjustment for other cardiovascular risk factors, with a 7% 
increase in events for every 10ml/min fall in eGFR (Manjunath et al., 2003).   
Patients with ESRD are subject to specific cardiovascular risks associated with the modality 
of renal replacement they receive. Those receiving HD are subject to acute cardiovascular 
complications such as cardiac stunning (McIntyre et al., 2008) and arrhythmia (Santoro et 
al., 2008), as well as longer term effects relating to chronic inflammation secondary to 
dialysis membrane bioincompatibility (Cheung, 1990), and vascular and infectious 
complications of vascular access, all of which increase cardiovascular mortality. Patients 
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receiving peritoneal dialysis (PD) may be at higher cardiovascular risk due to inflammation 
associated with repeated episodes of peritonitis, or due to retention of fluid and uraemic 
toxins associated with the lower clearance of PD. Whether either of HD or PD is associated 
with higher cardiovascular risk continues to be debated. For example whilst certain studies 
have found the highest arterial stiffness in PD patients (Covic et al., 2004), this has not been 
replicated in other studies (Chang et al., 2010). In a study of data derived from the Australia 
and New Zealand Dialysis and Transplant Registry, incident PD patients had lower mortality 
in the first 90 days of therapy, but higher mortality after 12 months (McDonald et al., 2009). 
Only PD patients who were younger than 60 years of age and without comorbidities enjoyed 
lower mortality up to the first 12 months of treatment, which reflects the findings of a 
retrospective cohort study of American patients commencing dialysis in 2003, in which PD 
patients had improved survival among subgroups aged below 65 years, without a history of 
CVD or diabetes (Weinhandl et al., 2010). In fact, HD was associated with lower mortality 
in patients with existing CVD upon starting dialysis. These conflicting results demonstrate 
that individual factors such as age, comorbidity and dialysis vintage, are at least as 
significant as dialysis modality in predicting cardiovascular risk.  
Patients with kidney transplants have improved outcomes compared to HD and PD patients, 
although are a self-selecting group who are sufficiently fit for surgery. Nevertheless the 
immunosuppressive regimes required to avoid rejection can induce diabetes, dyslipidaemia, 
and hypertension (Gillis et al., 2014b).  
1.1.3 The nature of cardiovascular disease in CKD 
CVD in normal renal function is typically manifest as atherosclerotic coronary artery 
disease, with infarction, ischaemic cardiomyopathy, and arrhythmia typically following as 
secondary phenomenon. As has been discussed, coronary artery disease is highly prevalent 
in CKD, but is characterised by medial calcification rather than the lipid laden 
atherosclerotic plaques seen in typical coronary artery disease. Furthermore, heart failure 
and arrhythmia are equal in importance to coronary artery disease as causes of cardiovascular 
morbidity CKD. Data from the US registry showed that the prevalence of congestive cardiac 
failure was 28.8% in CKD compared to 6.4% in the general population, whilst the prevalence 
of atrial fibrillation was 24.4% compared to 9.6%, and cardiac arrest and ventricular 
arrhythmia 4.5% compared to 1.3% (United States Renal Data System, 2011c). 
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Cardiovascular mortality has also been shown to be only partly related to the degree of 
atherosclerosis in CKD. In a recent study of 1541 patients referred for a computed 
tomography (CT) coronary angiogram, patients with renal impairment had a higher 
cardiovascular event rate, and higher rates of both occlusive and non-occlusive coronary 
disease (Bittencourt et al., 2015). Two thirds of cardiovascular events in CKD however, were 
secondary to a non-coronary cause, such as sudden death, arrhythmic death, or death from 
heart failure.  This was reflected in a retrospective longitudinal study of patients with CKD 
3 – 5, which found a negative correlation between eGFR and risk of cardiac death, but no 
association between degree of coronary artery disease and risk of cardiac death (Muntner et 
al., 2002).  Altogether, this demonstrates that patients with CKD are at risk not only of 
accelerated coronary artery disease, but also a broad range of other cardiovascular morbidity.   
1.2 Conventional cardiovascular risk factors 
The conventional cardiovascular risk factors applicable to the general population such as 
dyslipidaemia, hypertension, obesity, diabetes and smoking, are equally relevant to 
individuals with CKD. In many cases however, the interaction between risk factor and 
disease differs in CKD in comparison with the general population, reflecting the differences 
in cardiovascular pathology in this group. This discrepancy may explain the differences in 
response to conventional preventative strategies, as is discussed below.  
1.2.1 Dyslipidaemia 
In individuals with normal renal function, there is a well-accepted relationship between total 
cholesterol and low density lipoprotein (LDL) cholesterol and cardiovascular risk 
(Lewington et al., 2007).   Statin therapy effectively lowers LDL cholesterol and there is 
evidence that this is efficacious in the primary prevention of CVD. In a recent Cochrane 
review including 18 randomised controlled trials and over 56,000 patients, statin therapy 
was associated with a risk ratio of 0.75 for combined fatal and non-fatal coronary artery 
events and a risk of 0.62 for revascularisation events (Taylor et al., 2013). A meta-analysis 
confirmed the benefits of statin therapy even in individuals with low cardiovascular risk, 
with a relative risk of 0.90 for those with a less than 20% 10 year risk of CVD and 0.83 for 
those with less than 10% 10 year risk of CVD (Tonelli et al., 2011). 
One might expect the benefits of lipid lowering treatment to extend to patients with CKD, 
especially given the higher event rate and cardiovascular risk associated with renal 
impairment, however there are demonstrable differences in the epidemiology and 
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pathophysiology of dyslipidaemia in CKD that have historically resulted in controversy 
regarding the role of lipid lowering therapy. Additionally, as previously discussed, much of 
the cardiovascular burden in CKD relates to non-atherosclerotic disease which might 
diminish the benefits of statin treatment.  
In contrast to the general population, low total cholesterol levels are associated with 
increased all cause and cardiovascular mortality in haemodialysis patients, a phenomenon 
termed “reverse epidemiology” (Iseki et al., 2002) and this U-shaped relationship has also 
been observed in patients with CKD not requiring dialysis (Kovesdy et al., 2007). It is 
possible that low cholesterol in this context is a marker of inflammation and malnutrition, 
which is often associated with CKD and confers poor outcome. Supporting this hypothesis, 
in a study of 986 patients with CKD not on dialysis, the increase in mortality associated with 
low cholesterol was abrogated when adjusted for markers of inflammation and malnutrition 
(Kovesdy et al., 2007). In another study of 1167 dialysis patients, those with the lowest total 
serum cholesterol had the highest mortality, whilst those with the highest cholesterol had 
highest cardiovascular event rate. Only in those with a normal serum albumin was total 
cholesterol a significant predictor of mortality (Iseki et al., 2002). Together, these findings 
suggest that low cholesterol is an epiphenomenon of malnutrition and the mortality risk 
associated with this exceeds that associated with hypercholesterolaemia. 
Given these differences, it is not surprising to find that the profile of dyslipidaemia is quite 
different in CKD compared to the general population albeit varying according to individual 
factors such as modality of renal replacement therapy, use of immunosuppressive therapy, 
the presence of proteinuria and the nephrotic syndrome, and the severity of renal impairment.  
LDL cholesterol is often normal or low, and there is a greater abundance of modified LDL 
types which are often highly atherogenic. Oxidised LDL (ox-LDL), for example, is elevated 
tenfold in CKD in comparison to normal controls, in part due to reduced potency of HDL 
associated antioxidant enzymes (Samouilidou et al., 2012). Lipoprotein(a) (Lp(a)) is another 
modified form of LDL which is avidly taken up by atherosclerotic plaques and as such is a 
strong predictor of CVD (Enas et al., 2006). Lp(a) levels are largely genetically determined 
by the size of the inherited apo(a) isoform (Lackner et al., 1991), but presence of renal 
impairment (Kronenberg et al., 2000), degree of proteinuria, hypertrigylceridaemia and 
inflammation also increase Lp(a) (Uhlig et al., 2005). With reduced glomerular filtration, 
there is delayed catabolism of triglyceride rich lipoproteins due to reduced expression of 
vascular lipoprotein lipase (LPL) together with accumulation of the LPL inhibitors 
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apolipoprotein CIII (apo CIII) and apo CI. Ex vivo catabolism of very low density lipoprotein 
(VLDL) and chylomicrons (CM) derived from CKD patients is also reduced, suggesting that 
inherent changes to lipoproteins themselves also contributes to triglyceride accumulation. 
High density lipoprotein (HDL) is a negative predictor of CVD, exerting a protective effect 
by removal of cholesterol from lipid laden macrophages, by activating endothelial nitric 
oxide synthase (eNOS), and by exerting an antioxidant effect on oxidised LDL (Assmann 
and Gotto, 2004). Both the quantity and functionality of HDL is reduced in CKD and this is 
associated with adverse outcome (Baragetti et al., 2013).  
Early interventional studies failed to show any benefit of statins in CKD. For example in the 
Deutsche Diabetes Dialyse Studie (4D) of atorvastatin in dialysis patients, despite a lowering 
of LDL cholesterol by 42% there was no reduction in the primary endpoint (a composite of 
death from cardiac causes, nonfatal myocardial infarction, and stroke), although there was a 
reduction in the rate of all combined cardiac events (Wanner et al., 2005). Since then 
however, the largest study of lipid lowering in renal impairment was conducted in the Study 
of Heart and Renal Protection (SHARP) study, of 9270 non dialysis CKD patients. After a 
median follow up period of 4.9 years, those randomised to the intervention of simvastatin 
and ezetimibe enjoyed a 17% reduction in major atherosclerotic events (Baigent et al., 2011). 
These findings were consolidated in a recent meta-analysis involving 38 studies and 37,274 
patients, which showed a 20% reduction in cardiovascular events in CKD patients not 
requiring dialysis (Palmer et al., 2014).      
Despite the many differences in lipid pathophysiology in patients with CKD, there is now 
good evidence for the efficacy of lipid lowering therapy in CKD and this is reflected by the 
Kidney Disease Improving Global Outcomes (KDIGO) guidelines for lipid management. 
Statin therapy is recommended in individuals with CKD older than 50 years of age with 
eGFR < 60 mL/min/1.73m2 or with significant proteinuria, and in individuals aged 18 – 49 
years where there is an additional vascular risk factor including prior coronary artery disease 
or ischaemic stroke, diabetes mellitus, or estimated 10 year risk of CVD of > 10% (Kidney 
Disease Improving Global Outcomes, 2013). 
1.2.2 Hypertension 
In the general population, controlling HTN reduces cardiovascular and cerebrovascular 
event rate (Amery et al., 1985) and most studies have shown a linear relationship between 
blood pressure and cardiovascular risk (National Institute for Health and Care Excellence, 
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2011), with a 25% reduction in CVD following a 10 mmHg reduction in systolic blood 
pressure.  
HTN is common in patients with CKD, occurring as an aetiological factor, a consequence 
of kidney disease, or both. The prevalence of HTN in CKD is around 80% but varies 
according to body mass index (BMI), ethnicity, and age, as it does in the general population 
(Buckalew et al., 1996). Factors affecting the prevalence of HTN in CKD include degree of 
renal impairment, with an inverse relationship seen between GFR and blood pressure, and 
cause of CKD, with prevalence varying between 93% in renovascular disease, and 54% in 
glomerulonephritis (Ridao et al., 2001). Traditionally, hypertension was thought to be due 
to reduced renal sodium clearance (Tedla et al., 2011); now other mechanisms are thought 
to play an additional role including activation of the renin-angiotensin-aldosterone system, 
the sympathetic nervous system, and the endothelin system (Dhaun et al., 2006).  
There is a wealth of evidence to show the efficacy of treating HTN in CKD, both for reducing 
cardiovascular risk and progression of renal impairment. After 16 years of follow up in the 
Multiple Risk Factor Intervention Trial (MRFIT) of 332,544 men there was increased 
progression to ESRD in individuals with higher blood pressure, with an the incidence of 
ESRD of 5.43 per 100,000 person years in those with systolic blood pressure under 117 
mmHg, compared to 32.37 per 100,000 person years when systolic blood pressure was over 
140 mmHg (Klag et al., 1997). Sub group analysis of the Modification of Diet in Renal 
Disease (MDRD) Study showed slower decline and reduced proteinuria in those with 
effectively treated HTN (Peterson et al., 1995). In addition to this, a recent meta-analysis 
found that lowering blood pressure reduced CV risk to a similar extent in those with and 
without CKD (Ninomiya et al., 2013), with a reduction in major cardiovascular events of 
17% for every 5 mmHg reduction in blood pressure. Whilst inhibitors of the renin 
angiotensin system have been shown to be the most efficacious anti-hypertensive to reduce 
proteinuria and halt decline in renal function, no particular anti-hypertensive has been shown 
to be more effective at reducing cardiovascular risk. 
KDIGO guidelines recommend lowering blood pressure to below 140/90 mmHg in patients 
with CKD, and below 130/80 in patients with albuminuria more than 30 mg in 24 hours 
(Kidney Disease Improving Global Outcomes, 2013). There is evidence however, that 
excessive blood pressure lowering may be harmful, such that the target under which blood 
pressure should be lowered is a point of ongoing debate. Some studies have shown higher 
mortality associated with blood pressure below 130/70 mmHg (Kovesdy et al., 2013), 
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however low blood pressure in this context may represent hypotension associated with 
severe cardiac disease rather than overzealous blood pressure lowering on the part of 
clinicians. Other studies have shown adverse renal outcomes with blood pressure higher or 
lower than the range 130-139/60-79 mmHg (Sim et al., 2014), with the suggestion that very 
low blood pressure may compromise renal perfusion and hasten the progression of CKD. 
Further research into the ideal target for CKD populations is needed, and development of 
biomarkers of renal ‘stress’ or ‘injury’ may help clinicians to define optimal blood pressure 
targets and allow an individualised approach management in this groups of patients.  
1.2.3 Obesity and indolence 
The existence of a specific obesity related glomerulopathy has been known since 
Weisinger’s description in 1974, characterised histologically by focal and segmental 
glomerulosclerosis (FSGS), and clinically by heavy proteinuria and progressive renal 
impairment (Weisinger et al., 1974). There are important renal sequelae of obesity aside 
from this specific pathology however, due to the numerous haemodynamic and 
immunomodulatory effects of adiposity. As such, obesity has been shown to independently 
increase the risk of new onset kidney disease (Fox et al., 2004), as well as increase the risk 
of progression of CKD to ESRD up to 7 fold (Hsu et al., 2006). Obesity is therefore an 
important reversible cardiovascular risk factor as well as a contributing factor to the 
establishment and progression of CKD. 
Renal haemodynamics are altered in obesity with increased glomerular filtration and 
glomerular hypertension, leading to reduced nephron density and foot process effacement 
(Chen et al., 2006). Mediators of these haemodynamic effects include a potentiated renin 
angiotensin system, enhanced aldosterone secretion, plasminogen activator inhibitor – 1 
(PAI-1), and adiponectin (Camici et al., 2012). Adipose tissue contains an abundance of 
immune cells such as macrophages, lymphocytes and eosinophils and these cells are 
increased in number and activity in obesity (Xu et al., 2003). Release of inflammatory 
mediators such as tumour necrosis factor alpha (TNFα) and interleukin (IL) – 6 contributes 
to glomerulopathy and oxidative stress, and ultimately to the insulin resistance, HTN, and 
left ventricular hypertrophy are associated with obesity and collectively termed the 
metabolic syndrome. Obesity is also associated with development of secondary 
hyperparathyroidism in patients with CKD which itself predisposes to CVD (Kovesdy et al., 
2007).  
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There remains however, an ‘obesity paradox’, in that although increased BMI predisposes 
to CVD and worsening of CKD, there is evidence of a U-shaped relationship (Flegal et al., 
2013) between BMI and mortality in a range of conditions, including CKD, congestive 
cardiac failure (Kalantar-Zadeh et al., 2004) and acute illness (Landi et al., 2000). Data from 
the Atherosclerosis Risk in Communities Study (ARIC) showed that obesity is associated 
with metabolic syndrome both in patients with and without CKD, but an association between 
obesity and mortality existed only in the non CKD group (Flegal et al., 2013). This 
phenomenon has been described as “competing risks” with the adverse effects of obesity 
competing with the protective effects of adequate nutrition and muscle mass, and the relative 
importance of each differing according to clinical circumstances. This is effect is especially 
marked in patients with ESRD (Abbott et al., 2004), where the benefits of having adequate 
nutritional reserve when facing the catabolic challenge of haemodialysis outweigh the 
negative effects of adiposity, such that low body weight patients have worse outcome  
This leaves clinicians in a quandary when managing CKD and cardiovascular risk in patients 
with renal impairment; do the benefits of weight loss in terms of blood pressure, insulin 
sensitivity, and dyslipidaemia, outweigh the potential harms of aggravating protein calorie 
malnutrition in obese patients with CKD? A recent meta-analysis of weight loss regimes 
comprising a mixture of calorie restriction, exercise, and bariatric surgery showed effective 
reduction in proteinuria(Afshinnia et al., 2010). Similarly, a systematic review found 
improvements in BMI, systolic blood pressure and proteinuria associated with both surgical 
and non-surgical weight loss interventions (Palmer et al., 2014). For patients with CKD, no 
significant change in GFR was noted over a 7.4 month follow up however no control group 
was available for comparison, to determine if this represents a ‘positive’ result. Another 
recent study showed sustained weight loss achieved with a multi-disciplinary approach 
comprising diet, exercise, and orlistat (MacLaughlin et al., 2010). There was less 
deterioration in renal function in the weight loss treatment group, but the study was not 
powered to detect this. KDIGO guidelines simply advise maintaining healthy weight and 
undergoing regular physical activity without making a specific recommendation for 
individuals who are already obese. Further research is required into the effect of weight loss 
and physical activity of cardiovascular and mortality outcomes in patients with CKD.   
1.2.4 Glycaemia 
Diabetes mellitus (DM) is common in the CKD population and is an important and treatable 
cardiovascular risk factor in this group. Data derived from the UK registry of patients 
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commencing RRT show that diabetes is an aetiological factor in 25.4% of patients, and 
present as a co morbid disease in 9.4% (Rao A, 2013). In the general population diabetes 
and is associated with a 55% increase in the risk of myocardial infarction (The Health and 
Social Care InformationThe Health and Social Care Information Centre, 2012). The presence 
of kidney disease, defined as either reduced GFR or the presence of albuminuria, has a 
synergistic effect with diabetes, such that patients with both conditions experience a grossly 
elevated cardiovascular risk. In the Heart Outcomes Prevention Evaluation (HOPE) study, 
participants with diabetes and kidney disease had a relative risk of 1.97 for cardiovascular 
events in comparison to those with diabetes but normal kidneys (Gerstein et al., 2001). 
Similarly a systematic review of 11 cohort studies showed an odds ratio of 2.0 for CVD in 
those with microalbuminuria and type 2 diabetes, in comparison to those with type 2 diabetes 
without microalbuminuria (Dinneen and Gerstein, 1997).  
Current Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines suggest treating 
diabetes aiming for a target haemoglobin A1c (HbA1c) less than 7% in order to prevent or 
delay microvascular complications such as diabetic nephropathy (KDOQI, 2012). Early 
evidence for the efficacy of such intensive glycaemic control was derived from the Diabetes 
Control and Complications Trial (DCCT) (DCCT Research Group, 1993) and the United 
Kingdom Prospective Diabetes Study (UKPDS) (UKPDS Group, 1998). More recently, the 
Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release 
Controlled Evaluation (ADVANCE) trial showed a 21% reduction in prevention or 
progression of albuminuria with intensive glycaemic control (Patel et al., 2008).  
Nevertheless, caution must be exercised when aiming for such low glycaemic targets in 
CKD, given that renal impairment limits excretion of endogenous insulin and prescribed 
exogenous insulin and oral hypoglycaemic agents, resulting in an increased risk of 
hypoglycaemic events. Indeed, KDOQI guidelines suggest aiming for a higher HbA1c target 
in patients at risk of hypoglycaemia or in patients with co morbidities. ACCORD and 
ADVANCE both showed an increase in hypoglycaemic events when aiming for HbA1c 
below 7%, and mortality was higher in the intensively treated cohort of the ACCORD study. 
Furthermore, subgroup analysis of the ACCORD study showed that intensive glucose 
lowering resulted in 41% higher cardiovascular mortality in patients with CKD 
(Papademetriou et al., 2014). This is in keeping with an earlier retrospective study which 
showed the familiar U-shaped association between HbA1c and mortality as has been 
observed with other previously described biological parameters (Shurraw et al., 2011). 
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Therefore, whilst there is a desire for intensive glycaemic control in CKD both to prevent 
ESRD as well as ameliorate the cardiovascular risk associated with worsening uraemia, this 
must be tempered by the risk of hypoglycaemia. An individualised approach to diabetic 
management in CKD is to be advised.  
1.2.5 Smoking 
In the general population, smoking is an important reversible cardiovascular risk factor and 
is also implicated in the aetiology of a number of malignancies. In CKD, cigarette smoking 
has been shown to hasten progression of renal impairment in CKD (Hallan and Orth, 2011), 
and is also an independent risk factor for CVD (Jungers et al., 1997).  
1.3 Non-conventional cardiovascular risk factors 
As has been discussed, conventional cardiovascular risk factors are highly prevalent in CKD, 
even if the interaction between risk factor and outcome differs from the general population. 
In addition to this, a number of non-conventional risk factors have been identified which are 
specific to CKD.  
1.3.1 CKD mineral and bone disorder  
Regulation of bone biochemistry occurs via an interplay of a number of circulating factors 
and their target receptors in the gut, kidney, bone and parathyroid gland. In CKD these are 
invariably deranged, with the range of abnormalities observed collectively termed CKD 
mineral and bone disorder. Urinary excretion of phosphate is compromised by falling 
glomerular filtration rate and in response there is inducement of fibroblast growth factor – 
23 (FGF-23) secretion by osteocytes (Larsson et al., 2003). Circulating FGF-23 encourages 
phosphate excretion in the urine, via activation of a specific FGF receptor and its essential 
co receptor Klotho (Urakawa et al., 2006). Gut absorption of phosphate is also reduced, with 
the effect that serum phosphate is maintained within a normal range (Razzaque and Lanske, 
2007). Renal disease also impairs the secondary hydroxylation of vitamin D into its active 
form such that without treatment, there is effective vitamin D deficiency resulting in 
secondary hyperparathyroidism and ultimately leading to tertiary hyperparathyroidism, 
characterised by autonomous production of parathyroid hormone (PTH). Vitamin D 
deficiency is also exacerbated by FGF-23, which inhibits expression of 25-hydroxyvitamin 
D 1α-hydroxylase.  
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In a retrospective study of 6730 patients with CKD, there was a 35% increase in risk of 
myocardial infarction, and 23% increase in risk of death for every 1 mg/dL (0.323 mmol/L) 
increment of serum phosphate (Kestenbaum et al., 2005). Furthermore, even in normal renal 
function, higher serum phosphate is associated with increased cardiovascular risk (Dhingra 
et al., 2007), and with poor outcome in congestive cardiac failure (Ess et al., 2013). Higher 
levels of FGF-23 are also associated with increased all-cause mortality and cardiovascular 
risk, independently of renal function and serum phosphate. First demonstrated in incident 
dialysis patients, where those with the highest quartile of FGF-23 had a 20% increase in risk 
of death (Gutierrez et al., 2008), this was then observed in patients with CKD. Seiler et al 
found that CKD patients with higher FGF-23 were more than twice as likely to suffer a 
composite outcome of a vascular event or death (Seiler et al., 2010). As with serum 
phosphate there is now evidence linking FGF-23 with poor outcome even in normal renal 
function, with higher FGF-23 associated with greater left ventricular mass, higher coronary 
artery calcium score, and higher incident heart failure and coronary artery events 
(Kestenbaum et al., 2014). 
Disturbance in phosphate homeostasis is associated with a number of mechanisms which are 
responsible for this cardiovascular risk, including vascular calcification (Scialla et al., 2013), 
left ventricular hypertrophy (Yamamoto et al., 2013) (Patel et al., 2009), accelerated 
atherosclerosis (Foley et al., 2009) and endothelial dysfunction (Yilmaz et al., 2010).  
There has understandably been great interest in the modification of phosphate handling in 
CKD as a means to lower cardiovascular risk, typically by restricting dietary intake or by 
pharmacological reduction of its gastrointestinal absorption. In a randomised controlled 
prospective study, phosphate restriction led to a 33.5% reduction in FGF-23, and a 12% 
reduction in serum phosphate (Di Iorio et al., 2012). Similarly, phosphate binders have been 
shown to reduce serum phosphate and FGF-23 (Covic et al., 2013), especially in 
combination with dietary restriction (Isakova et al., 2013). There is however, little evidence 
of a beneficial effect of either approach on surrogate cardiovascular outcome measures 
(Seifert et al., 2013), with one study in fact showing an increase in vascular calcification 
following treatment with a range of phosphate binders, in comparison to placebo (Block et 
al., 2012).A randomised, double blinded, placebo controlled trial investigating the effect of 
phosphate lowering on cardiovascular end points is yet to be carried out.  
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1.3.2 Anaemia 
Anaemia is common in patients with CKD due to reduced red cell lifespan and production. 
Kidney fibroblasts normally respond to a falling haemoglobin by increasing erythropoietin 
production, which causes increased erythrocyte production in the bone marrow. In CKD this 
mechanism is impaired and a compensatory increase in erythropoietin secretion does not 
occur. Given the association of CKD with inflammation, either due to uraemia, the nature of 
the underlying kidney disease, or due to co-morbid conditions, anaemia can also arise due 
to the erythropoietin unresponsiveness and abnormal iron handling which occurs in anaemia 
of chronic disease (Babitt and Lin, 2012). 
Prior to the advent of recombinant erythropoietin, patients with ESRD often suffered severe 
anaemia, which was associated with a range of adverse clinical outcomes including left 
ventricular hypertrophy, blood transfusion dependency, and fatigue. One study found that 
for every 10 g/L reduction in haemoglobin, there was a 5% increase in risk of mortality, and 
8% increase in risk of (Locatelli et al., 2004). In the same study, even in patients with CKD 
not requiring dialysis who have a tendency to suffer less severe anaemia, there was a similar 
association between anaemia and morbidity and mortality. Similarly, in a prospective cohort 
study of Canadian patients with mild to moderate CKD, the likelihood of worsening left 
ventricular hypertrophy increased by 32% for every 5 g/L reduction in haemoglobin (Levin 
et al., 2006). A retrospective study of 5885 patients with CKD found that those with a 
haemoglobin less than 105 g/L were at significantly greater risk of cardiovascular events, 
death and progression to end stage renal disease (Thorp et al., 2009).  
Renal anaemia can now be effectively treated with the use of recombinant erythropoietin 
stimulating agents (ESA) and intravenous iron preparations. With the advent of ESA, there 
was optimism that cardiovascular outcomes could be substantially improved in CKD and 
dialysis patients due to sustained normalisation of haemoglobin levels.  This optimism has 
since diminished, after a number of clinical trials failed to demonstrate improved outcomes 
in a variety of renal scenarios such as pre dialysis CKD, dialysis, and transplant populations. 
It is now felt that the cardiovascular toxicity of these medications matches the morbidity 
associated with anaemia.  
In the Cardiovascular Risk Reduction by Early Treatment with Epoetin Beta (CREATE) 
study, 603 patients were randomly assigned to a haemoglobin target of either 130 to 150 g/L 
or 105 to 130 g/L (Drüeke et al., 2006). No significant difference was seen in cardiovascular 
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event rate, mortality, nor quality of life. In the Trial to Reduce Cardiovascular Events with 
Aranesp Therapy (TREAT) study, patients were randomised to either darbepoetin therapy 
with a target haemoglobin of 130 g/L, or to placebo, with darbepoetin rescue therapy given 
if haemoglobin fell to less than 90 g/L (Pfeffer et al., 2009). The treatment arm showed a 
significant reduction in blood transfusions, and a modest improvement in fatigue score, at 
the cost of a nearly doubled risk of stroke.  
The data suggests therefore, that the risks of normalising haematocrit, or the higher dose of 
ESA or iron required to achieve this, at least exceeds the cardiovascular risks associated with 
anaemia. Certainly, ESA have a range of undesirable biological side effects which could 
cause cardiovascular harm, including upregulation of endothelin-1 production (Briet et al., 
2013), calcification of vascular smooth muscle cells (VSMC) (Won et al., 2014), 
hypersensitivity of angiotensin II signalling(Yamakado et al., 1991), and an increase in 
circulating asymmetric dimethylarginine (ADMA) (Scalera et al., 2005).  Likewise, 
intravenous administration of iron can overwhelm the bodies typical iron sequestering 
mechanisms, allowing the reaction of poorly bound iron with hydrogen peroxide in the 
Fenton reaction, producing large quantities of ROS and inducing oxidative stress (Anraku et 
al., 2004).  
A retrospective study of 12733 dialysis patients found that higher ESA dosage was 
associated with worse outcome, with higher rates of mortality and hospitalisation in patients 
treated with more than 20000 units/week of epoetin (Servilla et al., 2009). Similarly, a meta-
regression analysis of 31 studies and 12956 patients found that high ESA dose was 
associated with increased cardiovascular events and mortality independent of haemoglobin 
concentration (Koulouridis et al., 2013). In contrast, another study found that deleterious 
effects of ESA and iron therapy occur only at high haematocrit levels. A retrospective 
analysis of Medicare haemodialysis patients allocated 269717 subjects into quartiles based 
on haematocrit levels (Brookhart et al., 2010). In those with haematocrit less than 0.33 
intensive use of iron and ESA was associated with reduced mortality, whilst in those with 
haematocrit greater than 0.33, higher use of iron and ESA was associated with increased 
mortality. In the pre dialysis population, Jing et al found a modest reduction in mortality in 
CKD patients when a low haemoglobin was targeted (around 100 g/L), whilst no difference 
in outcome was observed with any haemoglobin target in dialysis patients (Jing et al., 2012).   
A balance must be struck therefore, between maintenance of haemoglobin at a level 
sufficient to reduce need for blood transfusion and the cardiovascular sequelae of profound 
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anaemia, without excessive use of potentially harmful ESA or iron preparations, and without 
over compensation to a hazardous level of haematocrit. As such, Renal Association 
guidelines recommend a target haemoglobin of 100 – 120 g/L in ESA treated patients with 
CKD (Renal Association, 2010).   
1.3.3 Uraemic cardiomyopathy 
Left ventricular hypertrophy is a pathological outcome resulting from a number of 
mechanisms associated with renal impairment, and confers increased risk of adverse 
cardiovascular outcome. As discussed earlier, in contrast to the normal population CVD in 
CKD more often manifest as sudden death, arrhythmia, and heart failure than atherosclerotic 
coronary artery disease and myocardial infarction, and left ventricular hypertrophy 
predisposes to these events. Furthermore, the pathology of cardiomyopathy is different in 
CKD compared to the general population. 
Early echocardiographic studies into the nature of uraemic cardiomyopathy described a high 
prevalence of left ventricular (LV) hypertrophy and dilatation with LV mass and cavity size 
proving independent predictors of mortality. With the increased availability of cardiac 
magnetic resonance imaging (CMR), uraemic cardiomyopathy has been somewhat re-
described accounting for the over estimation of LV mass which occurs using 
echocardiography (Stewart et al., 1999). 
In a prospective study of 134 patients with ESRD receiving maintenance haemodialysis, 
Mark et al redefined the characteristics of uraemic cardiomyopathy using gadolinium 
enhanced CMR (Mark et al., 2006). 28.4% of patients had evidence of myocardial fibrosis 
demonstrated by late enhancement following administration of gadolinium contrast. Half of 
these had subendocardial fibrosis, typically caused by myocardial ischaemia, associated with 
LV hypertrophy and dilatation, systolic dysfunction, and occurred in patients with 
conventional risk factors for CVD. In the other half, a different pattern of cardiovascular 
abnormalities was observed, comprising more diffuse myocardial fibrosis, associated with 
LV hypertrophy but not dilatation nor systolic dysfunction, and occurring in the absence of 
conventional cardiovascular risk factors. 
Uraemic cardiomyopathy in patients with non-dialysis CKD is less well described. Park et 
al performed a cross sectional analysis of 3487 participants of the CRIC study who had 
undergone echocardiographic measurement of LV mass, and estimation of eGFR using 
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cystatin C (Park et al., 2012). Renal function and LV mass were negatively correlated, and 
after adjustment for conventional cardiovascular risk factors, albuminuria, haemoglobin, and 
bone biochemistry, the prevalence of left ventricular hypertrophy (LVH )was elevated 1.4-
fold in those with eGFR below 44 mL/min/1.73m2, and 2.2-fold in those with eGFR below 
30 mL/min/1.73m2.  
Edwards et al evaluated LV geometry and associations with aortic stiffness using CMR in 
CKD stages 2 and 3 (Edwards et al., 2008). Even at these early stages of renal impairment, 
abnormalities of LV geometry were observed, with significantly higher LV mass than 
controls, and up to a third of patients exhibiting LVH. Furthermore, aortic compliance 
measured using CMR was increased, as was arterial and ventricular stiffness measured using 
echocardiography, albeit with preserved ventricular-arterial coupling. The data suggest that 
LV mass and contractility are increased in response to arterial stiffness in order to maintain 
ventricular-arterial coupling and optimise LV function, at the cost of development of LVH 
and increased LV stiffness. 
A number of other mechanisms have also been identified as risk factors for the development 
of uraemic cardiomyopathy. In a cross sectional observational study of 70 patients with renal 
impairment and 30 patients with HTN and normal renal function, McQuarrie et al found that 
urinary mineralocorticoid excretion was an independent predictor of LV mass in CKD but 
not in HTN (McQuarrie et al., 2011). Further evidence for the role of aldosterone in 
development of uraemic cardiomyopathy was derived from the CRIB-2 randomised control 
study in which spironolactone was shown to improve markers of LV systolic and diastolic 
function in 112 patients with early CKD (Edwards et al., 2010). 
Uraemic cardiomyopathy is therefore a common clinical occurrence in CKD and occurs as 
a result of a number of pathophysiological processes, ultimately leading to a different 
pathology to the typical ischaemic cardiomyopathy observed in patients with normal renal 
function.   
1.4 Oxidative stress 
1.4.1 Oxidative stress 
Oxidative stress refers to a state where there is disturbance of physiological redox 
homeostasis in favour of an excess of oxidative free radicals and their derivatives. Reactive 
oxygen species (ROS) act as signalling molecules when present in physiological quantities. 
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In excess however, ROS and derived oxidative species such as reactive carbonyl (RCS) and 
nitrogen species (RNS), cause reduced bioavailability of the anti-atherogenic vascular 
signalling molecule nitric oxide (NO) and activation of pro-atherogenic redox sensitive 
signalling cascades.  
In contrast to other cardiovascular risk factors which are manifest as a disturbance in single 
molecules or physiological axes, oxidative stress is a nebulous term characterised by the 
excess of free radicals, evidence of oxidant damage to macromolecules such as lipids, 
proteins and DNA, and physiological effects of this such as endothelial and arterial 
dysfunction, accelerated atherosclerosis, and increased cardiovascular risk.  
1.4.2 Sources of reactive oxygen species 
ROS have a number of intracellular sources, with the relative contribution of each varying 
between cells and dependent on the quantity of various stimulatory factors. ROS are not the 
only important radical species: NO reacts with O2
- to produce peroxynitrite and other RNS 
which are more stable than highly reactive ROS, exerting oxidant effect distant from the site 
at which they are generated. Ultimately most processes which use oxygen as substrate 
produce ROS either by design or as a by-product, and the various sources of ROS are 
discussed below.  
1.4.2.1 Mitochondria  
Mitochondrial ROS (mtROS) are produced in vast quantities during oxidative 
phosphorylation, the essential cellular process by which ATP is generated by the electron 
transfer chain, a string of protein complexes residing on the inner mitochondrial membrane. 
Molecular oxygen is reduced to water by electrons donated by nicotine adenine dinucleotide 
(NADH) at complex I and flavin adenine dinucleotide (FADH2) at complex II. Meanwhile, 
protons are pumped into the intramembrane space to create a membrane potential resulting 
in a proton motive force which is harnessed by the enzyme ATP synthase in complex 5 to 
drive the synthesis of ATP from ADP and phosphate (Murphy, 2009).  
Not all oxygen is reduced to water during oxidative phosphorylation; it is estimated that 
0.2% to 2% is reduced to O2
- (Madamanchi and Runge, 2007). O2
- leak occurs in complex I, 
towards the mitochondrial matrix, and in complex II, towards both the intermembrane space 
and the mitochondrial matrix, where it is quickly dismutated to hydrogen peroxide (H2O2) 
by superoxide dismutase (SOD) 1 and 2. Although O2
- has a short half-life, within the matrix 
Chapter 1 39 
 
radical-radical interaction with NO can occur to form RNS. H2O2 is produced in large 
quantities in the intermembrane space, and is sufficiently stable to migrate outwith the 
mitochondrion and participate in cell signalling cascades elsewhere in the cell.  
A number of mitochondrial scavenger systems exist to eliminate ROS. As described, H2O2 
is produced from O2
- by SOD1 in the intermembrane space, and mitochondrion specific 
SOD2 in the matrix (Okado-Matsumoto and Fridovich, 2001). H2O2 is then reduced to water 
by glutathione peroxidase (GPx), resulting in oxidation of glutathione (GSH) in the process. 
H2O2 is also reduced by the enzyme catalase, but this is only present in cardiac mitochondria 
(Radi et al., 1991).  Peroxiredoxins are antioxidant enzymes with high affinity for H2O2. 
Overexpression of peroxiredoxin-3 prevents left ventricular hypertrophy and failure 
following myocardial infarction (Rhee et al., 2005) suggesting a role in cellular protection 
from excessive mtROS which occurs during ischaemia. Thioredoxins are another family of 
small proteins relevant to mtROS scavenging; thioredoxin-2 reduces mitochondrial 
permeability to ROS thereby preventing downstream effects of mtROS (He et al., 2008).  
Conversely, a number of local and systemic factors increase mtROS. There is a linear 
relationship between cellular oxygen concentration, and mtROS production, albeit with a 
paradoxical rise in the setting of profound hypoxia (Guzy and Schumacker, 2006). There is 
also an association between mitochondrial membrane potential and mtROS production, with 
an increase in O2
- occurring at extremes of both high and low values (Toime and Brand, 
2010). ROS itself increases mtROS production (Zorov et al., 2014), in a process termed 
“ROS induced ROS”. The mechanism behind this is poorly understood, but may occur 
through the protein p66Shc, found in the mitochondrial intermembrane space. p66Shc exists in 
an active and inactive state, and can be activated by oxidants such as oxidised LDL and 
inactivated by antioxidants such as GSH. When activated p66Sch forms a complex with 
cytochrome c and transfers electrons to molecular oxygen to directly form O2
- (Nemoto et 
al., 2006). Other factors which increase mtROS production include and transcription factors 
such as p53 and NFκB (Szczepanek et al., 2012). Angiotensin II also increases mtROS 
production via protein kinase C, resulting in depletion of mitochondrial GSH, and an 
increase in cellular H2O2 and peroxynitrite (Doughan et al., 2008).  
1.4.2.2 NADPH oxidase 
The NADPH oxidase (NOX) family of enzymes are membrane bound proteins which have 
the principle biological function of generating ROS by the transfer of electrons to molecular 
Chapter 1 40 
 
oxygen. There are seven subtypes of NOX which are expressed variably in a diverse range 
of cell types. NOX2 is the prototypical NADPH oxidase enzyme, expressed in phagocytes, 
typically existing in the membrane of intracellular vesicles in association with p22phox. Upon 
phagocyte stimulation, p22phox interacts with phosphorylated p47phox and other cytoplasmic 
subunits, resulting in the active NOX2 enzyme complex which binds with the plasma 
membrane, or phagosome membrane. NOX2 transfers electrons from its donor, NADPH, to 
molecular oxygen, producing ROS as part of anti-microbial defences (Babior et al., 2002). 
The other NOX isoforms share a number of features with NOX2, including their enzymatic 
activity, subunit structure, and transmembrane location. Several of the NOX isoforms are 
dependent on the same cytosolic subunits for activation, with p22phox associating with 
NOX1, NOX3 and NOX4, as well as NOX2 (Ambasta et al., 2004).  
All isoforms are widely distributed. In the vasculature, there is expression of NOX1, NOX4, 
and even NOX2 by endothelial cells (ECs) and VSMC (Brandes and Kreuzer, 2005). In the 
kidney there is high expression of NOX1, NOX4, and NOX5 in the cortex and by renal 
tubular cells (Gill and Wilcox, 2006). NOX expression and activity is induced by signalling 
molecules such as angiotensin II, and transcription factors such as TGFβ-1, TNFα and 
platelet derived growth factor (PDGF) (Manea et al., 2015). Expression of obligate subunits 
also represents a means of NOX regulation, and expression of p22phox and others is induced 
by angiotensin II.        
Evidence for the involvement of NOX in CVD can be found in patients with chronic 
granulomatous disease, who have an inherited mutation in genes encoding the components 
of NOX2. These individuals have early mortality due to impaired innate immunity, and also 
have increased production of pro-inflammatory mediators and recurrent infection. Despite 
the increased prevalence of vascular risk factors and presence of chronic inflammation, these 
patients have better endothelial function than matched controls, and reduced atherosclerotic 
burden, concomitant with reduced NOX2 activity and reduced levels of downstream markers 
of oxidative stress such as isoprostanes and oxidised LDL (Sibley et al., 2014). Furthermore, 
several NOX isoforms are inhibited by statins, a mechanism by which part of the beneficial 
effect of therapy might be mediated. Although NOX4 is most highly expressed in the 
vasculature, there is greatest evidence for the role of NOX1 in vascular disease. For example, 
mice which are NOX1 deficient have a lower systemic blood pressure (Gavazzi et al., 2006), 
and a blunted hypertensive response to angiotensin II (Matsuno et al., 2005). A similar effect 
is observed in p47phox deficiency, such that it has been postulated that NOX1 in association 
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with the p47phox subunit is responsible for ROS dependent hypertension (Landmesser et al., 
2002).  
Renal NOX expression has also been implicated in hypertension and CVD. For example, 
salt loaded rats were found to have increased expression of NOX2 and p47phox in the renal 
cortex, and increased markers of oxidative stress, even in the presence of renin angiotensin 
inhibition (Kitiyakara et al., 2003), suggesting a direct link between sodium intake and renal 
ROS production. NOX are also highly expressed in the renal cortex of spontaneously 
hypertensive (Chabrashvili et al., 2002), and 5/6 nephrectomised rats. In a human study using 
laser Doppler flowmetry as a marker of endothelial function, NO dependent vasodilatation 
was reduced in CKD but improved by tempol, and by the NADPH oxidase inhibitor 
apocynin (DuPont et al., 2014). Taken together, the data suggests the increased expression 
and activity of a number of NOX isoforms in patients with renal disease and their 
involvement in endothelial dysfunction. 
1.4.2.3 Xanthine oxidase 
Xanthine oxidoreductase (XOR) is part of the molybdoflavin enzyme family, and exists 
interchangeably as xanthine oxidase (XO) and xanthine dehydrogenase (XDH). In vivo, most 
XOR exists as XDH, but conversion can occur due to oxidation of thiol groups (Hille and 
Nishino, 1995). XOR reacts with many substrates, but its classical role is purine degradation, 
catalysing the conversion of hypoxanthine to xanthine, and xanthine to uric acid. XOR is 
widely distributed, and in mammals is found in highest amounts in the liver and the small 
intestine, but is also expressed within ECs and cardiac myocytes, both in the cytoplasm and 
on the cell membrane. Basal expression is low, but is upregulated by many cell specific 
transcription factors including IFN-γ, TNF-α, IL-1, IL-6, glucocorticoids and hypoxia 
(Hoidal et al., 1997).   
During oxidation of hypoxanthine or xanthine, electrons are donated first to the molybdenum 
site, then transferred via the FAD+ site, to reduce either molecular oxygen or NAD+ (Xia et 
al., 1999). XDH preferentially reduces NAD+, aside from in settings of NAD+ deficiency, 
which can occur in the setting of inflammation. Reduction of molecular oxygen results in 
production of O2
- and H2O2. In the past much focus has been on O2
- production by XOR, but 
more recent research has suggested that of the two forms of ROS, H2O2 is produced in far 
greater quantities (Kelley et al., 2010).  
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It is also increasingly understood that XOR exists within a complex redox system; for 
example XOR can also catalyse the formation of NO from its degradation products, 
especially in hypoxic conditions when NOS is inhibited (Millar et al., 1998). Furthermore, 
urate has both oxidant and antioxidant properties. On the one hand, several oxidants are 
scavenged and neutralised by urate, and XOR, and therefore ROS production, is also 
inhibited by urate. Conversely, urate has pro-oxidant effects, forming radicals with other 
oxidants including O2
- and peroxynitrite, and inducing ROS production by NOX (Hayden 
and Tyagi, 2004). Indeed, whilst uric acid is thought to be an important antioxidant in blood, 
hyperuricaemia induces hypertension in rats (Sanchez-Lozada et al., 2005), and causes 
endothelial cell dysfunction in culture (Choi et al., 2014).  
Nevertheless, there is evidence that XOR activity is involved in several cardiovascular 
conditions in humans, and that its inhibition may improve outcomes. Epidemiological 
evidence links hyperuricaemia with the presence of target organ damage in hypertension 
(Viazzi et al., 2005), and with poor outcomes in heart failure (Hamaguchi et al., 2011). In 
such patients, XOR activity is increased and is negatively correlated with endothelial 
function. A number of studies have investigated the use of the XOR inhibitor allopurinol and 
its metabolite oxypurinol, in a variety of cardiovascular settings including ischaemia-
reperfusion injury, acute and chronic heart failure, and coronary artery disease. Allopurinol 
was shown to reduce oxidative stress and myocardial events following primary percutaneous 
coronary intervention in a study of 40 patients suffering ST segment elevation myocardial 
infarction (Rentoukas et al., 2010). In another study of chronic heart failure, allopurinol 
improved endothelial dependent vasodilatation in a dose dependent manner (George et al., 
2006). A recent meta-analysis of XOR inhibition in CVD including 40 studies, found marked 
heterogeneity in outcome measures, with focus on surrogate markers rather than clinical end 
points (Higgins et al., 2012).  
The association between oxidative stress and progression of CKD will be discussed in 
greater depth later in this chapter, however an abundance of data links ROS with 
pathophysiological processes associated with progression of CKD. Accordingly, various 
modulators of ROS production have been studied to determine if these may slow the decline 
of renal function, including inhibitors of XOR. A recent systematic review found 19 
randomised control trials investigating the effect of allopurinol on CKD progression (Kanji 
et al., 2015), with meta-analysis finding in favour of allopurinol with a difference in eGFR 
of 3.2 ml/min.1.73m2, as well as a reduction in blood pressure.    
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Although XOR is therefore an important source of ROS, further research is therefore needed 
to clarify the role of XOR inhibition in ameliorating the pathological sequelae of oxidative 
stress.  
1.4.2.4 Uncoupled endothelial nitric oxide synthase 
All three isoforms of nitric oxide synthase (NOS) produce NO by a 5 electron oxidation of 
a guanidine group of its substrate, L-arginine. NOS activity is reliant on molecular oxygen 
and NADPH as co-substrates, and tetrahydrobiopterin (BH4), flavin mononucleotide (FMN), 
and flavin adenine dinucleotide (FAD) as cofactors of the reaction. NO production requires 
electron transfer from NADPH bound at the C-terminal, to a haem moiety at the N-terminal, 
via the flavin groups. Another electron is also probably donated by BH4. At the haem group, 
molecular oxygen is reduced and activated, and used for the oxidation of L-arginine, firstly 
to hydroxyl-L-arginine, and then to L-citrulline and NO (Förstermann and Sessa, 2012). 
Endothelial nitric oxide synthase (eNOS) is the principle isoform of NOS within the 
cardiovascular system, present in ECs, cardiac myocytes, renal tubular epithelial cells and 
platelets. Under physiological conditions, eNOS constitutively produces vascular NO, which 
is involved in vasodilatation, angiogenesis, platelet and inflammatory cell activation, and 
other aspects of vascular function.  
In certain circumstances, the reduction of molecular oxygen and haem becomes ‘uncoupled’ 
with the production of NO, such that O2
- is produced instead. When this occurs, uncoupled 
eNOS contributes to oxidative stress by reduced production of NO, and increased production 
of O2
- and its downstream products such as H2O2 and peroxynitrite (Forstermann et al., 
1994). There is evidence that eNOS uncoupling is involved in oxidative stress and 
endothelial dysfunction in the presence of a range of typical cardiovascular risk factors 
including dyslipidaemia (Stroes et al., 1997), hypertension (Higashi et al., 2002) and diabetes 
(Heitzer et al., 2000).  
A number of mechanisms are thought to be involved with eNOS uncoupling. Depletion of 
the essential cofactor BH4 is one putative mechanism behind eNOS uncoupling, suggested 
by the fact that NO production by eNOS correlates with intracellular concentrations of BH4 
(Werner-Felmayer et al., 1993), and that supplementation with BH4 increases NO production 
(Pieper, 1997). BH4 concentration is dependent on the balance between production by and 
degradation, as well as the degree of ‘recycling’ between BH4 and its oxidised metabolites. 
Factors which influence this include the presence of ROS and derivatives; for example, 
Chapter 1 44 
 
peroxynitrite causes oxidation of BH4 to BH3 and BH2, which have no cofactor activity with 
eNOS (Kuzkaya et al., 2003). In a mouse model of accelerated atherosclerosis, treatment 
with peroxynitrite results in strikingly depleted BH4 concentrations, and increased ROS 
production in a manner dependent on eNOS expression (Laursen et al., 2001).   
L-arginine deficiency is another mechanism by which eNOS uncoupling can occur. That 
said, the normal plasma concentration of L-arginine is around 100 µmol/L, whilst the level 
below which NO production is significantly reduced is around 3 µmol/L, such that one might 
not expect L-arginine deficiency to play a role in eNOS uncoupling in vivo (Closs et al., 
2000). Nevertheless, L-arginine supplementation has been shown to increase NO 
production, and improve endothelial function in hypertension and dyslipidaemia (Imaizumi 
et al., 1992).   
Asymmetric dimethyl-L-arginine (ADMA) is a circulating inhibitor of eNOS, and can also 
cause eNOS uncoupling at high levels. The enzymes involved in both production and 
degradation of ADMA are redox sensitive such that ADMA levels are elevated in oxidative 
stress. Furthermore, ADMA is excreted by the kidneys and is elevated in renal impairment. 
ADMA is considered separately in section 1.4.2.5.  
Finally, redox modification of eNOS can also lead to uncoupling. In conditions of oxidative 
stress, s-glutathionylation of thiol groups occurs and can alter enzyme function. S-
glutathionylation of cysteine residues within the reductase domain results in eNOS 
uncoupling. Arteries from spontaneously hypertensive rats (SHR) show eNOS s-
glutathionylation, associated with reduced NO and increased ROS production. This is 
associated with reduced endothelial dependent vasodilatation, and is ameliorated by reversal 
of s-glutathionylation by thiol specific reducing agents (Chen et al., 2010).   
Therefore, a number of mechanisms contribute to eNOS uncoupling, and given that renal 
impairment is associated with increased serum ADMA, oxidative stress, and antioxidant 
deficiency, it is likely that these mechanisms contribute to ROS production in CKD. 
Evidence for this comes from the fact that 5/6 nephrectomised rats showed reduced oxidative 
stress, and increased endothelial dependent vasodilatation when supplemented with BH4 and 
L-arginine; supplementation with both of these showed an additive effect (Arellano-
Mendoza et al., 2011).  
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1.4.2.5 ADMA 
ADMA, and its stereo-isomer symmetric dimethylarginine (SDMA), are by-products of the 
methylation of arginine residues on cellular proteins, a common translational modification 
resulting from the action of protein arginine methyltransferases (PRMT). PRMT-1 is found 
in a number of cells in the cardiovascular system, and symmetrically methylates arginine to 
produce ADMA which is released from cells via specific transporters. Methylated arginines 
are eliminated by urinary excretion and, in the case of ADMA, metabolised by 
dimethylarginine dimethylaminohydrolase (DDAH). In renal impairment, plasma ADMA 
levels are elevated due to reduced urinary excretion, as well as by inhibition of DDAH by 
hyperhomocysteinaemia (Tarnow et al., 2004). In states of oxidative stress, PRMT-1 is 
upregulated, and DDAH downregulated, which is another mechanism by which ADMA is 
increased in CKD. ADMA inhibits all isoforms of NOS, and also causes eNOS uncoupling 
resulting in O2
- production, and is therefore an important mediator of oxidative stress (Sydow 
and Munzel, 2003). 
ADMA has been identified as a marker of endothelial dysfunction and cardiovascular 
outcomes. Cardiovascular mortality and event rate has been shown to be correlated to plasma 
ADMA concentration in a number of settings including atrial fibrillation (Xia et al., 2008) 
and after coronary angioplasty (Cavusoglu et al., 2009). Furthermore, ADMA has been 
found to be associated with cardiovascular event rate in chronic kidney disease, as well as 
in haemodialysis patients (Zoccali et al., 2001) and those with kidney transplants (Frenay et 
al., 2015). For example, in a study of 820 patients with stage 3 and 4 CKD, a one standard 
deviation increment in serum ADMA was associated with a 19% increase in cardiovascular 
mortality (Lu et al., 2011).  
1.4.3 Regulation of oxidative stress by antioxidant systems  
Antioxidants are a diverse array of substances which neutralise oxidants, and/or prevent 
oxidation of downstream macromolecules. Antioxidants can be classified by whether they 
act in a non-specific ROS scavenging manner, or whether they act in a substrate specific 
manner. They can also be categorised by whether they are lipid or water soluble; the former 
being important in preventing oxidation of cell membrane components, whilst the latter 
regulating the redox state of plasma and cytoplasm. Similar to ROS production, the 
predominance of any particular antioxidant varies between cell type and intracellular 
locations.  
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1.4.3.1 Enzymatic antioxidants 
The major enzymatic antioxidants include SOD, catalase, peroxiredoxin, and glutathione 
peroxidase. The three SOD isoforms catalyse the breakdown of O2
- to H2O2 and O2, and are 
present in high quantities around cellular locations of ROS production, such as the 
mitochondria. In addition to mitochondrial SOD, the other SOD isoforms include 
extracellular SOD, which is produced and secreted by vascular smooth muscle cells and 
binds to components of the extracellular matrix to regulate interstitial redox status 
(Wassmann et al., 2004).  
Reduced glutathione plays an essential role in intracellular redox regulation by providing 
reducing potential for many cellular processes. Several isoforms of the enzyme glutathione 
peroxidase (GPx) are found in abundance in cytoplasm. GPx-1 reduces H2O2, whilst 
oxidised lipids are the preferred substrate of GPx-4. GSH is oxidised to glutathione 
disulphide (GSSG) in the process, which can be recycled to GSH by the enzyme glutathione 
reductase, with NADPH acting as the electron donor (Sindhu et al., 2005). 
Thioredoxins are a ubiquitous groups of small ubiquitous proteins which are important 
intracellular antioxidants. Thioredoxins contain reduced cysteine residues which allow 
enzymatic repair of oxidative damage to cellular proteins, by reducing thiol disulphide bonds 
which develop in the context of oxidative. The enzyme thioredoxin reductase reduces 
thioredoxins in order to recycle them for their participation these reactions (Ebrahimian and 
Touyz, 2008). Overexpression of thioredoxins increases the lifespan of transgenic mice 
(Yoshida et al., 2005), and reduces the development of diabetic nephropathy in a mouse 
model of diabetes (Hamada et al., 2007).  
1.4.3.2 Non-enzymatic antioxidants  
Non enzymatic antioxidants are generally low molecular weight proteins which remove ROS 
by undergoing oxidation themselves. These include ascorbic acid (vitamin C), vitamin E, 
glutathione, bilirubin and urate.  
Ascorbic acid is a six carbon ketolactone, which acts as an obligate cofactor for a number of 
enzymes. Humans, like all primates, cannot synthesize ascorbic acid such that we rely on 
dietary intake of ascorbic acid to prevent vitamin C deficiency. The current recommended 
daily intake of ascorbic acid is 90 – 100mg per day in non-smoking men and women (Carr 
and Frei, 1999), based on the amount required to prevent overt clinical features of scurvy, 
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the prototypical vitamin C deficiency syndrome. Ascorbic acid acts as a reducing agent to 
scavenge ROS, and also acts as an antioxidant by stabilising BH4, facilitating its action as a 
co-substrate for NO formation (Abudu et al., 2004). Conversely, ascorbic acid also has pro-
oxidant properties, producing ROS by reaction with iron. Of the group of eight tocopherols 
collectively termed “vitamin E”, α-tocopherol is the most biologically active, whilst γ-
tocopherol is the commonest in the typical Western diet. Vitamin E is a lipophilic 
antioxidant, particularly prevalent in the cell membrane (Ando and Tappel, 1985).  
Glutathione is a cysteine containing peptide and has a number of antioxidant actions 
typically exerted intracellularly, where it is found at high concentration. The active thiol 
group of the cysteine residues donate electrons to scavenge ROS and maintain NADPH in 
its reduced form (Masella et al., 2005). Additionally, reduced glutathione maintains ascorbic 
acid in its reduced form in order to facilitate its antioxidant effect. Oxidised glutathione is 
termed glutathione disulphide, and is reduced by glutathione reductase and NADPH; the 
ratio of glutathione to glutathione disulphide is often measured as a marker of redox state.  
1.4.3.3 Antioxidant regulation 
Key to regulation of antioxidant enzyme transcription is the nuclear factor (erythroid-derived 
2)-like 2 (Nrf-2) – antioxidant response element (ARE) signalling pathway. The Nrf-2 
transcription factor is a master regulator of antioxidant activity, and regulates transcription 
through binding with ARE promotor regions present on several antioxidant genes (Jaiswal, 
2004). Whilst there is constitutive activity of Nrf-2, this is limited by its ubiquitin dependent 
degradation. Nrf-2 is kept within the cytoplasm by Kelch-like ECH-associated protein 1 
(Keap-1) which facilitates its ubiquitination. Interaction between Nrf-2 and Keap-1 can be 
impaired directly by oxidation of Keap-1 thiol groups, or indirectly via Nrf-2 
phosphorylation by specific protein kinases; both of these mechanisms reduce Nrf-2 
ubiquitination and allow translocation to the nucleus where binding to ARE can occur. ARE 
was first discovered on the NADPH:quinone oxidoreductase 1 (NQO1) gene, but it is now 
known that Nrf-2 upregulates the transcription of many genes, including thioredoxin 
reductase, SOD, glutathione reductase, and many others, including those involved in GSH 
synthesis (Ma, 2013).  
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1.5 Endothelial dysfunction 
1.5.1 Endothelial dysfunction and cardiovascular disease 
The endothelium is the single cell luminal lining of the vascular system and releases a variety 
of factors which play an important role in regulation of VSMC tone and proliferation, 
inflammatory cell chemotaxis and activation, and platelet activation and aggregation. In 
particular, NO produced by ECs diffuses freely into VSMC where it activates guanylate 
cyclase and causes endothelium dependent vasodilatation (figure 1.2) (Ignarro, 1990), 
although vasodilatation is also mediated by other vascular signalling molecules including 
endothelium derived hyperpolarising factor (EDHF) (Félétou and Vanhoutte, 2006). 
 
Figure 1.2 VSMC relaxation in response to NO 
NO is generated from by NOS also utilising molecular oxygen whilst producing the by-product L-
citrulline. NO is freely diffusible through cell membranes, and moves from the endothelial cell to the 
vascular smooth muscle cell where it activates G-cyclase. The cGMP which is produced activates protein 
kinases which ultimately lead to release of intracellular calcium and smooth muscle relaxation. NO = 
Nitric oxide, NOS = Nitric oxide synthase, G-cyclase = Guanylyl cyclase, cGMP = cyclic guanosine 
monophosphate. 
NO also has cyclic guanine monophosphate (cGMP) independent effects, exerted via s-
nitrosylation (SNO) of protein cysteine residues on signalling molecules, which reduces their 
biological activity (Lima et al., 2010). In many cases, such as the SNO of mitogen-activated 
protein kinase phosphatase 7 (MPK7), NFκB and tissue factor, this has anti-atheromatous 
effects (Marshall and Stamler, 2001). Oxidative stress is associated with reduced 
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bioavailability of NO by a number of mechanisms already discussed: inhibition and 
uncoupling of eNOS, depletion of NO by its reaction with ROS to form peroxynitrite, and 
an increase in circulating ADMA. Thus, oxidative stress is associated with reduced 
bioavailability of favourable signalling molecules such as NO, together with alteration of 
signalling cascades which promote proliferation and inflammation, which ultimately 
predisposes to CVD.  
Data from the Multi Ethnic Study of Atherosclerosis demonstrated that the presence of 
endothelial dysfunction predicts future cardiovascular events in patients without a history of 
vascular disease, even after adjustment for conventional cardiovascular risk factors (Yeboah 
et al., 2009b). Endothelial dysfunction has also been observed in the presence of many 
cardiovascular risk factors including hypertension (Panza et al., 1993, Panza et al., 1990), 
hypercholesterolaemia (Kawano et al., 2002), diabetes (Nitenberg et al., 1993) and smoking 
(Heitzer et al., 1996). Endothelial function is reduced in the presence of established CVD 
and in proportion to its severity (Davignon and Ganz, 2004); for example, flow mediated 
dilatation (FMD) is 10.2% in patients without coronary artery disease, 7.7% in patients with 
single vessel disease, 5.2% in two vessel disease and 2.0% in triple vessel disease (Kaku et 
al., 1998). Taken together, it has been postulated that endothelial dysfunction represents the 
earliest stage of the development of atherosclerosis and CVD, as well as a final common 
mechanism by which conventional cardiovascular risk factors exert pathophysiological 
effect. 
1.5.2 Endothelial dysfunction and chronic kidney disease 
As has already been described, a number of factors can disrupt redox homeostasis via 
dysregulation of the various sources of ROS and antioxidant systems, including angiotensin 
II, oxidised LDL, and ADMA. It is therefore unsurprising that endothelial dysfunction has 
been observed in CKD, which is characterised by inflammation, activation of the renin 
angiotensin aldosterone system (RAAS), and an increase in circulating NOS inhibitors such 
as ADMA.  
Exposure of ECs in culture to uraemic serum results in switching to a pro-atherogenic 
phenotype. For example, a proteomic analysis showed increased expression of proteins 
relating to inflammation and oxidative stress, such as proteasome components, superoxide 
dismutase and glutathione peroxidase, which probably occurs via NFκB signalling (Carbo 
et al., 2008). Similarly, rabbit aortic ECs cultured in uraemic serum show increased NFκB 
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nuclear translocation and DNA binding, reduced NO production and increased TNFα 
production (Feng et al., 2011). In some studies uraemic serum was shown to increase EC 
proliferation (Monroy et al., 2015, Serradell et al., 2003) whereas in other studies reduced 
proliferation, and rather apoptosis was observed (García-Jérez et al., 2015). The effect may 
depend on the concentration of uraemic serum, with proliferation seen at lower 
concentration, and apoptosis at higher concentrations; or to draw a clinical correlation, the 
effect of uraemia on the vascular endothelium may depend on the severity of renal disease. 
Patients with chronic kidney disease also show reduced differentiation of endothelial 
progenitor cells (Goligorsky et al., 2010), which may reflect reduced capacity for vascular 
repair. 
In wire myography studies, isolated small resistance vessels derived from animal models or 
human tissue are mounted onto a myograph and exposed to various vasoactive substances in 
order to measure reactivity. Resistance vessels from patients with CKD show reduced 
vasodilatation to acetylcholine, but maintained vasodilatation to sodium nitroprusside, 
suggestive of impaired endothelial dependent vasodilatation. Application of the NOS 
inhibitor NG-nitro-L-arginine methyl ester (L-NAME) to control vessels results in a 
vasodilator profile similar to the CKD vessels, confirming that the reduced NO 
bioavailability is involved in the mechanism of endothelial dysfunction (Morris et al., 2001). 
These ex vivo results are reflected by the results of in vivo vascular function studies such as 
FMD and venous occlusion plethysmography. For example, in one study of 105 patients 
with CKD, FMD was reduced to 3.8% compared to 5.7% in controls (Dogra et al., 2006). In 
another study of 304 patients with CKD not on dialysis, FMD was reduced in a stepwise 
manner with increasing severity of renal impairment (Yilmaz et al., 2011). Similarly, 
endothelial function measured using plethysmography was shown to be reduced in CKD; 
brachial artery blood flow showed a lesser response to metacholine infusion in CKD as 
compared to controls, whilst response to nitroprusside infusion was the same in both groups 
(Morris et al., 2000).  
1.5.3 Causes of endothelial dysfunction in chronic kidney disease 
There is therefore evidence to show that uraemic serum is damaging to ECs in culture that 
explanted vessels from patients with CKD have an impaired vasodilator response, and that 
patients with CKD have endothelial dependent vasodilatation. There is also evidence that 
this effect is mediated by oxidative stress.  
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1.5.3.1 Upregulated sources of ROS 
Du Pont et al, measured cutaneous vascular function in response to a number of vasoactive 
substances in patients with CKD compared to healthy controls (DuPont et al., 2014). They 
found reduced NO dependent vasodilatation, which was improved by administration of the 
SOD mimetic tempol, and the NOX inhibitor apocynin, suggesting that the vascular 
dysfunction associated with CKD is at least in part mediated by NADPH oxidase derived 
ROS. 
In a study examining the determinants of endothelial dysfunction, CKD was associated with 
reduced endothelial function, with correlation between eGFR and FMD (Yilmaz et al., 
2006), and increased biomarkers of oxidative stress. On multivariate analysis, ADMA and 
oxidised LDL cholesterol were significant predictors of endothelial dysfunction. Other 
studies have found endothelium dependent vasodilatation to be positively correlated to total 
antioxidant activity and serum glutathione concentration, and negatively associated with 
oxidised glutathione (Annuk et al., 2001). Khaira et al found that FMD was positively 
associated with total antioxidant capacity and vitamin C, and to be negatively associated 
with the presence of oxidative end products such as thiobarbituric acid reactive substances 
(TBARS) (Khaira et al., 2011). 
1.5.3.2 The renin angiotensin system 
Angiotensin II impairs endothelial function by a number of mechanisms. Firstly, it causes 
tyrosine phosphorylation of eNOS, impairing NO production and impairing endothelium 
dependent vasodilatation (Loot et al., 2009). Secondly, it acts via angiotensin II type 1 (AT1) 
receptors and mitogen activated protein (MAP) kinase signalling to increase arginase activity 
which depletes L-arginine availability (Shatanawi et al., 2015). Lastly, it upregulates 
expression of the potent vasoconstrictor endothelin-1 (Hong et al., 2004). The RAAS is 
strongly activated in CKD, and pharmacological inhibition has been shown to improve 
endothelial function in other groups such as patients with coronary artery disease (Anderson 
et al., 2000) or hypertension (Goto et al., 2000). One study showed improvement in FMD 
after treatment with the ACE inhibitor Ramipril (Yilmaz et al., 2009). Similarly, aldosterone 
production is increased in CKD, and aldosterone has been shown to increase ROS production 
by NOX both in endothelial cells (Chrissobolis et al., 2014) and renal mesangial cells 
(Miyata et al., 2005). The role of mineralocorticoid antagonism in preventing complications 
of CKD is a subject of ongoing research.  
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1.5.3.3 Uraemic toxins 
Uraemic retention toxins are water soluble or protein bound substances in blood which are 
increased in concentration by renal impairment. Given the levels of these toxins correlate 
inversely with GFR, it can prove difficult to elucidate an independent association with 
cardiovascular risk and outcome.  Indoxyl sulfate is a protein bound uraemic toxin which is 
produced by the liver during tryptophan metabolism, and has recently been shown to 
independently predict CVD and mortality in CKD patients (Lin et al., 2012). Endothelial 
cells cultured in indoxyl sulfate show increased ROS production which is ameliorated by 
NOX inhibition, and show markedly reduced levels of the antioxidant glutathione (Dou et 
al., 2007). Indoxyl sulfate has also been associated with progressive renal impairment, and 
reduces renal Nrf-2 expression via NFκB signalling (Bolati et al., 2013). Other uraemic 
retention toxins implicated in causing endothelial dysfunction include p-cresyl sulfate and 
malondialdehyde (Watanabe et al., 2015).  
1.5.3.4 ADMA in chronic kidney disease 
As described earlier, ADMA is a circulating inhibitor of NO production and causes eNOS 
uncoupling, and its concentration in serum is inversely correlated to eGFR. ADMA reduces 
NO production by competing with the substrate L-arginine and also by other mechanisms, 
such as inhibition of eNOS phosphorylation at the Ser1177 residue (Kajimoto et al., 2012). 
ECs cultured in high concentrations of ADMA show impaired NO production higher affinity 
to mononuclear cells (Böger et al., 2000), whilst vessels exposed to ADMA show reduced 
endothelium dependent vasodilatation (Cardounel et al., 2007). In patients with CKD, 
ADMA has been shown to be an independent predictor of endothelial function, and for every 
0.1 µmol/L increase in ADMA, there is a 37% increase in a composite outcome of all-cause 
mortality, myocardial infarction and stroke (Tarnow et al., 2004). Indeed, even in healthy 
individuals with normal renal function, a negative correlation has been documented between 
ADMA and FMD (Ardigo et al., 2007). Moreover, baseline ADMA predicted FMD 
measured at six years of follow up (Furuki et al., 2008). 
1.5.3.5 Inflammation 
CKD is a state of low grade inflammation, characterised by an elevation in many 
inflammatory chemokines and activation of immune cells. For example, a number of studies 
have shown elevations in C reactive protein (CRP), IL-6, TNFα, and a number of adhesion 
molecules (Panichi et al., 2001, Lee et al., 2015). There is also activation of immune cells, 
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especially M1 macrophage (Li et al., 2015) and polymorphonuclear leukocytes (Sela et al., 
2005).  
Inflammation is highly associated with oxidative stress; many inflammatory pathways are 
activated by disturbed redox signalling, whilst ROS are also produced as an end result of 
many inflammatory processes. Activation of the immune system in CKD may in part be 
caused by increased activity of NFκB, which regulates expression of a number of 
inflammatory mediators (Li and Karin, 1999), and NFκB is upregulated by ROS and 
glutathione depletion (Morgan and Liu, 2011). NFκB also reduces Nrf-2 expression thereby 
reducing antioxidant capacity.  
A cross sectional analysis of patients with CKD 3 – 5 found elevations in inflammatory 
markers even in moderate renal disease, which was associated with platelet activation and 
increased von Willebrand factor, a circulating marker of endothelial damage (Landray et al., 
2004).  
1.5.3.6 Reduced antioxidant capacity 
In addition to these pro-oxidant processes which are augmented in CKD, endothelial 
dysfunction also arises from impaired antioxidant capacity. Firstly, there is a reduction in 
exogenous antioxidants: in a study of 58 patients with CKD, there was reduction in the serum 
concentration of vitamin C which correlated with eGFR, and this was associated with 
reduced FMD (Takahashi et al., 2011). Some studies have shown reduced vitamin E in 
patients with CKD, whilst others have found this only in patients receiving haemodialysis. 
Other non-enzymatic antioxidants such as bilirubin are also reduced, and total antioxidant 
capacity, a measure of extracellular non enzymatic reducing potential, has been shown to be 
reduced in proportion to severity of renal impairment. The levels of many enzymatic 
antioxidants are also reduced in CKD, including SOD, GPx, catalase, and paraoxonase-1 
(Johnson-Davis et al., 2011). Furthermore, regulation of antioxidant gene expression has 
also been demonstrated in CKD (Atamer et al., 2008). In an animal model of renal 
impairment, Kim et al, showed increased lipid peroxidation, glutathione depletion, 
mononuclear cell activation and increased NFκB signalling in 5/6 nephrectomised rats (Kim 
and Vaziri, 2010). This was associated with a reduction in Nrf-2, and increase in the 
repressor protein Keap-1, with resultant down regulation of Nrf-2 target genes such as 
catalase, SOD, glutathione peroxidase and NQO1.  
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1.6 Arterial function and stiffness 
In addition to the deleterious alterations in EC function, changes to vascular structure also 
occur in CKD which bestow cardiovascular risk. This vascular remodelling is caused by a 
number of pathophysiological processes associated with uraemia, many of which are 
common to endothelial dysfunction, and are also related to oxidative stress.  
1.6.1 Structure and function of the arterial system 
The role of the vasculature is to provide continuous blood flow to end organs which require 
constant perfusion in order to avoid tissue ischaemia and dysfunction. Vascular function 
therefore involves conversion of pulsatile blood flow occurring during each cardiac cycle 
into a constant flow, and facilitating transit of blood to peripheral organs and tissues. 
The aorta and large arteries are termed conduit arteries and are extremely compliant, which 
accommodates a large volume of blood which is ejected during systole. This elasticity 
generates potential kinetic energy which is released during diastole when the recoil of the 
aorta causes forward propulsion of blood. This results in a cushioning effect which dampens 
peak systolic pressure and augments diastolic pressure, which is thought to protect the end 
organ microcirculation from high pressure and maintain coronary blood flow during diastole. 
Small arteries are less distensible due to differences in the composition of their extracellular 
matrix and are termed resistance arteries (Westerhof et al., 2009).   
The arterial wall has viscoelastic properties which results from the nature of its underlying 
components, including VSMC, endothelial cells, and extracellular matrix. The relative 
proportions of the major scaffolding proteins, collagen and elastin, are especially important 
in determining vascular compliance, and alterations to the normal cycle of degradation and 
production of these can result in arterial stiffness.  
Arterial stiffness is therefore characterised histologically by disordered endothelial cells, 
increased collagen, damaged elastin and infiltration by inflammatory cells, pathologically 
by increased intima to media thickness, hypertrophied and proliferated VSMC, and vascular 
calcification, and clinically by systolic hypertension, and increased pulse pressure. These 
changes can be measured non-invasively as described in section 1.9.3, by characteristic 
abnormalities in the arterial waveform, and by an increase in the pulse wave velocity (PWV). 
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1.6.2 Alterations in the extracellular matrix 
Matrix metalloproteinases (MMP) are a group of endopeptidases involved in the turnover of 
elastin and collagen which are important in the determining the elasticity of the arterial wall 
(Hadler-Olsen et al., 2011). Excessive MMP activity results in uncoiled, ineffective collagen 
and degraded elastin and evidence exists which implicates MMP, especially MMP-2 and 
MMP-9, in the development of arterial stiffness (Yasmin et al., 2005). MMP-2 has been 
found to be upregulated in arteries of patients undergoing renal transplantation, with 
expression negatively correlated with contractility and endothelial dependent relaxation. 
Pharmacological inhibitors of MMP such as doxycycline improve arterial stiffness (Chung 
et al., 2008) and prevent aortic dissection in Marfanoid mice (Xiong et al., 2008), 
demonstrating the important of the endopeptidases to normal vascular structure and repair. 
The expression of MMP by inflammatory and endothelial cells is up regulated by cytokines 
and ROS. For example, ROS signalling through MAP kinase results in upregulation of 
MMP-1, and oxidative inhibition of tyrosine phosphatases results in downregulation of 
MMP inhibitors (Kar et al., 2010).   
Advanced glycation end products (AGE) result from the non-enzymatic reaction between 
cellular proteins and glucose via the Maillard reaction (McNulty et al., 2007) which occurs 
in a time dependent manner relative to serum glucose concentration.  AGE result in excessive 
and abnormal cross linking of collagen peptides, which results in a stiff and inflexible extra 
cellular matrix, and also cause collagen cross linking which inhibits its proteolysis, serving 
to perpetuate these undesirable collagen molecules within the vascular matrix (Semba et al., 
2009). AGE also stimulate production of inflammatory cytokines and reactive oxygen 
species by interaction with immunoglobulin superfamily receptors, establishing an 
inflammatory milieu ideal for promotion of arterial stiffness and endothelial dysfunction.  
1.6.3 Endothelial and vascular smooth muscle cell dysfunction 
VSMC tone is determined both inherently, by interaction with endothelial cells, and due to 
circulating factors such as angiotensin II. Hypertension, by increasing intraluminal pressure, 
results in mechanosensitive changes to calcium signalling within VSMC which increases 
muscle tone. Hypertension is therefore strongly associated with stiffness, both as a cause and 
a consequence. ECs are involved in regulating VSMC tone through a number of signalling 
molecules including NO and EDHF. The association between EC and VSMC function was 
investigated in a study of 89 healthy volunteers (McEniery et al., 2006). FMD was inversely 
associated with PWA, PWV, and central BP, which remained statistically significant after 
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adjustment for confounders, demonstrating the relationship between endothelial function 
and arterial stiffness.  
1.6.4 Effect of systemic factors on arterial function and stiffness 
Local and systemic activation of the RAAS is another contributor to arterial function and 
remodelling. VSMC tone is increased by circulating factors such as angiotensin II, 
endothelin and ROS, which are released locally by endothelial cells and can act in a paracrine 
fashion to reduce distensibility of the vascular wall. Angiotensin II also causes VSMC 
hypertrophy, proliferation, and conversion to an inflammatory phenotype. When angiotensin 
II is applied directly to VSMC, there is an increase in IL-6 production and NFκB activation, 
in a dose dependent manner which is abrogated by inhibition of ROS production (Kranzhofer 
et al., 1999). Remodelling is also mediated by angiotensin II via increased production of 
MMP (Takagishi et al., 1995) and collagen by VSMC (Mifune et al., 2000). These effects 
on arterial stiffness can be ameliorated by pharmacological RAAS blockade, and indeed this 
might account for some of the survival benefit of this treatment. In a study of 150 patients 
receiving maintenance haemodialysis, ACE inhibitors reduced cardiovascular and all-cause 
mortality in a blood pressure independent manner; those patients whose PWV was reduced 
by therapy were significantly more likely to have a survival benefit (Guerin et al., 2001).  
Aldosterone has also been implicated in the development of arterial stiffness. In 
normotensive rats, supplementation with angiotensin II caused arterial thickening, impaired 
endothelium dependent vasodilation, together with activation of NADPH oxidase and an 
increase in TBARs (Virdis et al., 2002). These effects were corrected by spironolactone, 
suggesting that aldosterone is a cause of vascular remodelling, mediated in part by 
endothelium dysfunction and oxidative stress. A randomised controlled trial of 
spironolactone in patients with stages 2 and 3 CKD found a significant reduction in arterial 
stiffness and left ventricular mass index (Edwards et al., 2009). The Randomised Aldactone 
Evaluation Study (RALES) was a large multi-centre randomised control trial which 
demonstrated the benefit of mineralocorticoid inhibition in heart failure. Subgroup analysis 
from the RALES study showed that patients with high levels of procollagen peptides had a 
higher risk of mortality, and these markers reduced during spironolactone therapy (Zannad 
et al., 2000); indeed those with higher markers of vascular fibrosis were more likely to 
benefit from mineralocorticoid inhibition. All things considered, these results suggest that 
aldosterone is involved in arterial remodelling via activation of pro-fibrotic pathways.  
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1.6.5 Vascular calcification 
The phenomenon of vascular calcification in renal impairment is readily appreciated by 
viewing an abdominal or pelvic X-ray of a patient receiving maintenance haemodialysis, 
where the radio-opaque tramlines of calcified vessels are clearly visible. Vascular 
calcification is characterised by deposition of calcium phosphate within vessels, and is now 
understood to be an active, cell mediated process, whereby VSMC convert to an osteoblast 
like phenotype, releasing matrix and inflammatory chemokines. Two types of vascular 
calcification exist: intimal calcification is a focal process associated with atherosclerosis, 
and results in localised inflammation and formation of occlusive plaques. Medial 
calcification is a diffuse process, typically characterised by mineralisation within the medial 
layer of conduit vessels. The latter, historically termed Mönckeberg's arteriosclerosis, is 
common in CKD. The two processes can coexist in the same patient, and indeed the same 
vessel, and both are associated with cardiovascular mortality. In a study of patients with pre 
dialysis CKD, vascular calcification was assessed by CT of the abdominal aorta and 
superficial femoral artery, and found to be associated with poor renal function and higher 
PWV (Toussaint et al., 2008).  
A number of elements of the uraemic milieu have been shown to promote vascular 
calcification. Disturbance in calcium and phosphate metabolism which occurs in CKD may 
cause calcification directly, by deposition within vessel walls, but also activates pro-calcific 
mechanisms in VSMC. Phosphate is transported into VSMC by sodium dependent 
phosphate co-transporter, Pit-1, and causes osteogenic differentiation by activation of 
transcription factors such as core binding factor a1 (cbfa-1) (Steitz et al., 2001). Uraemic 
serum also causes VSMC osteoblastic differentiation independently of phosphate 
concentration however, and this might be mediated through oxidative stress. For example, 
H2O2 was shown to induce an osteogenic phenotype in VSMC, signalling via Runx2, Msx2-
wnt, and NOX (Byon et al., 2008). Indeed, even the calcific effects of hyperphosphataemia 
are mediated in part through redox signalling. In a model of uraemic vascular calcification 
using bovine aortic smooth muscle cells, calcium deposition was abrogated by inhibition of 
mtROS production (Zhao et al., 2011). Amongst others, indoxyl sulfate is one specific 
uraemic toxin which has been shown to induce arterial calcification and expression of 
osteogenic proteins.  
Calcium based phosphate binders have historically been used in renal impairment to reduce 
serum phosphate concentration in order to manage CKD bone mineral disease. There is a 
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concern however, that iatrogenic calcium loading may contribute to the vascular 
calcification seen in these patients. As with phosphate, calcium causes calcification of 
VSMC in vitro, and studies of non-calcium containing phosphate binders have shown a 
reduction in vascular calcification compared with calcium based therapies. As yet however 
there is no evidence showing improved cardiovascular outcomes associated with a calcium-
free approach to phosphate lowering. There is a similar controversy regarding the role of 
vitamin D replacement. Vitamin D deficiency is common in CKD and induces 
hyperparathyroidism which is highly associated with cardiovascular outcome and arterial 
stiffness. Conversely, some studies have found no association between vitamin D levels and 
vascular calcification (Barreto et al., 2009), and it has been shown that high doses of 1-25-
vitamin D can induce osteoblastic differentiation of VSMC. 
As well as these biochemical, hormonal, and iatrogenic elements contributing to vascular 
calcification in CKD, there is deficiency of a number of protective mechanisms. Circulating 
regulators of extracellular calcium such as fetuin A and matrix GLA protein are reduced in 
CKD (Luo et al., 1997), and patients with the lowest levels of these inhibitors have worse 
cardiovascular outcomes. Pyrophosphate depletion causes massive arterial calcification in 
mice, and levels of this inhibitor are reduced by HD.  
1.6.6 Arterial stiffness and chronic kidney disease 
In summary then, CKD is associated with a number of processes which cause vascular 
calcification, VSMC proliferation and dysfunction, and alterations to the extracellular matrix 
which induce arterial stiffness. Patients with renal impairment suffer accelerated age 
associated arterial stiffening, and those patients with demonstrably higher arterial stiffness 
suffer worsened cardiovascular outcomes. 
1.7 Oxidative stress and endothelial dysfunction in the 
kidney  
The discussion so far has focused on oxidative stress as a mediator of CVD, however redox 
signalling has a role in the regulation of kidney function in normal physiology, and there is 
evidence that oxidative stress plays a role in the pathophysiology of renal impairment, and 
is an important mediator of progressive CKD. 
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1.7.1 Redox signalling in renal physiology 
Redox signalling plays a role in several aspects of renal function, and as such many of the 
regulatory components of redox physiology have been identified in the kidney. For example, 
all three isoforms of NOS are highly expressed, including eNOS which is expressed within 
the renal vasculature, especially in the glomerulus. Neuronal NOS is expressed by macula 
densa cells and is involved in tubuloglomerular feedback. Inducible NOS is expressed at 
high levels even under basal conditions, especially within the interstitium, although its 
transcription is further enhanced by a number of factors including lipopolysaccharide, 
hyperglycaemia and hypertension. Several NOX isoforms are also highly expressed, 
especially NOX-4 which is abundantly produced in the renal cortex.   
Infusion of L-NAME into rats with normal renal function causes afferent and efferent 
arteriolar vasoconstriction, reduced filtration fraction, reduced medullary blood flow and 
systemic hypertension (Zatz and de Nucci, 1991). Many of the effects of local and systemic 
RAAS are also mediated through redox signalling. For example, renal afferent arterioles 
infused with angiotensin II show impaired endothelium mediated dilatation, together with 
increased NOX mediated generation of O2
- and an increase in excretion of peroxidated lipids 
(Tojo et al., 2002). Angiotensin II infusion also results in upregulation of transcription 
factors such as NFκB, and cytokines which disrupt normal redox homeostasis. Co-infusion 
with tempol ameliorates this, and prevents isoprostane excretion (Ding et al., 2015). 
There is also evidence of redox signalling involvement in the tubuloglomerular feedback 
mechanism, by which macular densa cells sense sodium delivery to the distal tubule and 
regulate glomerular pressure. Accordingly, in response to increased tubular sodium delivery, 
vasoconstriction is induced primarily in the afferent arteriole, resulting in reduced 
glomerular pressure and a reduction in single nephron GFR. Macula densa cells show high 
expression of NOX and neuronal NOS. Microperfusion of L-NAME into macular densa cells 
enhances tubuloglomerular feedback leading to increased afferent arteriolar vasoconstriction 
and further reduced glomerular pressure (Welch et al., 2000). This effect tends to occur only 
during salt delivery, and is absent when tubular sodium is reduced by loop diuretic, 
suggesting that NO is involved in regulation of tubuloglomerular feedback only during salt 
loading.   
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1.7.2 Progression of chronic kidney disease 
CKD has a tendency to worsen despite treatment of blood pressure and any other reversible 
or aetiological factors, and there is evidence that common pathological mechanisms are 
responsible for this irrespective of the original renal insult. The rate of progression of CKD 
is extremely variable, relating to clinical parameters such as blood pressure, proteinuria, age, 
and the presence of various comorbidities. It was shown decades ago, however, that 
progression of renal impairment shows stronger correlation with degree of tubulointerstitial 
atrophy and fibrosis than the extent of glomerular disease (Schainuck et al., 1970) . It is 
thought that tubular atrophy is a final common mechanism by which CKD progresses to 
ESRD, due to inflammation, infiltration by fibroblasts and mesenchymal to fibroblast 
transition of resident epithelial cells, ultimately leading to tubulointerstitial scarring and 
fibrosis (Kuncio et al., 1991).     
For example, it was shown using a rat remnant kidney model that progressive renal 
impairment was more closely associated with dissociation between remaining glomeruli and 
associated tubules, than with sclerosis of remaining glomeruli (Gandhi et al., 1998). 
Similarly, in scoring systems used to measure likelihood progression to ESRD in many 
glomerular diseases including IgA nephropathy, the degree of tubulointerstitial atrophy on 
kidney biopsy is a significant predictor (Roberts et al., 2009). A number of mechanisms have 
been suggested by which glomerular damage can be transmitted to the interstitium. 
Periglomerular tubules may be obliterated by proliferative changes in the glomerulus, whilst 
leakage of filtrate out of the glomerulus may deposit toxic compounds and proteins around 
tubular epithelial cells. This in turn can lead to protein reabsorption which causes release of 
lyosomal enzymes and ROS production. Additionally, injured tubular epithelial cells 
produce cytokines and transcription factors which recruit inflammatory cells and cause 
apoptosis of normal glomerular and tubular cells (Chevalier and Forbes, 2008).  
Dysfunction of the renal microvasculature is an important component of the tubulointerstitial 
injury which drives CKD, such that tissue hypoxia and ischaemia is a characteristic feature 
of CKD. Bohle et al showed peritubular capillary loss in a range of human glomerular and 
tubulointerstitial diseases, which was associated with the degree of renal impairment (Bohle 
et al., 1996). The degree of peritubular capillary rarefaction is correlated with degree of 
tubulointerstitial fibrosis, glomerulosclerosis, and degree of renal impairment (Choi et al.). 
Microvascular dysfunction may also result from RAAS induced vasoconstriction, and vessel 
occlusion by inflammatory infiltrate.   
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1.7.3 Oxidative stress in the progression of chronic kidney 
disease 
Given the role of redox signalling in vascular function, one may postulate that oxidative 
stress may have a pathophysiological role in progressive CKD, and this has demonstrated in 
studies using agents which manipulate redox homeostasis.  
For example, Baylis et al showed that chronic supplementation of L-NAME to rats with 
normal renal function caused proteinuria, renal impairment, and glomerular damage (Baylis 
et al., 1992). Furthermore, Ding et al showed that tempol ameliorated renal impairment in 
5/6 nephrectomised mice, reducing NFκB expression, TGF-β induced fibrosis, and tubular 
atrophy (Ding et al., 2015). Similarly, the serine protease inhibitor camostat mesilate 
attenuated renal impairment and tubulointerstitial fibrosis in a mouse model of CKD, partly 
by reducing expression of NOX components and scavenging hydroxyl radicals (Ueda et al., 
2015). Enhanced signalling via epithelial growth factor (EGF) has been shown to be one 
mechanism by which a number of pro-fibrotic pathways are activated, and EGF inhibition 
has been shown to ameliorate renal fibrosis and progressive renal impairment. EGF is 
activated by a number of stimuli including MAP kinases, which are themselves activated by 
ROS. Rhyu et al implicated ROS activated MAP kinase pathways in the renal fibrosis which 
occurs in a rat model or allograft nephropathy; at least part of the attenuating effects of ROS 
inhibition may occur through these mechanisms (Rhyu et al., 2005).  
1.8 Vascular effects of antioxidants  
1.8.1 Antioxidants and cardiovascular mortality in the general 
population 
Due to the contribution of oxidative stress to endothelial dysfunction, arterial stiffness and 
therefore cardiovascular risk, there has been great interest in the therapeutic use of 
antioxidants.  
Interest in the role of antioxidants in the prevention of CVD began in the 20th century when 
epidemiological data arose that showed reduced mortality in individuals with a high intake 
of fresh fruit and vegetables. In a retrospective study of regional variations of fruit and 
vegetable intake in the United Kingdom, Acheson et al found reduced cardiovascular 
mortality associated with a high intake of fresh fruit (Acheson and Williams, 1983), and in 
an analysis of the National Health and Nutrition Examination Survey I (NHANES I) cohort, 
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the relationship between reported ascorbic acid consumption and cardiovascular mortality 
in the United States in the 1970s was studied (Enstrom et al., 1992); standardised mortality 
rates were reduced to 0.41 – 0.78 in men and 0.55 – 0.99 in women. Early prospective cohort 
studies seemed to confirm these results, with a study of 11,178 participants from the 
Established Populations for Epidemiologic Studies of the Elderly cohort finding a relative 
risk of 0.58 for cardiovascular events associated with vitamin E supplementation (Losonczy 
et al., 1996). 
Later observational data was more equivocal. For example in the Health Professionals 
Follow-up study of 39,910 male health professionals in the United States there was no 
significant reduction in cardiovascular death associated with high ascorbic acid intake, but 
there was a relative risk of 0.63 associated with high intake of α-tocopherol (Rimm et al., 
1993), with the results echoed in the Multinational Monitoring of Trends and Determinants 
in CVD (MONICA) study (Tuomilehto et al., 1987). In the Rotterdam study, the rate of MI 
in previously healthy individuals was inversely correlated with beta-carotene intake, but 
there was no association with vitamin C and E intake (Klipstein-Grobusch et al., 1999). In 
NHANES I there was a reduction in all-cause mortality in individuals with the highest 
ascorbic acid intake, whilst in NHANES II there was increased mortality in men with the 
highest ascorbic acid intake and no association in women (Enstrom et al., 1992). In trials 
which used self-reported dietary intake to dichotomise patients into high and low intake, a 
small but statistically significant protective effect was found for α-tocopherol (OR 0.74; 95% 
confidence interval 0.66 – 0.83) and ascorbic acid (OR 0.89; 95% CI 0.79 – 0.99), but not 
β-carotene (OR 0.88; 95% CI 0.77 – 1.01). When plasma or serum levels were measured β-
carotene (OR 0.46; 95% CI 0.37 – 0.58) and ascorbic acid (OR 0.58; 95% CI 0.47 – 0.72) 
reduced cardiovascular events but α-tocopherol did not (Asplund, 2002). Aside from 
anything else, this shows confounding effect that dietary self-reporting can have on study 
outcome.  
Furthermore, the protective effects of antioxidant vitamins have not been confirmed in 
interventional studies, with a number of randomised control trials carried out with equivocal 
results. One meta-analysis showed that vitamin E supplementation did not reduce mortality, 
cardiovascular death or cerebrovascular accidents in comparison with control treatment, 
whilst in fact β-carotene supplementation resulted in a small increase in all-cause mortality 
(OR 1.07; 95% CI 1.02 – 1.11) and cardiovascular death (OR 1.1; 95% CI 1.03- 1.17) 
(Vivekananthan et al., 2003). Another meta-analysis found no reduction in the incidence of 
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CVD associated with β-carotene, α-tocopherol, or ascorbic acid supplementation. Another 
systematic review and meta-analysis including nearly a quarter of a million patients 
suggested that β-carotene, vitamin A and vitamin E supplementation may increase all-cause 
mortality, and ascorbic acid supplementation had no significant effect (Vivekananthan et al., 
2003).  
There may be a number of reasons behind this discrepancy. Bias may be incurred in 
observational studies due to unreliable self-reporting of nutritional intake, underreported 
supplement intake, and the association of high vitamin intake with ‘healthy lifestyle bundle’, 
including exercise and other beneficial habits, which is not replicated merely by 
supplementation with single or multi vitamins. Intake of fresh fruit and vegetables, which 
represents the major dietary source of antioxidant vitamins, may also provide less well 
recognised dietary antioxidants, or other beneficial substances, which would also be absent 
from a supplement intervention.  
However, individuals with a greater burden of oxidative stress may show greater response 
to antioxidants. A more rewarding approach may be to target individuals with high levels of 
oxidative stress who would also be expected to have a greater incidence of cardiovascular 
events, and represent a cohort where a treatment effect may easier to demonstrate over the 
short follow up period involved in a clinical trial. For that reason, patients with CKD 
represent an ideal cohort to target with antioxidant therapy.  
1.8.2 Antioxidant therapy in chronic kidney disease 
In animal models of CKD, there is some benefit to antioxidant supplementation in terms of 
biomarkers of oxidative stress as well as cardiovascular outcomes. Antioxidant (5000 
units/kg α-tocopherol) fortified feed given to 5/6 nephrectomised mice improves their nitric 
oxide bioavailability, nitric oxide synthase expression and blood pressure (Maranon et al., 
2013). Similarly, Dahl salt sensitive rats fed on a high salt plus N-acetyl cysteine diet had an 
enhanced glutathione system and attenuated markers of renal inflammation in comparison 
to a high salt diet alone (Tian et al., 2006).  
There is some evidence that antioxidant therapy is efficacious in patients with end stage renal 
disease receiving haemodialysis, with various studies demonstrating a reduction in markers 
of oxidative stress, improvements in blood pressure and iron handling, but with only limited 
evidence to suggest improvements in cardiovascular end points. For example, The 
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Secondary Prevention with Antioxidants of CVD in End-stage renal disease (SPACE) trial 
was a randomised control trial of vitamin E supplementation in 196 haemodialysis patients 
with a history of CVD (Boaz et al., 2000). The intervention comprised of 800 IU α-
tocopherol per day for 500 days. Patients assigned to the treatment arm had a markedly 
reduced rate of composite cardiovascular events (RR 0.46; 0.27 – 0.78), myocardial 
infarction (RR 0.3; 0.11 – 0.78) compared to placebo, but no reduction in overall mortality. 
Similarly, in another study of 134 haemodialysis patients, 1.2g N-acetylcysteine per day was 
found to reduce a composite cardiovascular event rate by 40% (Tepel et al., 2003). Daily 
supplementation with 500mg ascorbic acid was found to increase serum ascorbate 
concentration, aggravate hyperoxalaemia, and have no significant effect on cardiovascular 
outcome in an older study of haemodialysis patients (Ono, 1989).  
Data regarding the use of antioxidants in haemodialysis patients was recently reviewed 
systematically, and marked heterogeneity in intervention, dosage, and outcome measure 
were,  reducing the applicability of meta-analytical statistics (Coombes and Fassett, 2012). 
Only three of 56 studies examined an effect on clinical outcomes, with the remainder 
investigating effect on oxidative stress biomarkers. In most of the 53 studies included, most 
found that antioxidant supplementation reduced oxidative stress. Most conclusive was the 
evidence for α-tocopherol and N-acetyl cysteine. Ascorbic acid supplementation was found 
to increase serum ascorbate levels, and to decrease oxidative stress in 4 of the 11 studies in 
which it was included.  
Several criticisms of these studies have limited the adoption of such interventions into 
routine clinical practice: the number of patients involved was small and few of the studies 
examined changes in clinical end points, whilst the remainder examined an array of oxidative 
markers too heterogeneous to allow meta-analysis. The SPACE trial has been criticised for 
not including a control group comprised of healthy age matched participants, in order to 
confirm that oxidative stress is greater in the dialysis cohort and to allow a demonstration of 
the mechanism of action of α-tocopherol. The same criticism can be made of the other two 
interventional studies examining changes to cardiovascular end points; in neither was it an 
inclusion criterion that patients must have a demonstrable increase in oxidative stress in 
comparison to a group of healthy controls. 
Equivocal results have also been found in interventional studies of antioxidant therapy in 
patients with CKD not requiring dialysis. Oral N-acetyl cysteine supplementation was found 
not to reduce proteinuria, plasma homocysteine levels, or systolic blood pressure in 20 
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individuals with renal impairment and albuminuria (Renke et al., 2010). The effect of 8 
weeks of vitamin E supplementation was studied in a pilot study of eight patients and six 
controls (Saran et al., 2003). Whilst concentrations of ADMA were reduced, no significant 
reductions in F2-isoprostanes were noted. A prospective double blinded randomised control 
trial investigated the use of an antioxidant cocktail (mixed tocopherols and alpha lipoic acid) 
to reduce markers of oxidative stress in moderate renal impairment (CKD stages 3 and 4) 
(Ramos et al., 2011). No reduction in F2-isoprostanes, protein thiols, CRP, or IL-6 was 
observed after 2 months of treatment in comparison to placebo. 
A number of studies have investigated the use of ascorbic acid on ameliorating endothelial 
dysfunction and oxidative stress. Cross et al used plethysmography to measure the forearm 
dilator response to acetylcholine, and measured the dilator response to shear stress in 
brachial and radial arteries, before and after intra-arterial infusion of ascorbic acid in 33 
patients with CKD (Cross et al., 2003). An increase in the dilator response to acetylcholine 
of resistance vessels was seen after ascorbic acid, which was abrogated by NOS inhibition. 
No increase in FMD was observed in the brachial or radial arteries. Similarly, whilst 2g oral 
ascorbic acid was found to increase FMD in haemodialysis patients, no improvement in 
endothelial function was observed in patients with pre dialysis CKD. Conversely, in a study 
of 13 patients with kidney transplants, and a mean serum creatinine of 126 µmol/L, oral 
ascorbic acid was shown to reduce markers of oxidative stress and improve endothelium 
dependent vasodilatation (Williams et al., 2001). 
A Cochrane systematic review recently investigated the utility of antioxidant therapy in 
patients with CKD and ESRD (Jun et al., 2012). With regard to patients not receiving 
dialysis, no benefit was observed in a meta-analysis of studies investigating cardiovascular 
outcomes, however there were a limited number of studies included, and none of which used 
ascorbic acid used as the intervention. Further investigation into the use of antioxidants as 
therapy in CKD is sorely needed.  
1.8.3 Agonists of endogenous antioxidant systems 
Recently, novel therapeutics have been developed which manipulate intrinsic antioxidant 
systems such as Nrf-2. Bardoxolone methyl is a first in class semi-synthetic triterpenoid, 
which binds to Keap-1 cysteine residues, preventing its association with the transcription 
factor Nrf-2, allowing its translocation to the nucleus where it up regulates several 
antioxidant genes. In phase 1 studies, initially designed to investigate an anti-tumour effect, 
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bardoxolone was shown to increase eGFR, as well as increase antioxidant enzyme NQO1 
mRNA in peripheral monocytes (Hong et al., 2012). The phase 2 Bardoxolone Methyl 
Treatment: Renal Function in CKD/Type 2 Diabetes (BEAM) study investigated the change 
in eGFR after 24 – 52 weeks of bardoxolone treatment in 227 patients with diabetic kidney 
disease (Pergola et al., 2011). In the 75 mg dose group, eGFR improved by 11 
mL/min/1.73m2 compared to placebo, with the main adverse effects comprising muscle 
pains, liver enzyme disturbances, hypomagnesaemia and GI upset. There was therefore some 
excitement regarding the phase 3 Bardoxolone Methyl Evaluation in Patients with Chronic 
Kidney Disease and Type 2 Diabetes Mellitus: the Occurrence of Renal Events (BEACON) 
study (de Zeeuw et al., 2013), which sadly evaporated when it was terminated early by the 
independent safety monitoring committee due to increased cardiovascular event rate in the 
treatment arm. In the bardoxolone arm 96 patients were hospitalised or died from heart 
failure, compared to 55 in the placebo group (HR 1.83, 95% CI 1.32 – 2.55), whilst no 
difference was seen in the primary end point of progression to ESRD. Interestingly, eGFR 
was increased in the treatment arm, at the expense of an increase in albumin to creatinine 
ratio and blood pressure. Explanations for this unexpected outcome include diastolic cardiac 
dysfunction occurring secondary to selective inhibition of endothelin-1 A receptors, or 
endothelial dysfunction and arrhythmia occurring secondary to hypomagnesaemia, another 
side effect of the medication.  
The role of Nrf-2 agonists like bardoxolone, and more broadly of other modulators of 
endogenous antioxidant systems, remains uncertain.  
1.8.4 Adverse effects of antioxidant therapy 
Despite the lack of clarity as to the benefit of antioxidant supplementation, one might 
postulate that this therapeutic intervention may be recommended purely on the basis of an 
absence of harm. Certain evidence has accumulated over the decades of antioxidant research 
that this may not be the case, with a number of prospective trials demonstrating a potentially 
harmful effect.  
For example both the Heart Outcomes Prevention Evaluation – The Ongoing Outcomes 
(HOPE-TOO) study (Lonn et al., 2005), and the GISSI-Prevenzione study (Marchioli, 1999), 
demonstrated a higher risk of heart failure associated with α-tocopherol. Whilst HOPE-TOO 
found no increase in overall mortality in the group receiving 400 IU/day α-tocopherol, there 
was a significant increase in incidence heart failure and concomitantly no benefit in terms of 
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cardiovascular or malignant outcomes. The Alpha-Tocopherol, Beta-Carotene Cancer 
Prevention (ATBC) trial (Albanes et al., 1995) found that α-tocopherol supplementation 75 
IU/day increased mortality from haemorrhagic strokes, although with no overall increase in 
mortality; β-carotene surprisingly increased the incidence of lung cancer, ischaemic heart 
disease, and overall mortality. Subgroup analysis of ATBC found that hypertensives 
receiving α-tocopherol also had a higher incidence of subarachnoid haemorrhage than 
controls. Systematic review of the data found increased mortality associated with beta 
carotene, vitamin E and vitamin A.  
Ascorbic acid also has some associated dangers. In vitro, ascorbate undergoes Fenton 
reaction with transition metal ions which results in the production of hydroxyl radicals, 
suggesting that ascorbic may have pro-oxidant properties in certain circumstances. It 
remains unclear, however, if this is an important source of oxidants in vivo, given that the 
concentration of transition metal ions is kept low by binding proteins such as transferrin and 
caeruloplasmin. Some have suggested that Fenton chemistry does occur in vivo, but rather 
than act in a deleterious manner causing oxidative stress, the H2O2 produced might act in a 
beneficial manner as a vasodilating endothelium dependent hyperpolarising factor. Garry et 
al, found that both ascorbate and BH4 caused NO independent relaxation of rabbit iliac artery 
rings that was abolished by the addition of catalase, which removes H2O2 (Garry et al., 2009). 
This suggests that even pro-oxidant effects of ascorbic acid (and BH4) might enhance 
vascular function through the EDHF effect by generating H2O2. This highlights the complex 
nature of redox homeostasis in the EC endothelial cell, and demonstrates the importance of 
NO independent pathways in VSMC function.   
Oxalic acid is the terminal metabolite of ascorbate which is excreted in the urine and 
therefore ascorbic acid represents an oxalate load which will possibly increase serum or 
urinary concentrations of oxalate. High dose supplementation is therefore may not be 
desirable in the CKD population who already have a tendency towards high serum oxalate 
concentrations. There are case reports of nephrocalcinosis and systemic oxalosis occurring 
after ascorbic acid supplementation, but this has tended to occur at extreme dosages over 
several years (Yaich et al., 2014). Other studies have shown an increase in oxalate levels in 
CKD patients supplemented with ascorbic acid, but with no adverse outcomes occurring as 
a result.  
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1.9 Measuring oxidative stress and vascular function 
The half-life of ROS is very short, and in the case of O2-, measured in milliseconds, which 
renders their measurement in biological samples extremely challenging. Additionally, ROS 
are produced by a number of sources, and the relative contribution of these to total 
production varies between cell types and tissues. Finally, as has been discussed, as well as 
an increase in ROS production, oxidative stress is manifest by reduction in beneficial 
vascular signalling molecules such as NO, and by disturbance in redox signalling. As such, 
it may be more useful to measure the downstream products of oxidative stress such as the 
oxidation products of lipids, proteins, and other molecules, which have a longer half-life and 
are more widely distributed. Similarly, it may be more meaningful to measure the 
pathophysiological sequelae of oxidative stress, such as the effects on endothelial and arterial 
function. 
1.9.1 Biomarkers of oxidative stress 
1.9.1.1 Characteristics of a useful biomarker  
The National Institutes of Health Biomarkers Definitions Working Group defined a 
biomarker as a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention (Strimbu and Tavel, 2010). Biomarkers are often used as secondary 
endpoints or surrogate markers of clinical outcomes in interventional studies, especially 
when a change in clinical outcome is difficult to measure because of the sample size or 
duration of study required, or because an invasive or harmful investigation would be 
required. A useful biomarker should therefore have a strong association with clinically 
relevant outcomes. In the case of CKD this could include mortality, cardiovascular events, 
or worsening of renal function. A corollary of this is that a change in the risk of an outcome 
following an intervention or any other clinical development should be reflected by a change 
in the biomarker.  
1.9.1.2 Biomarkers of oxidative stress 
Oxidative stress is therefore a broad term encompassing alterations in signalling cascades as 
well as an increase in short lived radical species which are produced in a regionalised 
manner, and oxidative damage to downstream macromolecules. As such, a variety of 
methods have been used in the measurement of oxidative stress, and typically a panel of 
biomarkers is used in clinical studies. There remains no standardisation of the panel of 
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biomarkers which should be used however, and no single measure widely accepted to 
represent oxidative stress. The merits of different biomarkers of oxidative stress are 
discussed below.  
1.9.1.3 Measurement of oxidative damage 
Lipids have numerous double bonds which render them especially susceptible to oxidative 
modification. Arachidonic acid is a polyunsaturated lipid present in cell membrane bound 
phospholipids. Prostaglandins, involved in immune signalling, are produced from 
arachidonic acid by cleavage from membrane phospholipids by phospholipase, and 
subsequent metabolism by cyclooxygenase. Isoprostanes are prostaglandin like compounds 
which are produced by radical induced lipid peroxidation of arachidonic acid, independently 
of cyclooxygenase enzymes (Morrow et al., 1990). F2-isoprostanes are a group of chemicals 
produced in this manner and named according to their chemical similarity to prostaglandin-
F2α. They are formed in situ on the cell membrane, and cleaved by phospholipases to be 
released into the circulation. Concentration of F2-isoprostanes are not affected by the lipid 
content of the diet, nor confounded by hepatic or renal dysfunction, which improves their 
specificity as biomarkers of oxidative stress (Morrow, 2005). As well acting as a marker, 
isoprostanes may act as secondary messengers, exerting some of the deleterious effects of 
radical damage; isoprostanes reduce GFR and renal blood flow in rats, and cause 
vasoconstriction in other vascular beds including in the pulmonary and cerebral circulations 
(Takahashi et al., 1992). Isoprostanes also stimulate proliferation of endothelial cells (Yura 
et al., 1999), cardiac myocytes (Kunapuli et al., 1998), and cause platelet activation (Davı̀ et 
al., 1999), all of which may contribute to processes underlying atherosclerosis and CVD. A 
number of studies have linked isoprostane levels and cardiovascular outcomes. For example, 
in a cross sectional study of 2850 patients those with the highest quartile of F2-isoprostanes 
had a 24% greater likelihood of having detectable coronary artery disease on cardiac CT, 
even after adjustment for conventional cardiovascular risk factors (Gross et al., 2005). 
Similarly, in a cohort study of 108 patients who had suffered a myocardial infarction, levels 
of F2-isoprostane had predictive value for estimating 30 day cardiovascular events (LeLeiko 
et al., 2009).  
Another product of lipid peroxidation which has been studied for its role as a marker and 
indeed mediator of oxidant stress is malondialdehyde. Malondialdehyde is produced by 
degradation of polyunsaturated lipids by free radicals, and is elevated in the context of 
cardiovascular risk factors such as diabetes and smoking, and in the presence of coronary 
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artery disease (Ayala et al., 2014). Malondialdehyde may be measured directly using ELISA 
(Bevan et al., 2003), or by the colorimetric TBARS assay (Meagher and FitzGerald, 2000), 
which is somewhat less specific but more suitable to high throughput analysis. Much like 
isoprostanes, as well as being a marker of oxidative stress, malondialdehyde also acts as a 
mediator of oxidative damage; DNA damage can occur by its reaction with deoxyadenosine 
and deoxyguanosine, which forms potentially mutagenic DNA adducts (Dedon et al., 1998). 
Additionally, malondialdehyde reacts strongly with lysine residues, and these aldehyde 
lysine adducts have been found in apolipoprotein B present on the surface of oxidised LDL 
(Vanderyse et al., 1992). It has been postulated that this may be a mechanism which 
facilitates the interaction between oxidised LDL and macrophage, resulting in foam cells 
and the beginnings of atherosclerosis. In a study of 634 patients with coronary artery disease, 
patients with malondialdehyde in the highest quartiles had relative risk of 3.3 for major 
cardiovascular events over three year period, independently of cardiovascular risk factors 
and markers of inflammation (Walter et al., 2004). Similarly, in a study of 71 patients 
receiving maintenance haemodialysis for ESRD, malondialdehyde was an independent 
predictor of mortality (Scott et al., 2003). In another study of 76 dialysis patients, 
malondialdehyde was a predictor of prevalent CVD (Boaz et al., 1999). Conversely, in a 
study of 94 patients with CKD stages 3 – 5, whilst malondialdehyde rose progressively in 
proportion to renal impairment, it was not a predictor of outcome, nor of arterial stiffness or 
calcification (Terrier-Lenglet et al., 2011). These differences could be accounted for by 
methodological differences (for example measuring TBARS compared to direct 
measurement), by changes in malondialdehyde binding which occurs in haemodialysis 
patients (De Vecchi et al., 2009), or due to differences in the pathophysiology of CVD 
between the two populations.  
In states of oxidative stress, radical mediated DNA modifications occur which result in a 
number of oxidised end products. In a rat model which entails using carbon tetrachloride 
poisoning to induce oxidative stress, 8-hydroxy-2′-deoxyguanosine (8-OHdG) was elevated 
in a dose and time dependent manner, confirming its use as a biomarker of oxidative stress 
(Kadiiska et al., 2005). Urinary 8-OHdG has commonly been measured as a marker of DNA 
oxidation, although this marker is neither specific nor sensitive. For example 8-OHdG does 
not represent all DNA oxidation products, and may represent oxidation of the dinucleotide 
pool prior to its incorporation into DNA  
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1.9.1.4 Measurement of antioxidant capacity  
As discussed earlier, antioxidants may be enzymatic or non-enzymatic. The total antioxidant 
potential (TAP) of a biological sample can be measured which represents its non-enzymatic 
reducing potential, which results from the concentrations of ascorbic acid, tocopherol, urate, 
and bilirubin, amongst others. Several studies have shown a surprising increase in TAP in 
patients with CKD: in patients receiving haemodialysis, TAP is elevated in comparison to 
controls but falls following a dialysis session (Jackson et al., 1995), and in patients with 
CKD, TAP is unexpectedly higher than healthy volunteers (Karamouzis et al., 2008). This 
result is possibly due to accumulation of urate, the reducing effect of which is measured in 
the assay. As discussed earlier however, urate has both pro and antioxidant capacity in vivo 
and the increase in urate and other unmeasured solutes could compensate for other 
antioxidants which are reduced in CKD. The role of TAP in evaluating overall redox state 
is unclear, but has some merit as a marker of serum antioxidant status. Additionally, levels 
of the major antioxidant vitamins in blood can be measured, but it should be considered that 
the levels of ascorbic acid and α-tocopherol in plasma may not represent total body pools 
and utilisation.    
The major enzymatic antioxidants which have been used as biomarkers of antioxidant 
capacity are glutathione peroxidase and SOD. Glutathione peroxidase is an important 
enzymatic antioxidant which catalyses conversion of hydrogen peroxide to water, converting 
the essential cofactor glutathione (GSH) to its oxidised form glutathione disulphide (GSSG) 
in the process. The ratio of GSH to GSSG has been used as a marker of the availability of 
GSH to participate in this reaction and has therefore been used as a biomarker of antioxidant 
capacity. Whilst, glutathione (GSH) shows correlation with eGFR and is reduced in 
moderate and severe CKD, GSSG remains stable regardless of the severity of renal 
impairment (Ceballos-Picot et al., 1996). GSH:GSSG ratio is therefore reduced in CKD and 
accordingly, there is a reduction in both plasma and erythrocyte glutathione peroxidase 
activity associated with this. In patients with CKD GSH:GSSG ratio correlates with FMD 
demonstrating the effect of reduced antioxidant capacity on endothelial function (Annuk et 
al., 2001). 
1.9.1.5 Direct measurement of ROS and other radicals 
As already described, direct measurement of ROS proves challenging for a number of 
reasons. Firstly, ROS production is highly compartmentalised, such that an increase in ROS 
from a particular source might not be reflected by an increase in total ROS levels within a 
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biological sample. Additionally, ROS are reactive and have a short half-life which render 
them difficult to measure. Finally, the complexity of redox biology is such that measurement 
of ROS alone might not even be desirable, as measurement of the downstream effects of 
ROS such as macromolecule oxidation and endothelial dysfunction may prove more 
meaningful. That said, there are a number of methods by which ROS can be measured, each 
of which have advantages and disadvantages specific to the radical being measured and the 
nature of the biological sample in which it is contained. 
ROS can be measured by chemiluminescence techniques, whereby the luminescent probe is 
activated upon oxidation by O2
-. Luminol and lucigenin are permeable to the cell membrane 
and therefore measure both intra- and extracellular quantities of ROS. Fluorescent probes 
can also be used, some of which have the advantage of being able to be rendered cell 
membrane impermeable, such that precise intracellular sources of ROS can be investigated. 
For example, dihydroethidium is permeable through the cell membrane whereupon it reacts 
with ROS to form an impermeable fluorophore which can be measured by flow cytometry 
or fluorescence microscopy (Wardman, 2007).  
Electron paramagnetic resonance (EPR) spectroscopy is another method which directly 
measures ROS, or indeed any other radical species (Spasojevic, 2011). Spin is an inherent 
property of electrons, which produces an intrinsic magnetic moment. Most oxygen 
molecules have paired electrons but O2
- and other radicals have an unpaired electron which 
creates a magnetic moment which can therefore interact with a magnetic field. When 
exposed to a magnetic field, an unpaired electron will align itself either parallel or 
antiparallel to the field, such that unpaired electrons will have one of two possible energy 
states depending on the direction of its spin. Electrons can move between the two states by 
either absorbing or releasing a photon of energy. When another magnetic field of varying 
strength is applied the energy difference between the two states increases until it matches 
the energy of the microwave radiation being applied. At this point electrons can transition 
between energy states, and because most electrons begin in the lower energy state, a net 
absorption of energy will occur, and this absorption can be measured by a spectroscopic 
detector. Certain spectral parameters such as the g-factor are specific for a given radical 
species, and the signal intensity of the spectra is dependent on concentration, which allows 
identification and measurement of individual radicals. In the case of short lived radical 
species such as ROS, a “spin trap” is used, which is a compound which fixes the radical 
group in a stable condition whilst evoking a characteristic spectroscopy tracing. The benefit 
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of EPR is that specific radical species can be measured at very low concentrations; the 
disadvantage being the cost of the equipment and the expertise required.        
1.9.2 Measurement of endothelial function 
1.9.2.1 Flow mediated dilatation 
It was shown in 1980 by Furchgott et al that stripping rabbit aorta of endothelial cells 
abrogated the vasodilator effects of acetylcholine, confirming the obligatory role of the 
vascular endothelium in mediating this response (Furchgott and Zawadzki, 1980). Later, it 
was shown that nitric oxide synthase (NOS) inhibitors also diminished vascular smooth 
muscle cell response to acetylcholine, confirming nitric oxide (NO) as the endothelial 
derived factor responsible for this (figure 1.2) (Moncada et al., 1988). It had also been known 
that the vasodilator response to shear flow was endothelium dependent (Pohl et al., 1986), 
and thought to be mediated through NO via a number of flow sensitive cation channels on 
the endothelial cell surface (Cooke et al., 1991, Lansman et al., 1987). In 1994, it was 
proposed by Celermajer and Deanfield that measurement of the vasomotor response of 
peripheral conduit arteries to shear stress could be measured as a marker of NO 
bioavailability and endothelial function (Celermajer et al., 1992). Since then there has been 
further elucidation of the physiology of FMD and its clinical significance. 
1.9.2.2 Physiology of flow mediated dilatation 
Several intra and extracellular components of endothelial cells are involved in converting 
shear stress to a chemical signal directed towards vascular smooth muscle cells, in a process 
termed mechanotransduction, and which results in both rapid changes in vascular tone and 
longer term changes to vascular modelling. 
Wherever there is flow, a force is exerted onto the luminal surface at a vector perpendicular 
to its direction. On the cell membrane, shear stress results in opening of specific potassium 
channels resulting in cell membrane hyperpolarisation and calcium influx (Cooke et al., 
1991). Tyrosine kinase receptors such as vascular endothelium growth factor receptor 2 
(VEGFR2), are also directly activated due to changes membrane fluidity caused by shear 
stress (Jin et al., 2003). Caveolae are small lipid lined invaginations on the cell membrane 
which are rich in proteins involved in cell signalling. Shear stress induces release of ATP 
and eNOS into the endothelial cell cytoplasm either directly, and/or indirectly due to calcium 
influx associated with shear sensitive ion channels, resulting in activation of signalling 
cascades, tyrosine kinase receptors, and an increase in NO production (Isshiki et al., 1998). 
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Extracellular components are also involved in mechanotransduction. For example shear 
stress directly results in re-organisation of intercellular junction proteins, such as platelet 
endothelial cell adhesion molecule and vascular endothelial cadherin, which leads to integrin 
activation and subsequent activation of downstream signalling cascades (Tzima et al., 2005). 
Additionally, physical deformation of the cytoskeleton results in signalling through 
membrane associated ion channels, via association with focal adhesion molecules, and also 
by its association with the nuclear membrane which may represent a mechanism by which 
shear stress results in longer term changes in arterial modelling via changes in gene 
expression (Alenghat and Ingber, 2002). A number of signalling cascades are initiated 
thereafter by the manifold mechanotransduction sensor sites, including MAP kinase, NFκB, 
focal adhesion kinase, and protein kinase C (Johnson et al., 2011). 
The next step is to link these signalling cascades with vascular smooth muscle cell function, 
by release of endothelium derived vasodilators, including NO but also including other 
vasoactive factors such as prostaglandins and the EDHF. NO is produced at a basal rate by 
endothelial cells but production is increased in response to shear stress as evidenced by the 
alterations that can be induced with the use of nitric oxide synthase inhibitors. For example, 
a meta-analysis of 20 studies found that during conventional FMD, namely that induced by 
distal arterial occlusion for 5 minutes, infusion of the nitric oxide synthase (NOS) inhibitor 
N(G)monomethyl-L-arginine (L-NMMA) reduced brachial artery dilatation from 6.5% to 
0.9% (Green et al., 2014). eNOS activity is regulated by a number of mechanisms. Firstly 
under basal conditions eNOS is primarily reserved within caveolae however a number of 
stimuli, including shear stress, can induce eNOS release into the cytoplasm where it is able 
to produce NO (Mineo and Shaul, 2012). Secondly, eNOS activity is calcium sensitive and 
calcium influx occurs via a number of mechanisms during FMD as previously discussed. 
Finally, eNOS activity is regulated by phosphorylation by kinases such as Akt (Dimmeler et 
al., 1999) and protein kinase A (Boo et al., 2002) which are activated by FMD induced 
pathways. Shear stress also affects gene transcription, generally inducing an anti-atherogenic 
phenotype, with increased expression of genes affecting vasodilators, antioxidant systems, 
and antithrombotic substances, and reduced expression of adhesion molecules and 
inflammatory cytokines (Himburg et al., 2007). Expression of eNOS is also increased 
through activation of NFκB (Davis et al., 2004). In this manner shear stress results in longer 
term changes to arterial structure through activation of transcription factors and alterations 
in gene expressing, as well as inducing shorter term changes in vascular function through 
direct activation of vasodilator pathways.  
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The dilator response is not entirely NO dependent, however. It has previously been shown 
that dilatation following 15 minutes of vessel occlusion is not attenuated by L-NMMA 
(Mullen et al., 2001). Similarly, when arterial occlusion is proximal to the site where the 
diameter is measured (Doshi et al., 2001), or when hyperaemia is provoked by an ischaemic 
hand grip manoeuvre rather than vessel occlusion (Agewall et al., 2002), FMD is NO 
independent. These observations have the implication that from a physiological perspective, 
factors aside from NO are involved in the endothelial response to shear stress. Furthermore, 
from an investigational perspective, the other implication is that attention must be paid to 
FMD methodology if a purely endothelium derived NO response is to be measured. 
1.9.2.3 Clinical significance of flow mediated dilatation  
The use of FMD as a surrogate marker of CVD relies on the principle that endothelial 
function is a systemic property whereby dysfunction measured at a peripheral site correlates 
with that systemically, including the coronary vasculature. Close correlation has been shown 
between brachial and coronary artery dilatation following hyperaemia induced by infusion 
of adenosine triphosphate (ATP) (r= 0.78, p < 0.001) (Takase et al., 1998), which supports 
this assumption. As such, measurement of FMD at a site amenable to non-invasive 
assessment provides a means by which to detect and quantify the early stages of 
atherogenesis.  
The original Celermajer and Deanfield study demonstrated reduced vasodilatation in 
children and adults with vascular risk factors in comparison to healthy controls, and many 
studies since then have shown reduced FMD associated with other conventional risk factors. 
FMD measured in individuals with type 1 diabetes was reduced to 5.0 ± 3.7% in comparison 
to 9.3 ± 3.8% in controls, and was proportional to duration of diabetes and LDL cholesterol 
levels (Clarkson et al., 1996). Furthermore, lowering of LDL cholesterol either by apheresis 
(Tamai et al., 1997) or by HMG CoA reductase inhibitors (Stroes et al.) has been shown to 
improve endothelial function. In cigarette smokers, FMD was shown to be absent, or reduced 
to 4 ± 3.9% compared to 10 ± 3.3% in controls, with FMD reduced in a dose dependent 
fashion according to quantity and duration of smoking (Celermajer et al., 1993). Ageing has 
also been shown to associate with reduced endothelial function; in men FMD was preserved 
until the age of 40 years, after which there was a decline of 0.21% per year, whilst in women 
FMD was preserved until 50 years, and declined by 0.49% thereafter (Celermajer et al., 
1994).  
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As well as acting as a marker of burgeoning vascular disease, there is evidence for a 
prognostic significance of FMD in certain populations. A number of studies have shown a 
relationship between reduced FMD and future cardiovascular events or deterioration of 
disease in the context of coronary artery disease (Kitta et al., 2009), congestive cardiac 
failure (Meyer et al., 2005), and following coronary intervention (Patti et al., 2005) (where 
FMD predicts in stent restenosis). In contrast, the evidence supporting the prognostic 
significance in healthy individuals at low risk of CVD is equivocal. One study of 2264 post-
menopausal women without CVD found reduced FMD was independently associated with 
future events (Rossi et al., 2008), whilst another study found that FMD did not provide 
predictive power over established predictive models such as the Framingham risk score 
(Yeboah et al., 2009a). 
Kidney disease has also been shown to lower brachial artery reactivity, with FMD reduced 
from 5.7 ± 0.6% in healthy volunteers to 3.8 ± 0.3% in patients with CKD (Dogra et al., 
2006). FMD is reduced in a stepwise fashion in relation to the degree renal impairment 
(Yilmaz et al., 2006), with 8.97 ± 1.36% dilatation in controls compared to 6.71 ± 0.38% in 
CKD stage 3 and 5.97 ± 0.52% in stage 4. More recently, FMD has been shown to be an 
independent predictor of cardiovascular outcome in CKD (Yilmaz et al., 2011), with a near 
50% reduction in fatal or non-fatal events for each 1% increase in FMD.  
1.9.2.4 Other methods of measuring endothelial function 
Other techniques have been used to measure endothelial function, which can be classified 
according to whether they are invasive or non-invasive, and by which circulatory bed which 
they examine.  
Coronary endothelial dysfunction can be measured by invasive cardiac catheterisation; 
coronary artery diameter can be measured angiographically whilst coronary blood flow can 
be measured using flow Doppler (Hasdai et al., 1997). In this manner, endothelial dependent 
vasodilatation can be measured following infusion of acetylcholine and compared to 
endothelial independent vasodilatation measured following adenosine infusion. A study of 
157 patients undergoing coronary angiography found increased cardiovascular event rate in 
those with the most severe endothelial dysfunction (Suwaidi et al., 2000). Clearly however, 
the procedure is time consuming, costly, and invasive. Forearm venous occlusion 
plethysmography entails measuring change in forearm volume after intra-arterial infusion of 
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vasoactive substances (Mather et al., 2001), but again, the technique is invasive and time 
consuming.  
Microvascular function can also be evaluated non-invasively using either peripheral artery 
tonometry or laser Doppler flowmetry. In the former, digital blood volume is measured using 
bilateral finger probes at baseline and during reactive hyperaemia, stimulated unilaterally 
using a sphygmomanometer inflated to supra-systolic pressure (Rubinshtein et al., 2010). 
The reactive hyperaemia peripheral artery tonometry (RH-PAT) index is the ratio of digital 
pulse volume during reactive hyperaemia to a baseline measurement taken on the 
unstimulated limb, and is a marker of endothelial function which correlates with its 
measurement using invasive coronary techniques. It has been suggested however that the 
measured response is not entirely endothelium dependent however, and may be affected by 
other factors including the sympathetic nervous system. Additionally, the test has not been 
well validated in CKD in part because the use of both upper limbs may not be possible in 
this population due to the confounding effects of dialysis vascular access. Laser Doppler 
flowmetry uses a low powered laser to emit light which penetrates skin a short distance 
whereby it undergoes a Doppler shift when it is scattered by red blood cells within the 
microvasculature. The light will therefore comprise both shifted and unshifted blood, the 
distribution of which is dependent upon the number and velocity of red blood cells and 
therefore relates to microvascular flow (Swiontkowski, 1991). The drawback of this 
methodology is that microvascular function is measured only in a small portion of skin, 
which may not be representative of microvascular function elsewhere.   
1.9.2.5 Circulating biomarkers of endothelial dysfunction 
As well as directly measuring endothelial function in the ways described above, circulating 
markers of endothelial damage can also be measured. Examples of these molecules and cells 
which can be measured in blood as signals of endothelial cell damage are shown in table 1.1. 
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Biomarker 
Markers of EC damage and repair 
Endothelial progenitor cells 
Circulating Endothelial cells 
 Endothelial microparticles 
Adhesion molecules E-selectin 
 ICAM-1 
 VCAM-1 
Markers of EC activation von Willebrand factor 
 Tissue plasminogen activator 
 Plasminogen activation inhibitor-1  
Table 1.1 List of circulating markers of endothelial dysfunction. 
 ICAM = Intercellular adhesion molecule, VCAM = Vascular cell adhesion molecule, EC = Endothelial 
cell. 
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1.9.3 Evaluation of arterial function 
1.9.3.1 Measures of arterial remodelling 
Currently, assessment of arterial pressure in routine clinical practice is confined to 
measurement of peak systolic and end diastolic pressure by sphygmomanometry at the 
brachial pulse. These measurements provide only a limited summary of the arterial pulse 
wave however, and furthermore may not be an accurate representation of the pressure within 
central arteries. Given the complexity of the arterial wave form, a more comprehensive 
analysis may allow for a better understanding of the cardiovascular sequelae of disturbances 
in arterial function.   
As described in section 1.6, the arterial system has two closely related functions. Firstly, 
there is a conduit function, by which blood is delivered from the heart to peripheral tissues 
which is achieved largely due to the composition of peripheral arteries. Secondly, there is a 
cushioning or ‘Windkessel’ function, whereby the oscillatory flow produced by left 
ventricular contraction is converted to smooth flow delivered to peripheral vessels. This is 
largely achieved by the viscoelastic nature of the large, proximal arteries, whereby a fraction 
of the energy produced is systole is converted into potential energy within the elastic vessel 
walls, which recoil during diastole resulting in forward flow of blood reserved within the 
vessels. This has the effect of dampening peak systolic pressure and increasing end diastolic 
pressure, protecting tissue capillary systems from extremes of pressure. 
The effectiveness of this second function is dependent on the elasticity and structure of the 
vasculature. This elasticity can be described by a number of intimately related physical 
parameters (Oliver and Webb, 2003). For example, compliance describes the change in 
volume which occurs given a certain change in pressure, whilst elasticity, or stiffness, is the 
inversion of this; meaning the change in pressure which occurs at a given change in volume. 
Distensibility is the degree of stretch which occurs at a given pressure, whilst the elastic 
modulus is the opposite; the amount of pressure required to stretch the vessel to double the 
resting diameter. Elasticity is non-linear, as at low pressure, tension is borne within elastin 
fibres in the vessel wall, whilst at higher distending pressures stiffer collagen fibres and 
smooth muscle tend to bear this energy. Knowledge of the distending pressure, meaning the 
mean arterial blood pressure, is therefore required for interpretation of these stiffness 
parameters.  
Chapter 1 80 
 
Clinically, arterial stiffness is evaluated by measuring the velocity of the pressure wave 
through the arterial system, by analysis of the pressure wave, or by measurement of the 
diameter to pressure curve at a certain point of the vasculature. A number of systems are 
commercially available which facilitate non-invasive measurement of these parameters. 
1.9.3.2 Pulse wave velocity 
The pulse wave velocity (PWV) is the speed at which the arterial pulse wave is transmitted 
through the vasculature. In order to measure this, the pulse wave is analysed at two different 
places along the arterial tree, and the time delay between a particular moment of the pulse 
wave occurring at each of the two locations is measured, usually by timing against the R 
wave on an ECG. The carotid and femoral pulses are typically utilised, such that the 
technique measures the PWV along the aortic and aorto-iliac routes. The distance between 
the two points is measured as an estimate of the distance the pulse wave travels, and PWV 
is derived by the distance divided by the time. The Moens-Korteweg equation describes 
PWV as proportional to the square root of the elastic modulus such that a higher velocity 
equates to a higher degree of stiffness (Gosling and Budge, 2003). Given that this technique 
is in effect measuring aortic PWV, this provides information regarding the ability of the 
central arteries to distend with changes in pressure, such as those which occur during the 
cardiac cycle.   
PWV is raised with ageing, and in association with a number of cardiovascular risk factors 
including hypertension, obesity, diabetes, and dyslipidaemia (Gottsater et al., 2015). In 
patients with hypertension, a 5 m/s rise in PWV is associated with a more than doubled 
likelihood of mortality, after adjustment of other risk factors. PWV is also higher in CKD, 
has also been shown to rise in proportion to the degree of renal impairment. Furthermore, 
the CRIC study showed that PWV was independently associated with a variety of vascular 
outcomes in CKD including heart failure, cognitive impairment, and progressive renal 
impairment. In a study of 241 patients with end stage renal disease receiving maintenance 
haemodialysis, PWV was a significant independent predictor of outcome, with patients with 
the highest third of PWV at 5.9 times risk of a cardiovascular event and 5.4 times risk of 
death.   
1.9.3.3 Pulse wave analysis 
In addition to PWV, analysis of the central arterial waveform also allows assessment of large 
arterial function and stiffness.  The antegrade pressure wave generated during left ventricular 
Chapter 1 81 
 
systole encounters many points of bifurcation as it travels along the arterial tree away from 
the heart. Wave reflections are generated at these points of impedance mismatch, where flow 
exceeds capacity, and are propagated in a retrograde direction back towards the heart. The 
shape of the arterial waveform therefore results from the summation of forward and 
backward flowing waves. Given that the effect exerted by the reflections will vary depending 
on their timing relative to the antegrade pressure wave, this summation will differ at different 
sites along the vasculature, and the arterial waveform accordingly varies at different sites 
from central to peripheral arteries. At sites of bifurcation in peripheral arteries where the 
reflections are generated, reflected waves are in phase with the antegrade pressure wave, 
resulting in augmentation of systolic pressure. Wave reflections reach central arteries during 
diastole, augmenting diastolic pressure with the physiologically desirable result of 
improving coronary blood flow, without increasing systolic pressure. This, together with the 
Windkessel effect, reduces pulse pressure whilst optimising afterload (Nichols et al., 2008).  
Arterial stiffness influences the nature of the waveform by a number of mechanisms. Firstly, 
the amplitude of the pressure waveform is increased when the left ventricle ejects into stiff 
central arteries. Secondly, higher PWV results in earlier return of reflected waves to the 
central arteries, augmenting systolic rather than diastolic pressure. Additionally, the 
amplitude, as well as the timing of reflected waves, is also affected by the elasticity of small 
arteries. The degree to which peak systolic pressure is augmented by reflected waves is 
termed the augmentation index (Aix) and is used as a marker of arterial stiffness. In addition 
to the timing and amplitude of reflections, left ventricular ejection time will also affect the 
overlap of forward and backward waves, such that when ejection time is short, such as in 
tachycardia, reflected waves are more likely to return during diastole. Aix is often adjusted 
to a heart rate of 75 bpm for this reason (Safar et al., 2003).  
Conventionally, applanation tonometry is used to non-invasively evaluate the arterial 
waveform at a readily accessible peripheral site, typically the radial artery, and a transfer 
function is used to derive the central arterial waveform from this. Whilst PWA has good 
reproducibility in both healthy and unhealthy populations, the use of a generalised transfer 
function may result in systematic error. One study compared invasively measured central 
waveforms and those derived from radial PWA, and found that individualised transfer 
functions were only marginally superior to the use of a generalised transfer function, 
although Aix tended to be underestimated by the use of radial PWA (Segers et al., 2000). 
Other studies have found that adjustment of the transfer function by parameters such as 
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gender and the presence of vascular disease provides more accurate analysis of central pulse 
pressures (Hope et al., 2002).  
1.9.4 Renal blood flow 
1.9.4.1 Measuring perfusion 
Renal perfusion is a crucial component of normal renal function, being one of the main 
determinants of glomerular filtration rate and tissue oxygenation. Blood flow to the kidney 
arrives via the renal artery, which divides in turn into the segmental arteries, the interlobar 
arteries, and the arcuate arteries, before forming the afferent arterioles which supply 
individual nephrons. A portion of blood, termed the filtration fraction, is filtered through the 
glomerular membrane into the Bowman’s capsule, whilst the remainder enters the 
peritubular capillary system. Discrimination can be made between renal blood flow, which 
refers to the velocity of blood travelling through the vasculature measured in millilitres per 
minute, and perfusion, which refers to the quantity of blood delivered to the capillaries at 
the tissue level, measured in millilitres per minute per unit mass of kidney tissue.  
Measurement of renal haemodynamics may provide important biomarkers in health and 
disease, but this has been hindered in both research and clinical practice by inherent 
drawbacks of existing methodologies. Clearance techniques have conventionally been used 
to measure effective renal blood flow, with para aminohippuric acid (PAH) clearance being 
the gold standard. However, this process is labour intensive, time consuming, invasive and 
inappropriate for use in clinical practice or in large clinical trials. Furthermore, availability 
of PAH in the UK is limited due to debate as to whether it meets the legislative requirements 
regarding its transmissible spongiform encephalopathy status. Dynamic perfusion studies 
performed using CT or MR imaging both require administration of an exogenous contrast 
compound. In the case of CT, iodinated contrast agents are nephrotoxic such that they tend 
to be avoided in CKD, and the modality also carries a radiation burden. Dynamic contrast 
enhanced (DCE) MR allows measurement of renal perfusion using kinetics of a non-
diffusible paramagnetic tracer containing gadolinium, however these agents, while generally 
safe, are inappropriate for use in renal impairment due to concerns regarding an association 
with nephrogenic systemic fibrosis (Collidge et al., 2007). Nuclear scintigraphy also requires 
exposure to ionising radiation rendering it inappropriate for repeated use or in research. 
Arterial spin labelling magnetic resonance imaging (ASL MRI) is an emerging technique 
which utilises magnetically labelled water protons in blood as an endogenous contrast agent, 
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and as such represents a non-invasive method of measuring renal perfusion without exposure 
to ionising radiation or exogenous contrast agents. 
1.9.4.2 Arterial spin labelling magnetic resonance imaging 
During an ASL MRI acquisition, water protons in blood within the arterial in flow of the 
tissue undergoing interrogation are magnetically labelled by an inversion or saturation pulse 
and an image is acquired after a defined time delay which is equal to the arterial transit time. 
The labelled water exchanges with water in tissue to alter magnetisation, and thereafter the 
labelling decays over a time related to the local T1 longitudinal relaxation time. A control 
image is also acquired without the labelling, and subtraction of the control from the labelled 
image produces a signal difference which is related to blood flow (figure 1.3).  
 
Figure 1.3 Pictorial representation of arterial spin labelling MRI 
 
A quantitative measure of perfusion can be extrapolated from this using modelling extended 
from the Bloch equations (Roberts et al., 1995). The standard ASL kinetic model (figure 1.4) 
disregards arterial transit time and assumes that there is complete macromolecular saturation 
which occurs over a negligible time period. Other parameters must be known including λ, 
the tissue-blood partition coefficient (0.8 mL/g in kidney), the T1 longitudinal relaxation 
time, and M0, the equilibrium magnetisation, in addition to ΔM, which is signal difference 
between the labelled and control images, at inversion time TI. Perfusion, f, is then 
determined by the equation (Martirosian et al., 2004):   
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Figure 1.4 The ASL standard kinetic model. 
By measurement of the ASL signal, in addition to T1 and M0, renal perfusion can be quantified. TI = 
Inversion time, λ = Tissue-blood partition coefficient, M0 = Equilibrium magnetisation, ΔM = ASL 
signal, T1 = T1 longitudinal relaxation time 
In reference to the earlier discussion of the differences between renal perfusion and blood 
flow, the ASL signal is produced by alteration of tissue magnetisation by labelled water 
protons in blood, and is therefore a true measure of perfusion: delivery of blood at the tissue 
level.  
The ASL signal has inherently low signal to noise ratio (SNR), such that a number of image 
acquisitions are performed to produce several subtractions, the average of which is used to 
measure perfusion. This has the drawback that a number of labelled and control images must 
be registered together such that motion artefact can confound the acquisition of the eventual 
perfusion map. A number of techniques have been used to minimise this problem including 
respiratory gating, breath holding, and automated post processing strategies. On the other 
hand, an advantage of ASL is that the half-life of the labelling is measured in milliseconds, 
so the technique can be repeated infinitely even over short time periods; in comparison, 
gadolinium contrast used in DCE MRI has a half-life of hours and accurate perfusion 
measurements cannot be made until the tracer is cleared. 
1.9.4.3 Validation of arterial spin labelling MRI  
ASL MRI has been validated in animal models and phantoms against a number of 
techniques. In a study of 11 swine, ASL MRI was compared to perfusion measured using a 
microsphere technique (Artz et al., 2011b). Fluorescent microsphere probes were infused 
into the left ventricle, and measured in renal cortical tissue at different time points and 
following a number of interventions designed to modify kidney perfusion. ASL MRI showed 
strong correlation with the microsphere technique (r = 0.81, p < 0.0001), albeit 
underestimating perfusion measurements at lower values. This agreement persisted during 
manipulation of renal blood flow by fluid bolus, cooling, and administration of acetylcholine 
or isofluorane. Similarly, ASL MRI was validated in explanted porcine kidneys undergoing 
haemoperfusion with whole blood at a number of flow rates (Warmuth et al., 2007b). There 
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was good agreement between the measurements made by ASL MRI and by the reference 
values, with the values differing by a maximum of 13%.  
1.9.4.4 Arterial spin labelling MRI in humans  
Similarly, in healthy volunteers and in certain disease cohorts ASL MRI has been validated 
against other methods of measuring renal blood flow. For example, Ritt et al determined 
renal perfusion using ASL MRI and compared these measurements with renal plasma flow 
measured using PAH clearance, in 24 patients with metabolic syndrome, before and after 2 
weeks of therapy with telmisartan (Ritt et al., 2010). The baseline measurements of perfusion 
made by the two methods showed moderate correlation (r = 0.575), as did the measured 
change in perfusion following ARB treatment (r = 0.548, p = 0.015). Similarly, Cutajar et al 
compared renal blood flow measured using ASL MRI with DCE MRI, and found reasonable 
agreement between the two techniques (Cutajar et al., 2014). 
Additionally, the use of ASL MRI has been studied in certain disease cohorts. In a study of 
12 patients with renal artery stenosis and 6 healthy volunteers, ASL MRI was able to 
discriminate severe stenosis from moderate, mild, or no renal artery stenosis (Fenchel et al., 
2006). In a small study of patients with early CKD stages 2 -3, with a mean inulin clearance 
of 69 mL/min, renal blood flow was reduced (Rossi et al., 2012), and similarly, in a 
transplant population, reduced renal blood flow was observed in patients suffering from 
acute transplant dysfunction manifest as a deteriorating eGFR (Lanzman et al., 2010). 
Studies of ASL MRI in human participants are summarised in table 1.2.  
Nevertheless, there has been little investigation into the use of ASL MRI in patients with 
CKD stages 3 – 5. Furthermore the application of ASL MRI into wider use, either in routine 
clinical practice or as a surrogate marker of renal function in trials of novel therapeutics, has 
been limited, hindered by lack of standardisation in acquisition technique, image sequence, 
and post processing strategies. 
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Author Journal Year ASL 
 
Field 
strength 
Population & number Perfusion (mL/min/100g) 
Whole kidney Cortex Medulla 
(Breidthardt 
et al., 2015) 
Eur. Radiol. 2015 FAIR 1.5T HF eGFR < 60 mL/min/100g (n=10) 
HF eGFR > 60 mL/min/100g (n=10) 
Age matched HV (n=10) 
HV < 40 years (n=10) 
 
 146 ± 50 
171 ± 31 
274 ± 65 
278 ± 59 
 
(Heusch et 
al., 2014) 
J. Magn. 
Reson. 
Imaging 
2013 FAIR True FISP  
 
 
 
 
1.5T & 3T Kidney transplant 
eGFR > 30 
eGFR < 30 
 
282.7 ± 60.8 
178.2 ±63.3 
  
(Rossi et al., 
2012) 
 
 
 
Invest. 
Radiol. 
2012 FAIR True FISP 3T HV (n=8) 
CKD (mean eGFR 69 ± 12 mL/min 
by inulin clearance) (n=9) 
 
301 ±  51 
 
244 ± 77 
329 ± 52 
 
263 ± 81 
 
(Artz et al., 
2011a) 
Magn. 
Reson. 
Imaging. 
2011 FAIR b-SSFP 1.5T HV (n=5) 
CKD (n=5) 
Kidney transplant with  
eGFR > 60 mL/min/1.73m2 (n=5) 
Kidney transplant with eGFR < 60 
mL/min/1.73m2 (n=10) 
 
 
 
427 ± 20 
225 ± 85 
314 ± 41 
 
235 ± 91 
85 ± 33 
60 ± 23 
37 ± 21 
 
36 ± 14 
(Lanzman et 
al., 2010)  
Eur. Radiol. 2010 FAIR True FISP 1.5T  Kidney transplant with stable 
function (n=6) 
Recent kidney transplant (n=7) 
Acute transplant dysfunction (n=7) 
 
 
 
 
 
304.8 ± 34.4 
 
296.5 ± 44.1 
181.9 ± 53.4 
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(Fenchel et 
al., 2006) 
Radiology 2006 FAIR True FISP  1.5T Patients with RAS (n=12) 
 
 
 
 
HTN but no RAS (n=6) 
 
 
Asymmetry of perfusion values 
Significant differences between perfusion 
in kidney with high grade compared to no 
or low grade RAS 
 
243 ± 59 
 
 
 
 
 
323 ± 79 
 
 
 
 
 
113 ± 22 
 
(Michaely et 
al., 2004) 
Invest. 
Radiol. 
2004 FAIR HASTE 1.5T CKD (renovascular or other 
aetiology) (n=46) 
Not quantified but reduced ASL signal on 
semi- quantitative analysis  
 
  
(Ott et al., 
2013) 
CJASN 2013 FAIR True FISP 1.5T HTN, before and after renal 
denervation (n=19) 
 
 
256.8 (IQR 241 – 278)   
(Schneider 
et al., 2012) 
CJASN 2012 FAIR True FISP 1.5T HTN, before and after 4 weeks of 
oral  aliskiren therapy (n=34) 
 
272 ±25   
(Ritt et al., 
2010) 
NDT 2010 FAIR True FISP 1.5T Males with metabolic syndrome 
before and after 2 weeks of oral 
telmisartan therapy (n=24) 
253 ±20   
(Cutajar et 
al., 2014) 
 
Eur. Radiol. 2014 Multi TI FAIR 3D 
GRASE 
 
1.5 T HV (n=16)  263± 41 
 
 
 
(Gillis et al., 
2014a) 
 
BMC 
Nephrol. 
2014 FAIR True FISP 
 
 
3 T HV (n=12) 229 ± 41 327 ± 63  
(Park et al., 
2013) 
Magn. 
Reson. 
Imaging. 
2013 Pseudocontinuo
us ASL 
3T HV (n=1)  
 
 
320 
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(Wang et al., 
2012) 
Acad. 
Radiol. 
2012 FAIR SSFSE 3T HV, before and after intravenous 
furosemide (n=11) 
 
 366.6 ± 41.2 
 
 
 
118.59 
 
 
(Cutajar et 
al., 2012) 
MAGMA 2012 Multi TI FAIR 3D 
GRASE 
1.5T HV (n=20) 147 ± 30.8 178 ± 40.7  
 
 
 
(Gardener 
and Francis, 
2010) 
 
Magn. 
Reson. 
Imaging. 
2010  
FAIR True FISP 
SE-EPI with & 
without BS 
1.5T HV (n=9) 
FAIR TRUE FISP 
SE-EPI with BS 
SE EPI without BS 
 
 
 
 
 
 
 
367 ± 50 
284 ± 75 
334 ± 65 
 
103 ± 27 
139 ± 55 
122 ± 48 
(Kiefer et al., 
2009) 
Acad. 
Radiol. 
 
2009 FAIR TrueFISP 3T HV (n=11)  245 ± 11 109 ± 5 
(Karger et 
al., 2000) 
Magn. 
Reson. 
Imaging. 
2000 FAIR UFLARE 1.5T HV (n=10) 213 ± 55   
Table 1.2. Human studies in arterial spin labelling MRI.  
Perfusion measurements are displayed as mean ± standard deviation unless otherwise stated. Studies are grouped by nature of cohort. TI = inversion time, FAIR = flow sensitive 
inversion recovery, GRASE = gradient and spin echo, FISP = fast imaging with steady state precession, SSFSE = single shot fast spin echo, SSFP = single shot free precession, 
spin-echo echo planar imaging, BS = background suppression, HASTE = half Fourier acquisition single shot turbo spin echo, UFLARE =  ultra-fast low angle rare, T = Tesla, HF 
= heart failure, HV = healthy volunteer, HTN = hypertensive, CKD = chronic kidney disease, RAS = renal artery stenosis, eGFR = estimated glomerular filtration rate.  
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1.10 Hypothesis and aims 
1.10.1 Oxidative stress in chronic kidney disease 
In summary then, CKD is a state characterised by oxidative stress, with endothelial and 
vascular dysfunction ensuing as a result, together with disturbance in renal haemodynamics 
that may play a role in the pathophysiology of the presence and progression of kidney 
disease. Antioxidant administration may ameliorate the oxidative stress which results from 
CKD and as a result improve endothelial and vascular function, and enhance renal 
haemodynamics.  
1.10.2 Aims 
The aims of this thesis are as follows: 
1. Characterise a population of patients with CKD in comparison with a control 
population matched for age, blood pressure, and other cardiovascular risk factors, in 
terms of baseline markers of oxidative stress and vascular function.  
2. Determine the effect of administration of ascorbic acid on the oxidative status and 
vascular function in CKD, in comparison to its effects on individuals with normal 
renal function.  
3. Establish a robust and accurate method for evaluating renal blood flow non-
invasively.  
4. Characterise a population of patients with CKD in comparison with a control 
population in terms of renal perfusion and other MRI parameters. 
5. Determine the effect of administration of ascorbic acid on renal perfusion in CKD, 
in comparison to its effects on individuals with normal renal function. 
90 
 
 
  
Methods 
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2.1 Study design 
2.1.1 Oxidative stress in Chronic Kidney Disease 
2.1.1.1 Participant recruitment  
Patients with chronic kidney disease were recruited from general nephrology and peritoneal 
dialysis (PD) clinics associated with the Glasgow Renal and Transplant Unit in the New 
Victoria and Stobhill Hospitals. A control group consisting of subjects with hypertension 
and normal renal function was recruited from the tertiary referral professorial hypertension 
clinic at the Western Infirmary Glasgow. Participants were excluded if they had diabetes, 
renovascular disease, or had active liver disease or infection. Participants were also excluded 
where there was a history of vitamin C supplementation, renal stone disease, or systemic 
oxalosis, given the oxalate loading associated with ascorbic acid (Baxmann et al., 2003). All 
patients gave written informed consent and the study was approved by the West of Scotland 
Research Ethics Committee. The study was carried out in concordance with the Declaration 
of Helsinki and is registered with a clinical trials registry (ISRCTN 31272864) (Levey et al., 
2009). 
2.1.1.2 Study protocol 
Participants attended at the same time of day after an overnight fast. A control infusion of 
100mL 0.9% normal saline was administered over 10 minutes, and after a further 10 minutes, 
phlebotomy was performed. After this assessments of arterial stiffness and endothelial 
function were carried out as described below. An intravenous infusion of 2000 mg ascorbic 
acid in 100mL 0.9% normal saline was then given over 10 minutes, and after 10 minutes 
phlebotomy was repeated, and the same assessments of arterial stiffness and endothelial 
function carried out. Phlebotomy was carried out for the third time 1 hour after 
administration of ascorbic acid. 
2.1.1.3 Biochemical measurements 
Baseline measurements were made of urea, creatinine, cholesterol, lipid subfractions, 
glucose, CRP, albumin, calcium and phosphate, and urinary protein quantification. The 
estimated glomerular filtration rate (eGFR) was calculated from serum creatinine using the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. 
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2.1.1.4 Measures of oxidant stress 
Blood samples were taken via an intravenous cannula contralateral to the infusion arm after 
the control infusion of saline, immediately after ascorbic acid administration, and 1 hour 
after ascorbic acid administration. A panel of markers of oxidative stress were measured, 
including total antioxidant potential (TAP), serum ascorbic acid concentration, ADMA, F2-
isoprostanes, and the ratio of glutathione (GSH) to its oxidised equivalent glutathione 
disulphide (GSSG). Electron paramagnetic resonance (EPR) spectrometry was also used to 
measure the rate of O2
- production. The protocol for sample collection and processing is 
described in appendix 4. 
2.1.1.5 Vascular function tests 
Flow mediated dilatation and SphygmoCor® pulse wave analysis was performed as 
described in sections 2.2 and 2.3 respectively.  
2.1.1.6 Statistics  
Results are displayed as mean ± standard deviation, unless otherwise stated. Between group 
data were compared using a two tailed Student’s t test or Mann Whitney U test where data 
were non-parametrically distributed. For related data, a paired samples Student’s t test, or 
Wilcoxon’s test was used.  P values < 0.05 were considered significant. The relationship 
between the change in ADMA following ascorbic acid and eGFR was examined via stepwise 
multiple linear regression analysis, with inclusion of variables at p values less than 0.05. A 
one-way analysis of variance (ANOVA) was performed in a subgroup analysis, to compare 
the change in vascular function and oxidative stress parameters between the HTN, CKD and 
PD groups. All statistical testing was performed using SPSS Version 22.0 (IBM, Armonk, 
NY, USA). 
2.1.2 Renal Arterial Spin Labelling Magnetic Resonance Imaging 
in Healthy Volunteers 
2.1.2.1 Study design and patient recruitment 
Healthy volunteers were recruited via local advertisement. Subjects attended on three 
occasions; firstly for clinical assessment and sampling of blood and urine, followed by ASL 
MRI performed during the second and third visits. Participants were fasted for 6 hours prior 
to imaging. All visits were completed within 4 – 28 days. All subjects gave written informed 
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consent and the study was approved by the College of Medicine, Veterinary and Life 
Sciences University of Glasgow Ethics Committee.  
Baseline serum biochemistry and haematology measurements and urinary protein and 
creatinine quantification were obtained at initial visit. Estimated glomerular filtration rate 
(eGFR) was calculated using CKD–EPI formula (Levey et al., 2009). The full methodology 
behind the ASL MRI sequence employed is described in section 2.4. 
2.1.2.2 Statistics 
Results are expressed as mean ± standard deviation. Comparison of renal perfusion between 
right and left kidney, and ASL MRI 1 and 2, were made using paired Student’s t tests with 
p < 0.05 deemed to demonstrate significant differences between methods. Pearson 
correlation coefficients were used to determine correlation between MRI measurements, and 
between MRI measurements and serum and urine parameters. Bland Altman plots were 
made of the mean perfusion values against the difference between the values, with the 95% 
limits of agreement calculated as the mean difference plus or minus 1.96 times the standard 
deviation of the difference. Repeatability was also assessed using intra-class correlation 
(ICC), which measures the contribution of between subject variances to total variance. ICC 
lies between zero and one, with values closer to one indicating a stronger agreement between 
measurements. A two way random effect model was used with a 95% confidence interval. 
The within subject coefficient of variance (CVws) is also expressed, which represents the 
ratio of the standard deviation of the differences between visits to the mean of all the 
perfusion measurements. Values closest to zero suggest good agreement between 
measurements. SPSS Statistics Version 19 was used for data analysis (IBM, Armonk, New 
York, USA).   
2.1.3 Renal Arterial Spin Labelling Magnetic Resonance Imaging 
in Chronic Kidney Disease 
2.1.3.1 Patient recruitment 
Patients with CKD were recruited from the general nephrology clinic at the Glasgow Renal 
and Transplant Unit, whilst healthy volunteers (HV) were recruited via local advertisement. 
All subjects gave written informed consent and the study was approved by the West of 
Scotland Regional Ethics Committee. The study is registered with a clinical trials database 
(ISRCTN 12301736) and was carried out in compliance with the Declaration of Helsinki.  
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2.1.3.2 Baseline biochemical measurements 
Baseline serum and urine samples for biochemistry and haematology analysis were obtained. 
eGFR was calculated from the measured serum creatinine using the CKD-EPI formula. 
Historical biochemical measurements were taken from the electronic patient record (SERPR, 
VitalPulse, UK). Proteinuria was measured using a spot protein to creatinine ratio (PCR) 
from a random urine sample. 
2.1.3.3 Study protocol in healthy volunteers 
Participants attended for clinical and biochemical assessment, and underwent ASL MRI 
according to the protocol described in section 2.4. 
2.1.3.4 Study protocol in chronic kidney disease 
After clinical and biochemical assessment, participants were cannulated in the left 
antecubital fossa. 100 mL of normal saline was administered and the first ASL MRI was 
performed. The participant remained in situ within the scanner, whilst 2000 mg of ascorbic 
acid in 100 mL of normal saline was administered intravenously. After 20 minutes, a second 
ASL MRI scan was performed.  
2.1.3.5 Statistics 
Results are expressed as mean ± standard deviation. T1 time and perfusion were measured 
in cortical and whole kidney ROIs, and ASL measurements are expressed by unit of mass 
(100 g) which is typical in the standard kinetic model. Whole kidney perfusion was factored 
with renal volume to give total kidney perfusion. Between group differences in T1 time, 
CMD, and perfusion were evaluated using Student’s t tests. Changes in perfusion before and 
after administration of ascorbic acid were assessed with a paired Student’s t test. Evaluation 
of correlation between MRI measurements and serum and urine biochemistry parameters 
was performed using Pearson’s correlation coefficient. Throughout, p values < 0.05 were 
deemed significant. Data were analysed using IBM SPSS Statistics version 22.0 (IBM, 
Armonk, New York, USA). 
2.2 Flow mediated dilatation 
2.2.1 Brachial artery ultrasound 
Subjects were supine with the upper limb held at 90o abduction at the level of the heart and 
held in situ within a semi-cylindrical frame, with the ultrasound transducer stabilised using 
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a pneumatic probe holder (figure 2.1). An inflatable cuff was positioned on the forearm, at 
least 10 cm distal to the recording site. Longitudinal recordings of the brachial artery were 
taken using 7MHz ultrasound transducer and a Siemens Accuson Sequoia ultrasound system 
(Siemens AG, Erlangen, Germany). Recordings were ECG gated with image capture 
occurring simultaneous with the R wave. A baseline recording was made for 2 minutes prior 
to cuff inflation. The cuff was inflated to 240 mmHg for 5 minutes. Following cuff release, 
a 5 minute recording was made. Endothelium independent vasodilatation was then measured 
using glyceryl trinitrate (GTN). Firstly, a second baseline measurement was made for 2 
minutes, before 25 micrograms of sublingual GTN was administered and a further 5 minute 
recording made. Brachial artery ultrasound was performed by the same operator on each 
occasion. 
This protocol was performed in adherence to the 2002 guidelines (Corretti et al., 2002) and 
recent update (Thijssen et al., 2011) regarding measurement of FMD, with the intention of 
measuring a purely endothelium dependent NO response. A brachial artery approach was 
used as endothelial function at this site has previously been shown to have close correlation 
with the coronary vasculature. ECG gated recordings were made in order to minimise the 
variability occurring during the cardiac cycle, and image capture at the end of diastole 
reduces the effect of vasculature compliance on arterial diameter. Peak brachial arterial 
diameter typically occurs within 180 seconds in healthy volunteers, but a 5 minute recording 
was made in order to capture peak FMD in the CKD cohort, which occurs later in patients 
with endothelial dysfunction (Black et al., 2008). As previously discussed, placement of the 
cuff distal to the recording site is more specific for a NO specific response. Response to GTN 
was measured in order to evaluate endothelium independent dilatation.  
  
Chapter 2 96 
 
 
 
 
Figure 2.1 Flow mediated dilatation measured using brachial artery ultrasound. 
A pneumatic probe holder and cylindrical limb rest is used to position the participant (A). Image analysis 
was then performed off line (B) using dedicated software utilising edge detection and tracking 
functionality. 
2.2.2 Image analysis 
Computer assisted analysis was carried out off line using dedicated edge detection and wall 
tracking software (Brachial Analyzer 5, Medical Imaging Applications LLC, Iowa, 
USA)(figure 2.1). The use of automation in FMD analysis has been shown to significantly 
improve accuracy (Woodman et al., 2001) and reduce intra-observer and inter-institution 
variability (Sonka et al., 2002). Baseline diameter is the mean diameter of the brachial artery 
measured over the 2 minute recording. The time point of the peak dilatation occurring 
following either cuff release or GTN was found, and peak diameter was taken as the mean 
of the measurements immediately before and after this. Degree of dilatation has been shown 
to be significantly and negatively correlated with baseline diameter; with larger vessels 
exhibiting proportionally less dilatation than smaller vessels. As such, FMD is expressed 
both as a proportion to baseline diameter as is conventional, as well as an absolute 
measurement, which has been proposed as a solution to this confounder (Atkinson et al., 
2013).  
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2.3 Arterial stiffness 
Arterial remodelling was evaluated using the SphygmoCor® Vx system (AtCor Medical, 
Sydney, Australia) of applanation tonometry, which allows measurement of Aix and PWV, 
as well as measurement of central blood pressures via a Fourier transformation. The 
theoretical basis for this has already been discussed in section 1.9.3 and subject preparation 
is discussed in section 2.1.1. 
Patients were semi-recumbent for 10 minutes prior to measurement, and ambient 
temperature was controlled at 21 – 23 oC. Three lead electrocardiogram (ECG) monitoring 
was performed throughout. Pulse wave analysis is confounded by arrhythmia such as atrial 
fibrillation and significant aortic valve disease, and the presence of this was assessed during 
clinical evaluation and ECG monitoring. All measurements were taken by the same trained 
investigator.   
2.3.1 Augmentation index 
Augmentation index was measured at the radial artery with the wrist in dorsiflexion. A 15 
second recording was obtained when a satisfactory waveform tracing was obtained. 
Waveforms were assessed for quality and consistency as shown in figure 2.2. The analysis 
software provides an operator index, which is a quality control rating comprised of a number 
of individual accuracy indices (average pulse height > 100 units, pulse height variation < 
5%, diastolic variation < 5%, shape variation < 5%). Measurements were deemed 
satisfactory if the operator index was greater than 85%.  
As described in section 1.9.3, peripheral waveforms are converted to a central waveform by 
a standardised Fourier transformation, and Aix is corrected to a heart rate of 75 bpm to derive 
the adjusted Aix. Three measurements of Aix@75bpm were made and an average was taken.  
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Figure 2.2 The SphygmoCor® system. 
Pulse wave analysis (A) and measurement of pulse wave velocity (B). 
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2.3.2 Central blood pressure 
Central blood pressure is derived from the central pulse wave which is constructed by 
transformation of the measured radial pulse wave. Peak systolic pressure, lowest diastolic 
pressure, and mean arterial pressure were measured.  
2.3.3 Pulse wave velocity 
Firstly the distances between the left carotid pulse and sternal notch, and between the sternal 
notch and the right femoral pulse via the umbilicus, were measured in millimetres. The 
SphygmoCor® system uses a subtraction method to calculate length, which represents the 
distance in the vasculature between the two pulses. Pulse wave analysis was then performed 
at the left carotid and right femoral pulses. The time between the R wave of the ECG and 
the upstroke of the arterial waveform was measured at each pulse. The difference between 
the proximal pulse upstroke and the distal pulse upstroke was calculated as the transit time. 
Velocity was then calculated as the distance travelled in metres divided by the transit time 
measured in seconds. PWV therefore represents a direct measurement of aortic pulse wave 
velocity. 
A 15 second recording was made, and SphygmoCor® calculates a PWV for each cardiac 
cycle within the recording and provides the mean and standard deviation. Measurements 
were deemed acceptable if the standard deviation was less than 10% of mean PWV. Three 
PWV recordings were made, and an average was taken (figure 2.2).  
2.4 Arterial spin labelling magnetic resonance imaging 
2.4.1 ASL MRI method development 
ASL MRI was performed using a Siemens work-in-progress sequence. Prior to the studies 
described here, there was little experience in the use of the method in the institute, 
necessitating an extensive period of method development prior to the conduct of clinical 
studies. This entailed the evaluation of different sequence parameters, breathing strategies, 
and imaging planes by scanning in-house volunteers in order to optimise image acquisition 
and data capture, whilst minimising scan time and participant inconvenience. Ultimately the 
sequence described below was found to obtain the clearest anatomical images and allow 
measurement of ASL signal. 
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2.4.2 Acquisition protocol 
The principles behind ASL MRI were described in section 1.9.4. Briefly, an inversion pulse 
is used to alter the spin of protons in blood proximal to a tissue of interest. An image is taken 
of the tissue before and after application of the inversion pulse and the subtraction of the two 
equates to a contrast image. Quantification of perfusion from this ASL contrast signal is also 
dependent on the T1 relaxation time of tissue, the tissue-blood partition coefficient, and the 
equilibrium magnetisation, and perfusion can therefore be measured using the ASL standard 
kinetic model. T1 longitudinal relaxation time is an inherent property of tissues, representing 
the duration of time taken for 63% of the longitudinal magnetisation vector to return after a 
90o radiofrequency pulse. An individual voxel is comprised of both cellular and extracellular 
compartments such that its signal intensity is a composite of the T1 time of both these 
structures. T1 has the tendency to be longer in fluids and shorter in fat, such that tissue which 
is more fluid in nature is darker on MRI, and vice versa.  
MRI was performed on a Siemens Magnetom Verio 3.0 Tesla scanner (Siemens AG, 
Erlangen, Germany), using a 6-channel phased array body coil. A half Fourier acquisition 
single shot turbo spin echo (HASTE) localiser sequence was used to identify the location of 
the kidneys and the major vessels. ASL was performed using a ﬂow-sensitive alternating 
inversion recovery (FAIR) perfusion preparation with true fast imaging with steady state 
free precession (True-FISP) sequence. Sagittal double oblique images were taken of both 
kidneys, with a single slice obtained at the mid-point of each axis, moved posteriorly to avoid 
major vessels. Three images with alternating selective and non-selective inversions were 
obtained in a single acquisition during a 12 second breath hold, and this was repeated five 
times.  In addition, an image with no ASL preparation was acquired to measure equilibrium 
magnetisation. Fair True FISP parameters were: inversion time 900ms, repetition time 
3.65ms, echo time 1.83ms, flip angle 60o, field of view 380mm by 380mm, in plane 
resolution 256 x 256 and slice thickness 10mm. T1 maps were obtained during a separate 
breath hold using a modified Look-Locker inversion recovery (MOLLI) sequence. 
2.4.3 Image analysis 
Renal anatomy was evaluated on the localiser images using a commercially available multi-
modality post processing workstation (Siemens Syngo, Siemens AG, Erlangen, Germany). 
Kidney length was measured on the coronal images and volume was measured using a voxel 
count method by tracing contours on each slice of a 22 slice transverse image. A 
conventional post processing workstation was also used to measure T1 time at the cortex, 
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medulla, and whole kidney, and corticomedullary differentiation (CMD) was calculated as 
the cortex to medulla T1 time. Image analysis was then performed off line in house software 
MATLAB (MATLAB 8.4 R2014b, MathWorks, Natick, Massachusetts, USA). The analysis 
software registered the ASL images, subtracted non-selective from selective images, and 
averaged the subtractions. The averaged ASL subtraction image was fitted to the M0 and T1 
data using the standard ASL kinetic model (Martirosian et al., 2004) to produce a perfusion 
map, onto which regions of interest (ROI) were drawn to measure cortical and whole kidney 
perfusion. ASL perfusion measurements, expressed by unit of mass (100 g), were factored 
with renal volume to give kidney perfusion. 
2.5 Biomarkers of oxidative stress 
2.5.1 F2-isoprostanes 
Measurement of F2-isoprostanes was carried out by Dr Andrew Duncan and his team at the 
Biochemistry Department, Glasgow Royal Infirmary. A competitive immunoassay with 
colourimetric quantification (Direct 8-iso-Prostaglandin F2α Enzyme Immunoassay Kit, 
Assay Designs, Enzo Life Science, New York, USA) was used to measure 8-iso-
prostaglandin F2α (8-iso-PGF2α), also termed F2-isoprostane, as a marker of lipid 
peroxidation. Blood samples were collected as described in section 2.1.1, and illustrated in 
appendix 4.  
Frozen serum samples were thawed at room temperature and mixed 4:1 with 10 mol/L 
sodium hydroxide, then heated at 45 oC for 2 hours in order to hydrolyse the sample. 500 µL 
of hydrolysed sample was then added to 100 µL of 12.1 mol/L hydrogen chloride and then 
50 µL of this to 50 µL of a neutralising reagent. 50 µL each of a blue solution of alkaline 
phosphatase conjugated with 8-iso-PGF2α, and a yellow solution of a rabbit polyclonal 
antibody to 8-iso-PGF2α was added. The plate was incubated at room temperature on a 
shaker for 2 hours at 500 rpm. The contents of the wells were emptied and washed three 
times with wash solution. 200 µL of p-nitrophenyl phosphate solution was added and the 
plate incubated for 45 minutes at room temperature before stop solution was applied. The 
optical density of the plate was then read at 405 nm. 8-iso-PGF2α was quantified by 
comparison to a standard curve derived from known concentrations.  
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2.5.2 Glutathione to glutathione disulphide ratio 
Measurement of GSH/GSSG ratio was performed by Mr Jim McCulloch and his team at the 
BHF Glasgow Cardiovascular Research Centre. The ratio of GSH to its oxidised equivalent, 
GSSG, was taken as a measure of GSH availability, and this was measured using a 
colorimetric assay (Bioxytech GSH/GSSG-412, OxisResearch, Percipio Biosciences, 
Burlingame, USA). The assay relies on the reaction of GSH with Ellman’s reagent, or 5, 5'-
dithiobis-2-nitrobenzoic acid (DTNB), which produces a spectrophotometric product at 412 
nm. To measure GSSG, the assay uses the thiol scavenging reagent 1-methyl-2-
vinylpyridinium trifluoromethanesulfonate (M2VP) to scavenge existing GSH within the 
sample, and then generates GSH from the remaining GSSG using glutathione peroxidase, as 
is shown in figure 2.2. 
 
 
Figure 2.3 Measurement of GSH:GSSG. 
The measurement of oxidised glutathione (GSSG) is difficult due to its low concentration and the 
tendency for reduced glutathione (GSH) coexistent within the sample to become oxidised during the 
reaction. The assay used here measures GSH by reaction with Ellman’s reagent. To measure GSSG, 
firstly any GSH in the sample is scavenged using 1-methyl-2-vinylpyridinium trifluoromethanesulfonate 
(M2VP). GSSG is then reduced by glutathione reductase (GR) with NADPH as a cofactor of the reaction 
to form GSH. During reaction with Ellman’s reagent (DTNB), GSH is oxidised to GSSG whilst 
producing a spectrophotometrically detectable product. 
Samples were obtained according to section 2.1.1. To prepare the GSSG samples, 10 µL of 
M2VP was added to a microcentrifuge tube, and 100 µL of whole blood was added to the 
bottom of the centrifuge tube. Samples were mixed and then frozen at –70°C. The sample 
was thawed at room temperature, 290 µL 5% metaphosphoric acid was added, and the 
sample vortexed for 15 – 20 seconds, and centrifuged at 1000 g for 10 minutes. 50 µL of the 
extract was added to 700 µL GSSG buffer and the diluted extract placed on ice. A control 
sample was made by adding 50 µL metaphosphoric acid to 700 µL GSSG buffer.  
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To prepare GSH samples, 50 µL of whole blood was added to the bottom of a 
microcentrifuge tube and was frozen at –70°C. The sample was thawed, and 350 µL cold 
5% metaphosphoric acid added to the tube. The sample was vortexed for 15 seconds and 
centrifuged at 1000 g for 10 minutes. 50 µL metaphosphoric acid extract was then added to 
3 mL assay buffer (NaPO4 with EDTA).  
The assay was then performed by adding 200 µL of standards, controls, or samples to the 
cuvettes. 200 µL of DTNB, and then 200 µL of glutathione peroxidase was added to each 
cuvette. The samples were mixed and incubated at room temperature for 5 minutes. 200 µL 
of NADPH was added and the change in absorbance at 412 nm was recorded for 3 min. 
To quantify the concentrations of both GSH and GSSG, firstly the reaction rate was 
calculated as the slope of the regression line of the change in absorption per unit of time. 
Calibration curves were constructed using GSH and GSSG standards of known 
concentrations, and the concentration of each analyte was determined using these references. 
The GSH to GSSH ratio was then calculated. 
2.5.3 Electron paramagnetic resonance 
EPR was performed by Mr Jim McCulloch and his team at the BHF Glasgow Cardiovascular 
Research Centre. Samples used to measure ROS using EPR were obtained in the manner 
described in section 2.1.1 and in appendix 4. Plasma which was obtained for EPR was 
immediately placed on ice and analysed using a Bruker e-scan EPR system. 
Firstly, Krebs-HEPES buffer was prepared, filtered, and adjusted to pH 7.4. A 10 mM 
solution of deferoxamine was produced, as was a 10 mM solution of diethyldithiocarbamic 
acid (DETC), and a 1 mM solution of the spin probe 1-hydroxy-3-carboxy-2,2,5,5-
tetramethylpyrrolidine (CPH). 100 µL of deferoxamine and 20 µL of DETC was added to 
the 40 mL of buffer, and then 900µL of the buffer and chelator solution was combined with 
100 µL of CPH. The CPH solution was then added 1:1 to the sample and 50 µL of this was 
placed into a glass EPR capillary tube. ROS within the sample react with CPH to produce 
stable CPH radicals, and the spectra produced when subject to EPR were recorded for 5 
minutes. The EPR signal is proportional to the quantity of ROS in the biological sample, and 
the rate of this production during the EPR measurement was taken as a measure of oxidative 
stress 
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2.5.4 Total antioxidant potential 
Quantification of total antioxidant potential (TAP) was performed by Mr Jim McCulloch 
and his team at the BHF Glasgow Cardiovascular Research Centre. TAP was measured using 
a qualitative colorimetric assay (Bioxytech AOP-450 Quantitative Assay for Total 
Antioxidant Potential, OxisResearch, Percipio Biosciences, Burlingame, USA). The assay is 
based upon the reduction of Cu2+ to Cu+ by the combined activity of all antioxidants within 
the sample. A chromogenic reagent selectively forms a stable complex with reduced copper, 
with a maximum absorption at 450 nm. A known concentration of Trolox (a vitamin E 
analogue) was used to create a calibration curve, such that TAP is expressed quantitatively 
as millimoles of Trolox equivalents.   
Samples were obtained and processed as described in section 2.1.1 and appendix 4, and then 
thawed at room temperature. Different concentrations of Trolox were made by dilution with 
deionised water. Samples and Trolox standards were diluted 1:40 in dilution buffer, and 200 
μL of mixture was placed into each well. The plate was read at 450 nm for a reference 
measurement. 50 µL of copper solution was then added to each well, which was incubated 
at 3 minutes at room temperature. Stop solution was then added and the plate was read for a 
second time at 450 nm. Net absorption of a sample is derived by subtracting the second 
measured absorption from the first measured absorption. A calibration curve was produced 
plotting the known concentration of Trolox along the X axis and the net absorption on the Y 
axis. Quantification of TAP was then calculated by referencing the absorption of a given 
sample to the calibration curve.  
2.5.5 Ascorbic acid 
High performance liquid chromatography was used to measure ascorbic acid, performed by 
Dr Andrew Duncan at the Biochemistry Department, Glasgow Royal Infirmary. Biological 
samples were obtained as described in section 2.1.1 and shown in appendix 4. Samples 
destined for ascorbic acid quantification underwent deproteinisation using 6% 
metaphosphoric acid prior to freezing. After thawing an aliquot of the sample was injected 
on to a C18 reverse phase chromatographic column and the ascorbic acid concentration 
assayed using an electrochemical detector.  
Chromatographic measurements were made using a Waters HPLC pump and autosampler 
(Waters Corporation, U.S.A), an ESA Coulochem 5100A Electrochemical Detector, and 
ESA Analytical Cell Model 501 (Dionex, U.S.A). A 25 cm Apex ODS HPLC column with 
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5µm particle size, and 1cm Apex ODS guard column with 5µ particle size was used (Grace 
Discovery Sciences, U.S.A). The mobile phase comprised chloroacetic acid 7.1 g, sodium 
hydroxide 2.3 g, sodium EDTA 0.43 g, L-octane sulphonic acid100 mg, dissolved in 500 
mL distilled water, and filtered using a 0.2 m  filter. The mobile phase was then pumped at 
1.5 mL per minute. Samples, quality control material and standards were allowed to thaw 
thoroughly at room temperature and were mixed thoroughly before use. Samples were 
vortexed then centrifuged at 3000 rpm for 10 minutes. 
200 µL of sample supernatant was then combined with 800 µL of a solution of dithiothreitol 
and metaphosphoric acid (750 mg dithiothreitol in 500 mL of 3% metaphosphoric acid) in 
an Eppendorf tube. Tubes were vortexed for 5 seconds then centrifuged in the Eppendorf 
microcentrifuge at 10,000 rpm for 5 minutes. The sample was then decanted into glass 
autosampler vials, and placed on the carousel. The ascorbic acid peak was identified by 
comparison with that of the ascorbic acid standard, and quantification was carried out using 
an external standard.  
2.5.6 Asymmetric dimethylarginine 
ADMA was measured by using HPLC methodology (Blackwell et al., 2009) by Dr Andrew 
Duncan at the Biochemistry Department, Glasgow Royal Infirmary, using cation exchange 
solid phase extraction (SPE), utilising a solvent delivery system and fluorimeter (Waters 
Corporation, U.S.A). Samples were obtained as described in section 2.1.1 and appendix 4.  
The analyte was extracted from plasma using Isolute PRS cation exchange SPE column 
(Biotage, Sweden) with a Vac Elut extraction system (Agilent Technologies, U.S.A). The 
columns were activated with 2mL methanol, then 2mL 50 mmol/L borate buffer. 200 µL of 
sample was then mixed with 720 borate buffer and 80 of the internal standard 
monoethylarginine, and loaded onto the SPE column. After washing with borate, water, and 
methanol, the analyte was eluted with a solution of methanol and ammonia. The eluent was 
then evaporated at 80 0C. HPLC was performed, with a mobile phase comprising 50 mmol/L 
acetate buffer with 9% acetonitrile, filtered via a 0.45 µ filter and pumped at 1.5 mL/min. 
ADMA was then measured fluorometrically at an excitement of 340 nm and emission of 455 
nm. Quantification was performed by comparison to a standard curve. 
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Oxidative Stress in Chronic Kidney Disease 
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3.1 Introduction 
The risk of CVD is significantly elevated in patients with chronic kidney disease (CKD) 
with cardiovascular risk increasing in parallel with the decline in renal function (Culleton et 
al., 1999). Indeed most patients with CKD will die of a cardiovascular event before they 
progress to the need for renal replacement therapy. This cardiovascular risk can be explained, 
in part, by shared risk factors and the age of the CKD population, but does not account fully 
for the degree of observed CVD. Indeed, such shared risk factors can confound the study of 
CVD in CKD, but nevertheless, the prevalence of CVD remains higher in this group even 
when adjusted for age and co-morbidities (Go et al., 2004). 
The presence of non-conventional risk factors specific to CKD has been suggested as a 
mechanism contributing to CVD, such as hyperphosphataemia, anaemia, chronic 
inflammation and structural heart disease specific to CKD, so called ‘uraemic 
cardiomyopathy’. Oxidative stress is another cardiovascular risk factor characterised by an 
excess of reactive oxygen species (ROS) and other oxidants, leading to a derangement in 
redox signalling which activates pathways which lead to deleterious changes to vascular 
biology (Jones, 2008).  
In vivo, this is demonstrated by evidence of endothelial dysfunction and by an increase in 
oxidative modification of macromolecules. For example, advanced oxidative protein 
products (AOPPS), 8-hydroxydeoxyguanosine, and F2-isoprostanes are all elevated in CKD, 
and renal transplantation results in a significant reduction in these biomarkers of oxidative 
stress (Simmons et al., 2005, Yilmaz et al., 2005). Furthermore, circulating levels of the 
nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA) are increased 
in renal impairment which also leads to increased ROS production via uncoupling of 
endothelial NOS (Fujiwara et al., 2011, Valli et al., 2007, Oberg et al., 2004).  
Previous studies have investigated the use of exogenous antioxidants either as therapy, or as 
manipulators of redox homeostasis as a means to explore the mechanisms behind oxidative 
stress in CKD. For example, antioxidant supplementation has been shown to improve 
markers of oxidative stress and blood pressure in animal models of CKD and hypertension 
(Tian et al., 2006, Shing et al., 2014) . In humans, however, the data is conflicting, with some 
studies showing certain benefits of antioxidant therapy in patients with CKD (Boaz et al., 
2000, Williams et al., 2001), and other studies finding no such effect (Cross et al., 2003, 
Ramos et al., 2011). 
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The effect of antioxidant administration in renal impairment on vascular function was 
therefore investigated in order to explore the mechanisms underlying oxidative stress and 
endothelial dysfunction in CKD. A cross over study of intravenous ascorbic acid and normal 
saline was carried out in a population of patients with CKD stages 3 – 5 (Kidney Disease 
Improving Global Outcomes, 2012), in comparison to a matched population of patients with 
hypertension (HTN). 
3.2 Methods 
The methodology behind the Renox study was described in detail in section 2.1.1 and shown 
in figure 3.1. Three groups of participants were recruited: patients with CKD were recruited 
from general nephrology clinics, patients receiving peritoneal dialysis were recruited from 
the PD clinic, and a control group of hypertensives with normal renal function were recruited 
from a tertiary referral blood pressure clinic.   
To summarise the study protocol, after clinical evaluation had taken place, 100 mL of 0.9% 
normal saline was administered intravenously. After 10 minutes, blood samples were taken 
in order to measure baseline biochemistry, and biomarkers of oxidative stress. Arterial 
stiffness was then assessed using the SphygmoCor® system, as described in section 2.4, and 
evaluation of endothelial function was undertaken by measurement of flow mediated 
dilatation using brachial artery ultrasound, as described in section 2.2. After a rest period, 
2000 mg of ascorbic acid was administered intravenously in 100 mL 0.9% normal saline. 
After ten minutes, blood samples were taken for a second occasion for measurement of 
oxidative stress biomarkers and the vascular function studies were repeated. Phlebotomy 
was performed for a third occasion 60 minutes after administration of ascorbic acid.   
Biomarkers of oxidative stress which were measured are shown below, in table 3.1. The 
pathophysiological basis for these markers was discussed in section 1.9, and the 
methodology behind their measurement described in detail in section 2.5. 
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Figure 3.1 Renox study protocol 
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Biomarker Rationale Methodology 
GSH/GSSG Reduced glutathione is an important 
buffer, and ratio of glutathione to its 
oxidised equivalent is a marker of 
oxidative stress 
 
Colourimetry 
F2-isoprostanes Indicator of lipid oxidative modification Immunoassay with 
colourimetric quantification 
O2- ROS are a physiologically important 
radical species 
Electron paramagnetic 
resonance 
Ascorbic acid Water based antioxidant vitamin High performance liquid 
chromatography 
Total antioxidant potential Measure of non-enzymatic reducing 
potential in serum 
 
Colourimetry 
ADMA Circulating inhibitor of NO production 
which is elevated in CKD 
High performance liquid 
chromatography 
Table 3.1 Biomarkers of oxidative stress measured in the Renox study 
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3.3 Results 
3.3.1 Clinical characteristics  
30 subjects with CKD (22 with stages 3- 5 CKD and 8 patients receiving PD) and 20 subjects 
with HTN were recruited. eGFR was 22.4 ± 12.6 mL/min/1.73m2 in the CKD group 
compared to 94.4 ± 11.7 mL/min/1.73m2 in the HTN group (p < 0.001). The two groups 
were well matched for age, body mass index (BMI), smoking status and medication history, 
but blood pressure was higher in the HTN group. Baseline parameters are fully described in 
table 3.2, and medication history is shown in table 3.3. 
3.3.2 Biomarkers of oxidative stress 
Baseline ascorbic acid was significantly lower in patients with CKD than in HTN (22.45 ± 
27.49 vs. 43.96 ± 14.13 µmol/L, p = 0.023), whilst ADMA (0.61 ± 0.14 vs. 0.48 ± 0.07 
µmol/L, p < 0.001) and TAP (0.66 ± 0.15 µM Trolox vs. 0.58 ± 0.10 µM Trolox, p = 0.027) 
were significantly higher. There were no significant differences in F2-isoprostanes (1073.98 
± 1048.38 pg/mL vs. 898.96 ± 643.02 pg/mL, p = 0.61), GSH/GSSG (110.71 ± 266.17 vs. 
140.03 ± 448.80, p = 0.75), and O2
- production (0.50 ± 0.29 arb. units vs. 0.37 ± 0.95 arb. 
units, p = 0.08) between the two groups at baseline (table 3.4). 
After ascorbic acid, TAP and O2
- production both transiently rose and then fell to a level 
higher than baseline in both groups. In CKD, TAP changed from 0.66 ± 0.15 to 1.24 ± 0.20 
(p < 0.001) to 1.11 ± 0.22 µM Trolox (p < 0.001), whilst O2
- production altered from 0.50 ± 
0.29 to 0.63 ± 0.22 (p = 0.038) to 0.55 ± 0.18 arb. units (p = 0.42). In HTN, TAP changed 
from 0.58 ± 0.10 to 1.15 ± 0.22 (p < 0.001) to 0.85 ± 0.14 µM Trolox (p < 0.001) and O2
- 
changed from 0.37 ± 0.10 to 0.50 ± 0.14 (p = 0.005) to 0.43 ± 0.10 arb. units (p = 0.007). 
There was no reduction in F2-isoprostanes observed in the HTN group (899 ± 643 to 729 ± 
464 pg/mL, p = 0.18) or the CKD group (1074 ± 1048 to 862 ± 389 pg/mL, p = 0.37), and 
neither was there a change in GSH/GSSG observed in either HTN (140.0 ± 448.8 to 111.3 
± 390.4, p = 0.35) or CKD (94.6 ± 256.2 to 46.70 ± 83.2, p = 0.21) (figure 3.2).  
After administration of ascorbic acid there was a reduction in ADMA in the CKD group 
(0.61 ± 0.14 to 0.58 ± 0.14 µmol/L, p = 0.039), but not the HTN group (0.48 ± 0.07 to 0.51 
± 0.07 µmol/L, p = 0.36), which reached statistical significance in the second but not the 
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third phlebotomy time point. The degree of change in ADMA was also significantly different 
between the two groups (-0.04 ± 0.09 vs 0.02 ± 0.06, p = 0.013). 
Table 4 shows the result of multivariate regression analysis on the determinants of the 
response of ADMA to ascorbic acid with age, eGFR, BMI, blood pressure and gender 
entered into the model. Age (B = 0.002 (95% CI 0.000, 0.004), p = 0.041) and eGFR (B = 
0.001 (95%CI 0.000, 0.002), p = 0.005) were independent determinants, whilst BMI, blood 
pressure, and gender were not significant predictors of response to ADMA.  
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Parameter HTN CKD p value 
 n = 20 n = 30  
Age (years) 56 ± 10 59 ± 14 0.34 
Body mass index (kg/m2) 30.9 ± 5.4 28.1 ± 6.7 0.13 
Peripheral BP (mmHg) 150/95 ± 17/10 141/82 ± 15/10 0.04* 
Mean arterial BP (mmHg) 112 ± 12 101.6 ± 10.2 0.002* 
Primary renal diagnosis (n)    
Glomerulonephritis  14  
Renovascular disease  1  
Reflux nephropathy  3  
Polycystic kidney disease  4  
Unknown  4  
Other  4  
CKD stage (n)    
3a 
3b 
4 
5 
 
1 
7 
14 
0 
 
 n = 20 n = 22  
Creatinine (µmol/L) 71 ± 11 359 ± 274 < 0.001* 
eGFR (mL/min/1.73m2) 94.4 ± 11.7 22.4 ± 12.6 <0.001* 
Table 3.2 Baseline parameters in the Renox study. 
Asterisks (*) indicate a significant difference. CKD participants receiving peritoneal dialysis are not 
included in comparison of creatinine and eGFR. HTN = Hypertension, CKD = Chronic kidney disease, 
BP = Blood pressure, eGFR = Estimated glomerular filtration rate. 
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Current medications 
HTN 
n (%) 
CKD 
n (%) 
ACE inhibitor 9 (45) 15 (50) 
Angiotensin receptor blocker 6 (30) 7 (23) 
Beta blocker 3 (15) 10 (33) 
Calcium channel blocker 10 (50) 15 (50) 
Statin 6 (30) 16 (53) 
Allopurinol 2 (10) 10 (33) 
Spironolactone 2 (10) 0 (0) 
Current smoker 4 (20) 6 (20) 
Table 3.3 Medication and smoking history 
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3.3.3 Arterial function 
Table 3.6 demonstrates measurements of vascular function studies before and after ascorbic 
acid. Baseline central blood pressure was significantly higher in the HTN group (132/85 ± 
15/11 vs. 142/97 ± 18/10 mmHg, p = 0.042) but there was no difference in adjAix (25.6 ± 
8.0% vs. 24.4 ± 12.3%, p = 0.70). PWV was significantly higher in the CKD group (10.2 ± 
2.5 vs. 8.6 ± 1.7m/s, p = 0.022).  
Following administration of ascorbic acid central blood pressure fell significantly in both 
CKD (132/85 ± 15/11 to 120/75 ± 21/11 mmHg, p = 0.005) and HTN (142/97 ± 18/10 to 
130/81 ± 25/15 mmHg, p = 0.002). There was no significant difference in the degree of 
change between CKD and HTN (p = 0.86). 
A significant reduction in adjAix was also seen in CKD (25.6 ± 8.0% to 15.8 ± 10.4%, p < 
0.001) and HTN (24.4 ± 12.3% to 17.6 ± 11.3%, p < 0.001), and again, the degree of change 
was not different between groups (p = 0.09). No change in PWV was observed in either 
group following ascorbic acid in either group (figure 3.3).  
3.3.4 Endothelial dysfunction 
At baseline, no significant difference was observed in the diameter of the brachial artery 
between the HTN and CKD groups (4.71 ± 0.81mm vs. 4.40 ± 0.67mm, p = 0.18). Neither 
was there a between group difference in FMD in either absolute (0.19 ± 0.07mm vs. 0.19 ± 
0.12mm, p = 0.27) or proportional (4.13 ± 1.99% vs. 4.70 ± 3.21%, p = 0.51) terms.  
In the HTN group, after administration of ascorbic acid, FMD changed from 0.19 ± 0.07 to 
0.49 ± 0.25 (p = 0.12) and percentage FMD changed from 4.13 ± 1.99 to 4.95 ± 2.86 (p = 
0.31). In the CKD group FMD changed from 0.19 ± 0.12 to 0.35 ± 0.21 mm (p = 0.10) and 
proportional FMD changed from 4.71 ± 3.21 to 5.96 ± 3.66 (p = 0.35) after ascorbic acid. 
There was a significant reduction in endothelial independent dilatation after ascorbic acid 
administration, in both the HTN group (12.30 ± 5.91 vs. 6.68 ± 4.95 %, p < 0.001) and the 
CKD group (14.66 ± 6.22 vs. 7.73 ± 5.30 %, p <0.001) (figure 3.4). 
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Parameter HTN CKD p value 
Ascorbic acid (µmol/L) 44.0 ± 14.1 23.7 ± 27.7 0.023* 
ADMA (µmol/L) 0.48 ± 0.07 0.61 ± 0.14 <0.001* 
F2-isoprostanes (pg/mL) 899.0 ± 643.0 1074.0 ± 1048.4 0.61 
Total antioxidant potential (µM Trolox) 0.58 ± 0.10 0.66 ± 0.15 0.027* 
GSH/GSSG 140.0 ± 448.8 110.7 ± 266.2 0.75 
O2- production  0.37 ± 0.10 0.50 ± 0.29 0.08 
Table 3.4 Comparison of biomarkers of oxidative stress at baseline.  
Asterisks (*) indicate a significant difference. HTN = Hypertension, CKD = Chronic kidney disease, 
ADMA = Asymmetric dimethylarginine, GSH = Glutathione, GSSG = Glutathione disulphide, O2- = 
Superoxide. 
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Unstandardized 
coefficient  
Significance 
95% 
confidence 
interval 
 B p  
R2 = 0.212    
Constant -0.170 0.006 -0.288, -0.051 
eGFR 0.001 0.005 0.000, 0.002 
Age 0.002 0.041 0.000, 0.004 
Table 3.5 Determinants of the change in ADMA in response to ascorbic acid. 
Evaluated using a multiple stepwise linear regression analysis with a stepwise paradigm which 
included variables with p values less than 0.05. 
 
  
  
 
1
1
8
 
 HTN CKD 
Parameter Before After p value Before After p value 
Central blood pressure (mmHg) 142/97 ± 18/10* 130/82 ± 25/15† 0.002 132/85 ± 15/12* 120/75 ± 21/11† 0.005 
Adjusted augmentation index (%) 24.4 ± 12.3* 17.6 ± 11.3† <0.001 25.6 ± 8.0* 15.8 ± 10.5† <0.001 
Pulse wave velocity (m/s) 8.62 ± 1.69* 8.42 ± 1.45 0.28 10.19 ± 2.45* 9.70 ± 3.04 0.11 
Brachial artery diameter (mm) 4.71 ± 0.81 5.15 ± 0.84† < 0.001 4.40 ± 0.67 4.76 ± 0.87† <0.001 
Flow mediated dilatation (mm) 0.19 ± 0.07 0.25 ± 0.13 0.12 0.19 ± 0.12 0.27 ± 0.15 0.10 
Percent flow mediated dilatation (%) 4.13 ± 1.99 4.95 ± 2.86 0.31 4.71 ± 3.21 5.96 ± 3.66 0.35 
GTN mediated dilatation (mm) 0.55 ± 0.25 0.33 ± 0.24† <0.001 0.63 ± 0.21 0.35 ± 0.21† <0.001 
Percent GTN mediated dilatation (%) 12.30 ± 5.91 6.68 ± 4.95† <0.001 14.66 ± 6.22 7.73 ± 5.30† <0.001 
Table 3.6 Vascular function tests before and after administration of ascorbic acid.  
The p value refers to a paired Student’s t test comparing the parameter before and after ascorbic acid. Asterisks (*) indicate parameters where there was a significant difference 
in baseline values between the two groups, whilst the dagger (†) indicates a significant difference values measured before and after ascorbic acid. HTN = Hypertension, CKD = 
Chronic kidney disease, GTN = Glyceryl trinitrate.
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Figure 3.2 Effect of ascorbic acid on biomarkers of oxidative stress. 
Ascorbic acid increases O2- production (A) and total antioxidant potential (B) in both groups, whilst 
reducing ADMA in patients with CKD (C). Measurements of biomarkers of oxidative stress made in 
both groups are shown at baseline (1), after ascorbic acid (2) and at one hour after ascorbic acid (3) (see 
figure 1). Asterisks (*) indicate a significant difference (p < 0.05) in comparison with baseline. HTN = 
Hypertension, CKD = Chronic kidney disease, O2- = Superoxide, ADMA = Asymmetric 
dimethylarginine. 
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Figure 3.3 Effect of ascorbic acid on large arterial function. 
Ascorbic acid reduces central blood pressure (A) and augmentation index (B) in both hypertension and 
CKD. Changes in central BP (A), adjusted augmentation index (B) and pulse wave velocity (PWV) are 
shown in both groups. Asterisks (*) indicate a significant difference (p < 0.05) occurring after ascorbic 
acid. Error bars represent standard error of the mean. HTN = Hypertension, CKD = Chronic kidney 
disease, SAL = Normal saline, AA = Ascorbic acid, NS = Not significant.  
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Figure 3.4 Effect of ascorbic acid on flow mediated dilatation. 
No significant change was seen in endothelial function after administration of ascorbic acid. Results of 
brachial artery dilatation are shown, in terms of both absolute (A & B) and relative (C & D) 
measurements. Error bars represent standard error of the mean. HTN = Hypertension, CKD = 
Chronic kidney disease, SAL = Normal saline, AA = Ascorbic acid, NS = Not significant.      
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3.3.5 Subgroup analysis 
The results of a subgroup analysis comparing the change in FMD, adjAix, PWV, blood 
pressure and ADMA which occurred in the HTN, CKD and PD groups are shown in table 
3.7. There was no significant difference in the change in FMD (F(2, 37) = 0.02; p = 0.98) or 
PWV (F(2, 42) = 2.58; p = 0.09) between groups. There was significant difference in the 
change in MAP (F(2, 44) = 4.26; p = 0.02), adjAix (F(2, 47) = 4.75; p = 0.01) and ADMA 
(F(2,44) = 3.45; p = 0.04). Lower reduction of blood pressure and adjAix and greater 
reduction of ADMA was observed in the PD group. 
 
HTN CKD PD p 
Flow mediated dilatation 
(mm) 
0.07 ± 0.18 0.08 ± 0.17 0.06 ± 0.29 0.98 
Augmentation index (%) -6.8 ± 5.5 -11.4 ± 6.4 -5.5 ± 3.4 0.01* 
Mean arterial blood pressure 
(mmHg) 
-14.1 ± 14.1 -14.5 ± 12.7 -0.1 ± 6.9 0.02* 
Pulse wave velocity (m/s) -0.19 ± 0.74 -0.76 ± 1.40 0.47 ± 1.81 0.09 
ADMA (µmol/L) 0.02 ± 0.06 -0.3 ± 0.09 -0.05 ± 0.10 0.04* 
Table 3.7 Subgroup analysis 
The change in parameters from measurement 1 to measurement 2 is shown and compared across groups. 
Values representing the mean ± standard deviation of the change in parameter between measurements. 
In the PD group there is lower reduction of blood pressure and augmentation index, with greater 
reduction of ADMA. Asterisks (*) demonstrate a significant difference between groups. HTN = 
Hypertension, CKD = Chronic kidney disease, PD = Peritoneal dialysis, ADMA = Asymmetric 
dimethylarginine.   
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3.4 Discussion 
CVD is the commonest cause of death in patients with CKD. The prevalence of 
atherosclerotic coronary artery disease, congestive cardiac failure and arrhythmia are all 
elevated in patients with CKD in proportion to the severity of renal impairment (United 
States Renal Data System, 2011a). Whilst part of this can be explained by the presence of 
shared risk factors, the burden of disease is not fully accounted for by these alone, and the 
existence of non-conventional risk factors specific to CKD may also contribute to 
cardiovascular risk (Go et al., 2004). 
3.4.1 Oxidative stress in CKD 
Oxidative stress describes a state of disturbed redox signalling due to an excess of ROS and 
their derivatives, and a consequent depletion of cardioprotective signalling molecules such 
as nitric oxide (NO). Oxidative stress occurs in CKD due to a number of mechanisms, such 
as stimulation of NADPH oxidase by an activated renin angiotensin system (DuPont et al., 
2014) and downregulation of the antioxidant master gene regulator Nrf-2 (Kim and Vaziri, 
2010). Clinically, oxidative stress is manifest by endothelial dysfunction and previously, 
several studies have shown reduction in endothelial function in a step wise manner relative 
to the stage of CKD (Yilmaz et al., 2011). Novel therapeutics which modify these pathways 
may reduce the burden of CVD in patients with CKD.  
3.4.2 Ascorbic acid in CKD 
In this study, it was found that serum ascorbic acid levels were significantly lower in CKD 
than hypertensive controls. Whilst it is generally accepted that symptoms of scurvy occur 
with serum ascorbic acid levels below 11.4 µmol/L, the lower limit of the recommended 
range is around 40 µmol/L (Gey et al., 1993) and blood concentrations below this may be 
associated with adverse outcome. Our findings are in keeping with earlier studies showing 
reduced ascorbic acid levels in CKD, both with and without diabetes (Takahashi et al., 1252), 
and lower still in patients receiving haemodialysis (Deicher and Horl, 2003). Patients with 
CKD are often advised to adhere to a low potassium diet, which can limit intake of 
micronutrients such as ascorbic acid. Furthermore, CKD is associated with low grade 
inflammation which can increase utilisation of ascorbic acid (Langlois et al., 2001), and 
clearance of ascorbic acid is increased by proteinuria and diuretic use (Hirsch et al., 1998). 
Interestingly, the reduction in ascorbic acid is offset by an apparent increase in the other non-
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enzymatic antioxidant systems present in serum which comprise the total antioxidant 
capacity, such that TAP was in fact higher in CKD than HTN.  
Administration of ascorbic acid not only increased antioxidant capacity in this study, but 
also increased O2
- levels in both groups, in keeping with some previous studies showing 
mixed pro- and antioxidant effects. Ascorbic acid reacts with several transition metal ions 
facilitating their interaction with hydrogen peroxide in the Fenton reaction to generate 
hydroxyl radicals. That said, it remains unclear to what extent these reactions are relevant in 
vivo, as most transition metals are sequestered to chelates such as transferrin and 
caeruloplasmin. Our study has shown in controlled conditions that infusion of ascorbic acid, 
as well as having antioxidant effects, results in increased production of O2
-. 
3.4.3 Regulation of ADMA in CKD 
ADMA is a by-product of the methylation of arginine residues, which acts as a competitive 
inhibitor of L-arginine to reduce NO production, and also causes decoupling of eNOS 
leading to ROS production instead of NO (Sydow and Munzel, 2003). ADMA is increased 
in CKD in proportion to the severity of renal impairment and is an important predictor of 
cardiovascular outcomes. Oxidative stress also increases ADMA concentration by 
upregulating the synthetic enzyme protein arginine methyltransferase-1 (PRMT-1) and 
downregulating the degradation enzyme dimethylarginine dimethylaminohydrolase 
(DDAH) (Matsuguma et al., 2006). It was found that intravenous ascorbic acid level 
transiently reduces ADMA in CKD but not HTN, echoing the results of earlier studies which 
have shown a reduction in ADMA levels in patients with CKD supplemented with vitamin 
E (Saran et al., 2003). Given that ADMA is a significant predictor of cardiovascular outcome 
(Zoccali et al., 2001), this may represent an important mechanism by which antioxidants 
exert a beneficial cardiovascular effect.  
3.4.4 Effect of ascorbic acid on central BP 
Conversely, ascorbic acid reduced central blood pressure in both HTN and CKD groups by 
12/15, and 12/10 mmHg respectively, and this was associated with a reduction in Aix. This 
was also reflected by an increase in the diameter of the brachial artery at the baseline stage 
of FMD, suggesting that this might have occurred due to systemic vasodilatation. Juraschek 
et al (Juraschek et al., 2012) previously conducted a meta-analysis of the effect of 
longitudinal ascorbic acid supplementation on blood pressure, finding that systolic and 
diastolic blood pressures were reduced by 4.85 and 1.67 mm Hg, respectively. It should be 
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remembered that Aix is dependent on blood pressure and ventricular contractility as well as 
velocity of reflected pulse waves (Lemogoum et al., 2004, Laurent et al., 2006), such that 
adjAix is a less direct method of measuring arterial stiffness than PWV, which is a direct 
measure of aortic stiffness. As such, it is not surprising that PWV is unchanged where Aix 
is reduced, and suggests that the acute action of ascorbic acid lies primarily in lowering blood 
pressure, rather than altering vascular geometry. That baseline brachial artery diameter was 
increased after ascorbic acid suggests a vasodilatory effect. Interestingly, the reduction in 
blood pressure was significantly lower in the PD group; it is possible that in this group blood 
pressure and Aix is more dependent on fluid status than other dynamic factors.  
3.4.5 Effect of ascorbic acid on endothelial function 
With regards to FMD, it is notable that there was no difference in baseline endothelium 
dependent vasodilatation between groups. Baseline FMD in the CKD group was similar to 
other studies in this cohort (Recio-Mayoral et al., 2011, Takahashi et al., 1252, Yilmaz et 
al., 2006), but in the HTN group, FMD was 4.13%, which is lower than in many other studies 
in similar populations. Having been recruited from a tertiary referral blood pressure clinic, 
it might be the case that this represents a population with higher cardiovascular risk and 
inherently worse endothelial function than other populations with hypertension and normal 
renal function (Shimbo et al., 2010). Similarly, although the two study groups were well 
matched for age, BMI, smoking status and medication history, blood pressure was 
significantly higher in the HTN group, such that higher blood pressure might offset the 
difference in endothelial function due to renal impairment. 
In both study cohorts, there was a numerical increase in FMD following administration of 
ascorbic acid but this did not reach statistical significance. Previous studies have shown 
conflicting effects of ascorbic acid on vascular function in CKD populations. Cross et al 
(Cross et al., 2003) found no improvement in FMD after parenteral administration of 
ascorbic acid, although Williams et al (Williams et al., 2001) have previously shown in 
improvement in endothelium dependent vasodilatation after ascorbic acid supplementation, 
in a cohort of transplant patients with mildly impairment kidney function. Additionally, it 
was found that impaired endothelium independent vasodilatation after administration of 
ascorbic acid. This may be another consequence of the pro-oxidant effects of ascorbic acid, 
or may simply be artefactual and due to nitrate tolerance or vessel fatigue.   
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3.4.6 Conclusion  
In summary, in comparison to matched hypertensive controls, CKD patients have ascorbic 
acid deficiency but otherwise similar levels of oxidative stress. Parenteral ascorbic acid 
reduces central blood pressure and augmentation index in subjects with hypertension and 
CKD, in a manner independent of endothelial function. Further studies are required to assess 
the effects of chronic ascorbic acid on vascular function in these populations. 
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Renal Arterial Spin Labelling Magnetic Resonance 
Imaging in Healthy Volunteers 
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4.1 Introduction 
As described in section 1.7, renal perfusion is a crucial component of normal renal function, 
being one of the main determinants of glomerular filtration rate and tissue oxygenation 
(Leong et al., 2007, Rosen et al., 1992). Serum creatinine and the derived estimated 
glomerular filtration rate (eGFR) are the conventional measures of renal function (Levey et 
al., 2009) used in clinical practice, however these are less sensitive to alterations in renal 
physiology. Furthermore, alterations in renal perfusion and endothelial function may 
represent pathophysiological mechanisms involved in the perpetuation of CKD. Existing 
methods of measuring renal perfusion have inherent drawbacks, as has already been 
discussed in section 1.9.4, but ASL MRI shows promise as a methods of non-invasively 
measuring perfusion without the administration of a potentially harmful tracer  
Most perfusion MRI imaging in the literature is carried out at field strengths of 1.5 Tesla 
(Cutajar et al., 2012, Ritt et al., 2010). As magnetic labelling decays over the relaxation time 
T1, which is longer at higher field strengths, 3.0 Tesla MRI is associated with greater signal 
to noise ratio (SNR), which should result in enhanced image quality and allow more accurate 
analysis of renal perfusion. To this end, the reproducibility of ASL at 3.0 Tesla MRI in 
healthy volunteers with normal renal function was investigated.  
4.2 Methods 
The methodology of this study has already been discussed in section 2.1.2, but is summarised 
again in figure 4.1. Participants were recruited by local advertisement. ASL MRI was 
performed as described in section 2.4, and image analysis was performed offline using 
bespoke software written with MATLAB. The primary outcome measure was repeatability 
of ASL MRI parameters.  
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Figure 4.1 VolRASL study protocol. 
Participants were recruited by advertisement. The study comprised three visits, on the first a clinical 
and biochemical assessment was carried out. On the second and third ASL MRI was performed. 
4.3 Results 
4.3.1 Participant demographics 
12 participants completed the study protocol with a mean age of 44.1 ± 14.6 years. Mean 
blood pressure was 136/82mmHg and no participants receiving antihypertensive therapy. 
All subjects had normal renal function with a mean CKD EPI eGFR of 98.3 ± 
15.1mL/min/1.73m² (table 4.1) without proteinuria.  Images of appropriate quality for 
analysis were obtained at both visits for all participants (figure 4.2).  
4.3.2 Renal morphology 
Mean kidney length was 10.6 ± 0.8 cm at ASL MRI 1 and 10.8 ± 0.8cm at ASL MRI 2 (table 
4.2) with significant correlation between the two (r = 0.89, p < 0.001). Kidney volume 
measured using the ellipsoid formula was 120.5 ± 26.1cm³ at ASL MRI 1 and 126.4 ± 
24.9cm³ at ASL MRI 2. Kidney volume measured using the voxel count method was 155.7 
± 29.2cm³ at ASL MRI 1 and 157.7 ± 28.6cm³ at ASL MRI 2. Volume measurements made 
by the voxel count method were 30% higher than those made by the ellipsoid method, and 
there was significant correlation between both methods (r = 0.70, p <0.001) (figure 4.3).  
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Parameter Result 
 n = 12 
Age (years) 44.1 ± 14.6 
Male (number) 5 
BMI (kg/cm2) 26.5 ± 6.6 
Systolic BP (mmHg) 136 ± 23 
Diastolic BP (mmHg) 82 ± 9 
Urea (mmol/L) 5.0 ± 1.1 
Creatinine (μmol/L) 72.3 ± 10.6 
CKD EPI eGFR (mL/min/1.73m2) 98.3 ± 15.1 
Total Cholesterol (mmol/L) 4.8 ± 0.7 
HDL cholesterol (mmol/L) 1.8 ± 1.2 
Glucose (mmol/L) 5.2 ± 1.0 
Haemoglobin (g/L) 144 ± 12 
Protein to creatinine ratio (mg/μmol) 0.58 ± 2.02 
Albumin to creatinine ratio (mg/μmol) 0.17 ± 0.32 
Adjusted serum calcium (mmol/L) 2.47 ± 0.05 
Serum phosphate (mmol/L) 0.96 ± 0.35 
Calcium phosphate product (mmol/L) 2.38 ± 0.89 
Table 4.1 Baseline clinical and biochemical assessment in the VolRASL study. 
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Figure 4.2 Renal anatomy correlation plot. 
Correlation between ellipsoid formula and voxel count methods of measuring renal volume. r is the 
Pearson correlation coefficient. 
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Figure 4.3 Renal ASL MRI in a healthy volunteer.  
Representative renal arterial spin labelling MRI images in a healthy volunteer with normal renal 
function showing (A) ASL subtraction image, (B) M0 image demonstrating magnetisation equilibrium, 
(C) T1 map and (D) composite image of 5 ASL MRI contrast images registered with post processing.  
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4.3.3 Comparison of right and left kidneys 
Measurements of right and left kidneys were compared to exclude any confounding effect 
by differences in adjacent tissue types. No significant difference was observed in the T1 
relaxation time of the cortex (p = 0.74), nor whole kidney (p = 0.56). Neither was there a 
difference in perfusion of the cortex (p = 0.93), or whole kidney (p = 0.28). There was a 
significant correlation between the perfusion measured in the right and left kidneys of each 
participant between visits 1 and 2, both in the cortex (r = 0.79; p < 0.001), and the whole 
kidney (r = 0.80; p < 0.001) (figure 4.4). 
4.3.4 T1 relaxation time 
No difference in T1 longitudinal relaxation time was observed between visits either in the 
whole kidney ROI (1491 ± 61 vs 1499 ± 52 ms; p = 0.52), cortical ROI (1376 ± 104 vs 1406 
± 96 ms; p = 0.07), or medullary ROI (1651 ± 86 vs 1639 ± 80 ms; p = 0.38). 
4.3.5 Perfusion 
Similarly, no difference in perfusion measured with ASL MRI was observed between visits. 
Whole kidney perfusion was 228 mL/min/100g at ASL MRI 1 and 230 mL/min/100g at ASL 
MRI 2 (p = 0.66), with significant correlation between the two MRIs (r = 0.75, p < 0.001). 
Cortical perfusion was 321 mL/min/100g then 334 mL/min/100g (p = 0.18), with significant 
correlation between the two (r = 0.74, p < 0.001). Absolute kidney perfusion was 367 ± 66 
mL/min at ASL MRI 1 and 379 ± 86 mL/min at ASL MRI 2 (p = 0.33), whilst total perfusion 
was 734 ± 117 mL/min at ASL MRI 1 and 757 ± 156 mL/min at ASL MRI 2 (p = 0.42) 
(figure 4.5). 
4.3.6 Indices of repeatability 
Bland Altman plots were constructed of the cortical and whole kidney perfusion 
measurements made at ASL MRIs 1 and 2 (figure 4.6). These showed good agreement 
between measurements, with a random distribution of means plotted against differences 
observed. The intra-class correlation for cortical perfusion was 0.85 (95% confidence 
interval 0.65 – 0.94), whilst the CVws was 9.2%. The intra-class correlation for whole kidney 
perfusion was 0.86 (0.68 – 0.94), whilst the CVws was 7.1%. 
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 MRI 1 MRI 2 p  value 
Kidney length (cm) 10.6 ± 0.8 10.8 ± 0.8 0.022* 
Kidney volume Ellipsoid formula (cm³) 120.5 ± 26.1 126.4 ± 24.9 0.019* 
Kidney volume voxel count (cm³) 155.7 ± 29.2 157.7 ± 28.6 0.39 
Whole kidney T1 (ms) 1491 ± 61 1499 ± 52 0.52 
Cortical T1 (ms) 1376 ± 104 1406 ± 96 0.07 
Medullary T1 (ms) 1651 ± 86 1639 ± 80 0.38 
Whole kidney perfusion (mL/min/100g) 228 ± 40 230 ± 41 0.66 
Cortical perfusion (mL/min/100g) 321 ± 63 334 ± 63 0.18 
Absolute perfusion (mL/min) 367 ± 66 379 ± 86 0.33 
Table 4.2 MRI measurements of T1 longitudinal relaxation time and ASL perfusion.  
p value refers to a Student’s t test comparison between the two visits. Asterisks (*) indicate parameters 
where there was a significant difference. 
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Figure 4.4 Correlation of right and left kidney perfusion measured by ASL MRI.  
r is the Pearson correlation coefficient. 
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Figure 4.5 Perfusion correlation plot 
Correlation between whole and cortical kidney perfusion measurements made at MRI 1 and 2. r is the 
Pearson correlation coefficient. 
  
Chapter 4 137 
 
 
 
Figure 4.6 Reproducibility of ASL MRI. 
Bland Altman plots of cortical (A) and whole kidney (B) perfusion measurements made at MRI 1 and 2. 
Solid line and adjacent number indicates mean difference, whilst dashed line and number indicates 
limits of agreement.  
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4.4 Discussion 
This study demonstrates the reproducibility of perfusion measurements made using FAIR 
True FISP ASL on a 3 T MRI in healthy volunteers, with no significant differences found 
between the first and second measurements made of both T1 relaxation time and renal 
perfusion. 
4.4.1 T1 and ASL MRI data in the literature 
T1 values were somewhat higher than reported in the literature, at 1491 ms for the whole 
kidney, 1375 ms at the cortex, and 1651 ms at the medulla. This is in comparison to reported 
values of 1142 ms at the cortex and 1545 ms at the medulla reported in one previous study 
which used an inversion recovery method with different inversion times, in contrast to the 
multiple look locker sequence used here. MOLLI determination of T1 has advantages such 
as faster scan time and smaller limits of agreement between repeated measures than 
traditional T1 mapping techniques, and has been validated at least in cardiac tissue.  
Published data using ASL to measure renal perfusion in subjects with normal renal function 
show a wide range of values from 197 mL/min/100g to 329 mL/min/100g. This variation 
may represent physiological or population differences but factors pertaining to the ASL 
method are likely to also contribute. A number of ASL protocols exist differing in labelling 
and image acquisition strategy. In addition to the numerous ASL sequences in use, different 
acquisition strategies have been employed in order to minimise the error caused by 
respiratory motion. Consistent with the approach here, other studies have employed breath-
holding techniques, which whilst minimising respiratory motion, can prove difficult for 
participants to comply with. In this study all of the healthy volunteers were able to comply 
with a 25 second breath hold, however this strategy may not be appropriate for patients with 
kidney or co-morbid diseases. Other strategies which have been employed include prolonged 
acquisition during light free breathing, respiratory triggering, navigator echo and parallel 
imaging methods. Post-acquisition image realignment has been shown to improve visual 
quality and background noise suppression can be combined with parallel imaging to allow 
whole kidney data to be collected during free breathing. The same study demonstrated that 
background suppression resulted in under estimated perfusion measurements, whilst motion 
correction led to improved estimation of perfusion. Further research is required to improve 
the application of these techniques in order to give accurate quantification of renal perfusion.  
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4.4.2 Reproducibility of ASL MRI 
Good reproducibility was demonstrated in the perfusion measurements made at 3.0 T MRI, 
with within subject coefficient of variation calculated at 9.2 % for cortical perfusion, and 7.1 
% for whole kidney perfusion. This is similar to measures of reproducibility found in other 
studies at 1.5 T (Cutajar et al., 2012). Therefore there was no demonstrable difference in the 
reproducibility of ASL measurements made at 1.5 T or 3.0 T in healthy volunteers. Signal 
to noise ratio is greater at higher field strengths, and whilst no advantage in terms of 
reproducibility was observed in this study, this may be of more benefit in the imaging of 
patients with chronic kidney disease where image quality may be compromised by patient 
factors such as obesity or breath holding ability, or tissue factors such as kidney fibrosis. 
Perfusion maps generated via post processing result in a heterogeneous appearance of the 
renal medulla, probably due to the presence of larger vessels and the renal pelvis. This 
resulted in a degree of variability in the measurement of perfusion in this region, hence the 
measurement of whole kidney perfusion in preference to medullary perfusion. Improved post 
processing techniques may allow for differential quantification of cortical and medullary 
perfusion and measurement of these values may reveal differences in relative perfusion in 
patients with chronic kidney disease. Ideally automated detection of the differentiation 
between cortex and medulla using a digital threshold for signal intensity would generate 
more reliable, less operator dependent and hence more reproducible data.  
This study provides further evidence for the reproducibility of FAIR ASL and confirms this 
at higher field strength than in previous work. To ensure normality of renal function and 
minimal variation in scan conditions in this cohort, subjects underwent biochemical 
screening of blood and urine and physical assessment to confirm normal kidney function 
prior to imaging.  Furthermore, participants attended at a fixed time of day after a stated 
period of fasting to ensure constant study conditions. It is possible that differences in the 
ASL sequence, MRI systems or subject factors used in different studies may account for the 
variation in perfusion measurements.  
Future work is required to refine renal perfusion measurements using ASL. Quantitative 
analysis of ASL images is possible using a model derived from the extended Bloch equation. 
A limitation of this is that the model ignores transit time and exchange effects of water 
molecules in blood. Some of the labelling is lost during transit from the location of tagging 
to the location of capillary exchange in tissue, to a degree which is relative to the transit 
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time, such that perfusion values might be confounded by this. These limitations will have to 
be borne in mind during the use of ASL MRI in patients with chronic kidney disease given 
there may be inter individual differences in transit time between CKD and healthy 
populations, and intra individual differences which accrue over time, as CKD progresses. 
Transit time could be measured as part of the ASL imaging protocol and perfusion values 
adjusted for this; further research is required to determine if this would be the appropriate 
approach.  
4.4.3 Conclusions 
In summary, development of renal ASL MRI represents a technique, which may be 
applicable, both for diagnostic purposes and for monitoring response to therapeutic 
interventions. This study shows that ASL MRI is reproducible in healthy volunteers with 
normal kidney function at 3.0 Tesla. Further research is required to investigate its utility 
across a spectrum of renal disease.  
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5.1 Introduction 
As was discussed in section 1.7, renal perfusion is an important physiological parameter in 
health and disease. In normal physiology, renal blood flow is an important determinant of 
oxygen supply and glomerular filtration rate (Evans et al., 2013).  In chronic kidney disease 
(CKD), renal microvascular dysfunction is one of a number of pathological mechanisms 
involved in the progression of disease, irrespective of the initiating insult. Endothelial 
dysfunction is typically association with oxidative stress, and there is accumulating evidence 
implicating these processes in the progression of CKD (Baylis, 2012). Furthermore, previous 
studies have shown an improvement in renal plasma flow following administration of 
antioxidants such as ascorbic acid (Delles et al., 2004).   
In chapter 4, satisfactory reproducibility of ASL measurements in volunteers with normal 
renal function was demonstrated, with a coefficient of variance of 9.2% and 7.1% for cortical 
perfusion and whole kidney perfusion respectively. The utility of ASL MRI as a marker for 
disease severity and progression in CKD, and as a measure of response to therapy, is yet to 
be determined however. This study was therefore designed to investigate the use of ASL 
MRI for the assessment of patients with CKD and their response to administration of 
ascorbic acid. 
5.2 Methods 
The methodology of this study has already been described in section 2.1.3 and is summarised 
by figure 5.1. The CKD group was formed of patients attending the local general nephrology 
clinic, and are a separate cohort from those who participated in the Renox study. Healthy 
volunteers were recruited from the live donor transplant clinic. ASL MRI was performed 
according to the protocol described in section 2.4 and image analysis was performed offline 
using bespoke software written with MATLAB. 
 
Figure 5.1 KidRASL study protocol 
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5.3 Results 
5.3.1 Baseline data 
24 HV and 17 patients with CKD were recruited; the demographic data for each group is 
displayed in table 5.1. The CKD group was significantly older (47 ± 14 vs 56 ± 10 years, p 
= 0.040), and had higher blood pressure (132/83 ± 15/8 vs 151/90 ± 26/14 mmHg, p = 
0.006/0.047). CKD-EPI eGFR was 39.8 ± 25.2 mL/min/1.73m² in the CKD group and 99.6 
± 14.0 mL/min/1.73m² in the HV group (p < 0.001). 
5.3.2 Renal anatomy 
Renal anatomical data is shown in table 5.2. Kidney length was significantly shorter in the 
CKD group compared with the HV group (10.5 ± 0.8 vs 9.7 ± 0.9 cm, p = 0.005) however 
renal volume was no different between the two (167.1 ± 35.0 vs 160.1 ± 53.4 cm3, p = 0.62). 
The CKD group had significantly higher T1 longitudinal relaxation time both measured in 
the cortex (1366 ± 122 vs 1529 ± 77 ms, p < 0.001) and the whole kidney (1472 ± 91 vs 
1550 ± 81 ms, p = 0.007) ROI (figure 5.2). Furthermore, CMD was significantly higher in 
CKD than in HV (0.84 ± 0.07 vs 0.94 ± 0.07, p < 0.001). 
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Parameter 
Healthy 
volunteers 
Chronic kidney 
disease 
p value 
 n = 24 n = 17  
Age (years) 47 ± 14 56 ± 10 0.040* 
Body mass index (kg/m2) 26.5 ± 5.3 29.3 ± 3.4 0.06 
Blood pressure (mmHg) 132/83 ± 15/8 151/90 ± 26/14 0.006/0.047* 
Mean arterial blood pressure 
(mmHg) 
99 ± 9 110 ± 17 0.011* 
CKD-EPI eGFR (mL/min/1.73m²) 99.6 ± 14.0 39.9 ± 25.2 < 0.001* 
Serum creatinine (µmol/L) 68 ± 10 184 ± 69 <0.001* 
Serum creatinine 1 year 
previously (µmol/L) 
66 ± 11 165 ± 57 < 0.001* 
Primary renal diagnosis (n)    
Diabetes 
Glomerulonephritis 
Renovascular disease 
Other 
Unknown 
 
2 
8 
4 
2 
1 
 
CKD stage (n)    
1 
2 
3 
4 
5 
 
2 
1 
4 
10 
0 
 
Table 5.1 Baseline clinical and biochemical data in the KidRASL study.  
Asterisks (*) indicate significant a difference between the two groups. 
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Parameter 
Healthy 
volunteers 
Chronic 
kidney 
disease 
p value 
Kidney length (cm) 10.5 ± 0.8 9.7 ± 0.9 0.005* 
Kidney volume (cm3) 167.1 ± 35.0 160.1 ± 53.4 0.62 
Cortical T1 time (ms) 1366 ± 122 1529 ± 77 <0.001* 
Whole kidney T1 time (ms) 1472 ± 91 1550 ± 81 0.007* 
Corticomedullary differentiation 0.84 ± 0.07 0.94 ± 0.07 <0.001* 
Mean cortical perfusion 
(mL/min/100g) 
279 ± 69 136 ± 37 <0.001* 
Mean whole kidney perfusion 
(mL/min/100g) 
221 ± 38 146 ± 24 <0.001* 
Mean kidney perfusion (mL/min) 366 ± 79 223 ± 75 <0.001* 
Total renal perfusion (mL/min) 731 ± 159 446 ± 150 <0.001* 
Table 5.2 Baseline T1 longitudinal relaxation time and perfusion 
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Figure 5.2 T1 and renal perfusion in CKD and HV 
Box and whisker plots showing T1 longitudinal relaxation times and ASL MRI perfusion measurements 
for CKD and HV groups. 
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5.3.3 Intra-observer variability 
Intra-observer variation of cortical perfusion measurements was 7.3% with intra-class 
correlation (ICC) of 0.98, whilst variation of whole kidney perfusion measurements was 
found to be 4.4% with ICC of 0.96. 
5.3.4 Acquisition strategy  
Whole kidney perfusion was higher when measured from a single acquisition compared to 
using five acquisitions (241 ± 40 vs 227 ± 41 mL/min/100g, p < 0.01) but the two techniques 
were significantly correlated (r = 0.86, p < 0.001). ICC was 0.82 (95% CI 0.53 – 0.93; p < 
0.001) and mean variation was 7.8%. Cortical perfusion measured from a single acquisition 
was not significantly different from that measured from 5 acquisitions (292 ± 58 vs 296 ± 
75 mL/min/100g), and these measurements were significantly correlated (r = 0.84, p < 
0.001). ICC was 0.82 (95% CI 0.63 – 0.92; p < 0.001) and mean variation was 10.7%. Image 
quality, however, was subjectively poorer when perfusion maps were derived from a single 
acquisition (figure 5.3).  
5.3.5 Renal perfusion 
Renal perfusion was significantly lower in the CKD group (table 5.2 and figure 5.4). In the 
CKD cohort, mean cortical perfusion was 136 ± 37 mL/min/100g in comparison to 279 ± 69 
mL/min/100g in the HV cohort (p < 0.001). Similarly, whole kidney perfusion was reduced 
in the CKD group, at 146 ± 24 mL/min/100g compared to 221 ± 38 mL/min/100g (p < 
0.001). Furthermore, total renal perfusion was 446 ± 150 mL/min in CKD compared to 731 
± 158 mL/min in HV (p < 0.001). Typical perfusion maps from both groups are shown in 
figure 5.4.  
5.3.6 Correlation of clinical, biochemical and MRI parameters 
Both cortical and whole kidney perfusion were found to have a negative association with 
age (respectively, r = -0.48, p = 0.002; r = -0.51, p = 0.001). Whilst there was no association 
between blood pressure and cortical perfusion, a negative correlation was observed between 
whole kidney perfusion and mean arterial blood pressure (r = -0.33, p = 0.049). 
Correlation was seen between CKD EPI eGFR and both whole kidney T1 longitudinal 
relaxation time (r = -0.40, p = 0.011) and cortical T1 time (r = -0.58, p < 0.001). Furthermore, 
significant correlation was seen between CKD-EPI eGFR and both cortical perfusion (r = 
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0.73, p < 0.001) and whole kidney perfusion (r = 0.69, p < 0.001). There was also significant 
correlation between total renal perfusion and eGFR (r = 0.69, p < 0.001). PCR was negatively 
correlated with both cortical (r = -0.60, p = 0.002) and whole kidney perfusion (r = -0.43, p 
= 0.037). The percentage rise in serum creatinine over the preceding 12 months prior to the 
study was also negatively correlated with total perfusion (r = -0.52, p = 0.028) (figure 5.5).  
5.3.7 Change in perfusion following ascorbic acid 
Perfusion measurements made before and after administration of ascorbic acid are shown in 
table 5.3. No statistically significant differences were observed (table 5.3). Cortical perfusion 
was 137.2 ± 38 pre and 128.4 ± 40.0 mL/min/100g post ascorbic acid (p = 0.38), whilst 
whole kidney perfusion was 146.6 ± 17.8 mL/min/100g pre and 156.0 ± 22.5 mL/min/100g 
post (p = 0.31). Total kidney perfusion was 471.0 ± 156 mL/min before and 515.2 mL/min 
after ascorbic acid administration (p = 0.32). 
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Figure 5.3 Single versus multiple acquisitions 
Comparison images and Bland Altman plot of using a single acquisition versus using multiple 
acquisitions. 
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Before 
ascorbic acid 
After  
ascorbic acid 
p value 
Cortical perfusion (mL/min/100g) 137.2 ± 38.2 128.4 ± 39.7 0.38 
Whole kidney perfusion 
(mL/min/100g) 
146.6 ± 17.8 156.0 ± 22.5 0.31 
Mean kidney perfusion (mL/min) 235.5 ± 78.0 257.6 ± 108 0.32 
Total kidney perfusion (mL/min) 471.0 ± 156.1 515.2 ± 216.0 0.32 
Table 5.3 Perfusion measurements before and after ascorbic acid 
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Figure 5.4 Perfusion maps in CKD and HV 
ASL MRI perfusion maps from patients with healthy volunteer (A), in comparison to a participant with 
CKD (B). Demonstrates right and left whole kidney perfusion (1 & 2), and right and left cortical 
perfusion (3&4).
  
1
5
2
 
 
 
Figure 5.5 Perfusion vs clinical parameters 
Correlation plots showing associations between (A) cortical perfusion and eGFR, (B) whole kidney perfusion and eGFR, and (C) change in serum creatinine over the preceding 
year and total perfusion. 
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5.4 Discussion 
CKD has a tendency to worsen despite treatment of blood pressure and any other reversible 
or aetiological factors, and there is evidence that common pathological mechanisms are 
responsible for this irrespective of the original renal insult. Renal damage has been shown 
to correlate primarily with tubulointerstitial injury (Schainuck et al., 1970), characterised by 
a vicious cycle of microvascular dysfunction leading to tubular atrophy and fibrosis (Bohle 
et al., 1990). In vivo biomarkers to assess renal progression are lacking and emerging 
techniques such as ASL MRI may provide much needed insight into renal perfusion and thus 
extent of renal damage. 
5.4.1 Renal perfusion in CKD  
Cortical perfusion is lower in CKD, at 136 mL/min/100g compared to from 279 
mL/min/100g in HV with correlation between perfusion and degree of renal impairment 
quantified by CKD-EPI eGFR. Whole kidney perfusion is similarly reduced, from 221 
mL/min/100g to 146 mL/min/100g. This is in keeping with previous measurements of renal 
perfusion in health and disease, and the finding of reduced native kidney perfusion in CKD 
has also previously been demonstrated (Artz et al., 2011a, Rossi et al., 2012). Whilst these 
perfusion values are lower than found in other studies, this CKD cohort represents the largest 
to undergo ASL MRI and included patients with more advanced renal impairment than 
previously studied. These findings demonstrate strong correlation of renal function to 
perfusion across a broad range of CKD-EPI eGFR, ranging from 20 to 126 mL/min/1.73m2. 
Furthermore, an association was found between perfusion and decline in renal function, such 
that patients with lower total perfusion were more likely to have undergone progression of 
their disease over the preceding year. ASL MRI may therefore be used to identify patients 
who will benefit from interventions used to optimise renal haemodynamics, such as 
inhibitors of the renin angiotensin system, in order to improve outcomes. Earlier pilot studies 
have shown the utility of ASL MRI in monitoring the response to such interventions (Ritt et 
al., 2010).  
Previous human studies using ASL MRI are summarised in table 1.2, which demonstrates 
the range of perfusion values previously found using this technique, in both health and 
disease. As discussed in chapter 4, this could be ascribed to differences in ASL sequence, 
imaging strategy, and post processing as well as true differences in study population. For 
example, different strategies have been employed to circumvent the problem of renal 
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respiratory motion, including breath-holding, respiratory gating, or post processing 
registration. Gardener & Francis (Gardener and Francis, 2010) found no difference in 
perfusion measurements made with either breath-holding or free breathing, but found 
reduced perfusion when background suppression was used to improve image quality, 
showing that some variations in imaging approach cause differences in perfusion 
measurements. Typically, a number of acquisitions are taken given the low signal to noise 
inherent to ASL, however this increases scan time and leads to patient tiring. No difference 
in perfusion measurements with increasing acquisitions was found here, but greatly 
improved image quality was observed, such that repeated image acquisition is to be 
recommended where tolerated. This ASL protocol resulted in a scan time of 15 minutes, and 
breath-holding time of 12 seconds, which was tolerated by all participants.  
ASL has been validated in animal models using microsphere techniques and using explanted 
organs undergoing haemoperfusion. In normal renal function, strong correlation between 
ASL and both DCE MRI perfusion (Cutajar et al., 2014), and PAH clearance (Ritt et al., 
2010) has been shown. Validation of ASL against a gold standard perfusion technique has 
never been undertaken in a CKD population. Given that quantitative measurement of 
perfusion using the standard ASL kinetic model is dependent on T1 time, it is possible that 
structural changes in CKD are at least partly responsible for the functional changes suggested 
by ASL MRI. In keeping with previous studies (Huang et al., 2011), T1 time was 
significantly higher in CKD, and showed strong correlation with CKD-EPI eGFR. Lee et al 
(Lee et al., 2007) previously showed that cortical T1, but not medullary T1 time showed 
strong correlation with single kidney GFR measured by renography. These differences may 
be accounted for by changes in extracellular composition, fibrosis, or changes in the 
microvasculature. Further investigation into how structural changes affect measurement of 
functional MRI parameters is needed, to confirm that ASL provides true assessment of 
perfusion in CKD. That said, T1 time itself has been shown to have biological relevance in 
cardiac imaging, with prolongation observed in association with the diffuse fibrosis of 
hypertrophic cardiomyopathy (Puntmann et al., 2013). Further research is required in larger 
patient cohorts to determine the utility of T1 time as a biomarker in CKD.  
5.4.2 Effect of antioxidant administration on renal perfusion 
It was hypothesized that antioxidant administration would ameliorate oxidative stress, 
reduce endothelial dysfunction and improve renal perfusion, however no increase in renal 
blood flow was seen following administration of ascorbic acid in patients with CKD. In 
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contrast to these findings, an earlier study by Delles et al (Delles et al., 2004) showed that 
L-arginine increased renal plasma flow measured by PAH clearance in patients with type 2 
diabetes and healthy volunteers, whilst co infusion of ascorbic acid further increased 
perfusion only in patients with diabetes. This contradiction could be explained by 
methodological differences between PAH clearance and ASL, or by the fact that this study 
administered ascorbic acid as a monotherapy. Alternatively, the renal perfusion 
abnormalities seen in this cohort with advanced CKD may be fixed and less responsive to 
changes in oxidative stress than in the population of patients with early diabetic nephropathy. 
Regardless, this study demonstrates the feasibility of the use of ASL for measuring the acute 
response to an intervention highlighting the utility of this technique for assessing response 
of renal physiology to novel therapeutics. The half-life of the ASL tracer is measured in 
seconds, relating to the T1 time of blood, such that the technique is well suited for the rapid 
repeated acquisition such as that performed in this study.  
5.4.3 Study limitations 
This study has a number of limitations. This CKD cohort has a variety of renal pathologies 
and whilst common pathological mechanisms underpin all chronic kidney disorders it is 
possible that perfusion abnormalities may predominate in certain aetiologies of CKD over 
others. Despite being one of the largest ASL studies in CKD, even larger studies are required 
to confirm these findings and exclude the possibility of group effects confounding some of 
the associations with the biochemical parameters which were measured. Furthermore, the 
standard ASL kinetic model was used here which is primarily validated in healthy volunteers 
and assumes constant arterial transit time and blood tissue exchange. Differences in these 
factors may artefactually alter perfusion measurements in CKD, and as previously discussed 
further research is necessary to validate the use of ASL in the CKD population. Lastly, this 
study was carried out using 3.0 T MRI, which is in general less available in clinical use and 
further work will be required to translate these findings to 1.5 T platform, as it is more 
commonly used in clinical practice.  
5.4.4 Conclusions 
In conclusion, this study demonstrates significant differences in renal perfusion measured 
with ASL MRI in a group of patients with advanced CKD, and shown correlation to renal 
parameters such as eGFR. Correlation between progression of CKD over the preceding year 
and perfusion measurement was also shown. In the future, non-invasive imaging such as 
ASL MRI may be used as a biomarker to identity patients at high risk of progressive renal 
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impairment who may benefit from aggressive therapy, or as a surrogate marker in clinical 
trials of novel therapeutics.
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6.1 Principle findings 
6.1.1 Oxidative stress in chronic kidney disease 
CKD is associated with excess cardiovascular morbidity and mortality which is not entirely 
explained by conventional cardiovascular risk factors. As discussed in chapter 1, CKD 
causes a state of oxidative stress due to increased ROS production and depletion of 
antioxidant capacity. In this state of oxidative stress, there is disruption of redox signalling 
and depletion of signalling molecules such as NO, leading to vascular and endothelial 
dysfunction which have an important role in the early stages of atherosclerosis and other 
forms of CVD. Interventional studies using antioxidants to modulate oxidative stress to 
improve endothelial function and reduce cardiovascular risk have had conflicting results. 
The aim of the oxidative stress in CKD study was therefore to determine the effect of 
parenteral ascorbic acid on vascular biology in a cohort of patients with CKD stages 3 – 5.  
A crossover comparison of intravenous saline and ascorbic acid was carried out in patients 
with stages 3 – 5 CKD and a group of matched hypertensive controls. Biomarkers of 
oxidative stress were measured at baseline, and at 10 and 60 minutes following ascorbic 
acid. Arterial function was evaluated using the SphygmoCor® system, and brachial artery 
FMD was measured after each intervention.  
Participants with CKD had lower ascorbic acid, higher TAP and ADMA, together with 
higher adjAix and PWV. There was no difference in baseline FMD between the groups. 
Intravenous ascorbic acid increased TAP and O2
-, and reduced central BP and adjAix in both 
groups, and lowered ADMA in the CKD group only. No effect on FMD was observed. As 
discussed, there is conflicting evidence regarding the effect of ascorbic acid on vascular 
function; this study highlighted the mixed pro- and antioxidant effects of ascorbic acid, and 
whilst there was an effect on vascular biology in terms of a central blood pressure and 
ADMA, there was no change in endothelial function.  
The strengths of this study include the recruitment of a well characterised cohort of patients 
without a history of vascular disease. The effects of ascorbic acid administration were 
investigated using gold standard techniques performed by a single operator. Despite there 
being no effect on endothelial function, this study lends credence to the idea of ascorbic acid 
as a vasoactive substance.  
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6.1.2 Renal arterial spin labelling MRI in healthy volunteers 
As discussed in section 1.7, regulation of renal perfusion is also in part sensitive to redox 
regulation. Established methods of measuring renal perfusion non-invasively have inherent 
drawbacks, including the need for administration of a contrast agent which may be 
nephrotoxic or harmful in renal impairment. ASL MRI is an emerging technique which 
allows quantitative measurement of kidney perfusion without administration of a harmful 
contrast agent. In earlier studies, ASL MRI showed good agreement with perfusion 
measured using a microsphere technique in a porcine animal model (Artz et al., 2011b), and 
had good accuracy in measuring perfusion in explanted organs undergoing haemoperfusion 
(Warmuth et al., 2007a). In humans, ASL MRI has good agreement with other in vivo 
measures of kidney perfusion such as DCE MRI (Cutajar et al., 2014) and PAH clearance 
(Ritt et al., 2010). At the onset of this work, local experience with ASL MRI was limited and 
few studies had examined the repeatability of ASL MRI at 3.0T in healthy volunteers. The 
VolRASL study was designed to establish local experience with the technique and 
investigate the reproducibility of the technique in healthy volunteers at a field strength of 
3.0T.   
Healthy volunteers attended on three occasions: firstly for biochemical and clinical 
assessment, and on the second and third occasions underwent ASL MRI. Renal anatomy was 
evaluated on sagittal HASTE images, T1 longitudinal relaxation time was measured using a 
MOLLI sequence and FAIR True-FISP ASL MRI was carried out to measure perfusion.   
T1 time was 1376 ms in the cortex, 1651 ms in the medulla, and 1491 ms for whole kidney 
ROI. Whole kidney perfusion was found to be 228 mL/min/100g, cortical perfusion was 321 
mL/min/100g and absolute perfusion was 367 mL/min per kidney. In terms of 
reproducibility, the CVws was 9.2 % for cortical perfusion and 7.1 % for whole kidney 
perfusion, and good agreement was demonstrated on Bland Altman analysis.  
A broad range of perfusion values have been found in previous studies employing ASL MRI 
and our findings lie within this range. The T1 longitudinal relaxation times are higher than 
in earlier literature, although this is to be expected at higher magnetisation, and there is 
limited data regarding renal T1 values at 3.0 T. Good reproducibility was shown, with 
acceptable values of coefficient of variation, and good agreement on Bland Altman analysis. 
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6.1.3 Renal arterial spin labelling MRI in chronic kidney disease 
Subsequently, the redox regulation of kidney perfusion was investigated in the KidRASL 
study, by measuring the response to parenteral ascorbic acid using renal ASL MRI. Earlier 
work has showed that renal function is regulated in a redox sensitive manner. For example, 
infusion of the NOS inhibitor L-NAME reduces medullary blood flow and filtration fraction 
in rats with normal renal function (Zatz and de Nucci, 1991), whilst chronic supplementation 
results in proteinuria and renal impairment (Baylis et al., 1992). Conversely, 
supplementation with the SOD mimetic tempol ameliorates renal impairment and tubular 
atrophy in 5/6 nephrectomised mice (Ding et al., 2015). There are limited human studies into 
the redox regulation of renal perfusion, and so the KidRASL study was designed to 
investigate the effect of ascorbic acid on renal perfusion, measured using ASL MRI.  
No significant difference in kidney perfusion was shown following administration of 
ascorbic acid, either measured in the cortex or in the whole of the kidney. This is in contrast 
to an earlier study by Delles et al, in which parenteral administration of ascorbic caused 
increased perfusion in patients with type 2 diabetes co-infused with L-arginine (Delles et al., 
2004). In this earlier study, participants had much earlier renal disease in comparison to the 
population of patients with CKD stages 3 – 5 recruited here. The discrepancy in the two 
studies could therefore be accounted for by the need for the simultaneous administration of 
NOS substrate to increase renal perfusion, or by the fact that irreversible changes to renal 
function have developed in this later stage of CKD.  
The strengths of this study include the fact that this is one of the largest studies employing 
ASL MRI to investigate patients with CKD, especially such a well characterised cohort of 
patients and at a field strength of 3.0 T. Ascorbic acid was administered in a controlled 
environment and perfusion was measured using a technique that was well validated, at least 
in healthy volunteers. Although no change in renal perfusion was found following ascorbic 
acid, it was found that ASL MRI demonstrated significant differences between those with 
normal renal function and participants with CKD stages 3 – 5, with increased cortical and 
whole kidney T1, and reduced cortical and whole kidney perfusion. Interestingly, absolute 
perfusion showed a weak but significant correlation with progression of kidney disease over 
the preceding year. 
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6.2 Limitations and criticisms 
6.2.1 Antioxidant intervention 
Intravenous parenteral ascorbic acid was used as a modulator of oxidative stress and a 
number of criticisms of the choice and administration of the agent could be made. For 
example, ascorbic acid has not only antioxidant actions but acts as an essential cofactor to 
several other enzymes including dopamine β-monooxygenase, peptidyl glycine α-
monooxygenase, 4-hydroxyphenylpyruvate and prolyl hydroxylase, and as shown here, also 
has pro-oxidant effects in addition to its antioxidant activity. As such it could be argued that 
ascorbic acid is not the “cleanest” of antioxidant agents, however this criticism could also 
be made of other antioxidant agents available for use in humans.  
For example, N-acetylcysteine administered parenterally is associated with drug reaction in 
over 10% of patients, with anaphylactoid reactions occurring in 8% to 18% of patients 
(Schmidt and Dalhoff, 2001). In addition to their antioxidant effect, tocopherols also have 
enzyme regulatory activity, for example in relation to protein kinase C. Whilst the route of 
administration of ascorbic acid could be criticised for being non-physiological, the 
intravenous route avoids the problems of inter- individual or group differences in absorption 
and compliance which are associated with oral supplementation. The intravenous route 
therefore allows for study of the effects of ascorbic in a controlled and standardised manner. 
6.2.2 Participants and recruitment 
In the Renox study, patients with CKD were recruited from general nephrology clinics, 
whilst controls were recruited from a tertiary referral blood pressure clinic, in order to match 
for blood pressure and other non-renal aspects of cardiovascular risk. Whilst participants 
were well matched for age and BMI, the CKD group had significantly lower blood pressure. 
In contrast to earlier studies, there was no difference in FMD between groups, and it was 
postulated that the excess endothelial dysfunction associated with CKD might have been 
offset by the lower blood pressure in the cohort. Alternatively, it is possible that uraemia 
itself is a smaller contributor to oxidative stress in comparison to other cardiovascular risk 
factors. Whilst many studies have shown an association between CKD and FMD, other 
studies have failed to show this relationship. Unfortunately the Renox study failed to 
comprehensively answer this question due to the discrepancy in matching. Whilst avoidance 
of participants with pre-existing vascular disease, diabetes, or in the case of the control 
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group, microalbuminuria, should be considered a strength of the study, these exclusion 
criteria contributed to difficulties in recruitment. 
Similarly, in the KidRASL study the CKD group had significantly higher age and blood 
pressure than the control group. Given that there was an association between perfusion and 
both age and systolic blood pressure, this discrepancy in matching could have confounded 
the differences in ASL measurements, however, on stepwise linear regression analysis eGFR 
remained a significant determinant of renal perfusion after adjustment for age. Nevertheless 
the conclusions regarding differences in MRI findings could be stronger with better 
matching between CKD and control groups. 
6.2.3 Biomarkers of oxidative stress 
As discussed in chapter 1, there are numerous molecules previously posited as ideal markers 
of oxidative stress, including ROS and RNS themselves, as well as the downstream end 
products of oxidative damage to lipids, proteins and other macromolecules. There remains a 
lack of consensus however regarding the most informative and appropriate biomarkers 
which should be measured during clinical studies into oxidative stress. A major criticism of 
any biomarker is that measurement of its circulating concentration in serum or blood, may 
not reflect its concentration in the relevant tissues being studied, for example, in endothelial 
cells or vascular smooth muscle. The situation is complicated by the fact that there may not 
be a direct relationship between burden of oxidative stress, and resultant endothelial 
dysfunction and cardiovascular outcome. 
In the Renox study, CKD was associated with lower ascorbic acid, and higher TAP and 
ADMA, whilst there was no difference in F2-isoprostanes, GSH/GSSG ratio, or O2
-. This 
contradicts earlier studies where an increase in markers of oxidative stress were observed. 
This disagreement could be related to true differences in populations, methodological 
differences, or related to lack of power. Certainly, with regards to the latter, the study was 
powered to detect a difference in FMD rather than the secondary aims of oxidative stress 
biomarkers, and all biomarkers were numerically higher in CKD. With regards to 
methodological issues, all biomarkers were tested in whole blood or serum samples, which 
in some cases may not be appropriate. The vast majority of glutathione, for example, is found 
intracellularly such that measurement of erythrocyte or polymorphonuclear leukocyte 
glutathione may be more appropriate (Jacobson and Moldeus, 1994). 
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6.2.4 Magnetic resonance imaging 
Significant differences in T1 longitudinal relaxation time and renal perfusion measured by 
ASL MRI were measured in patients with CKD compared to controls. A number of 
criticisms could be made of the imaging strategy employed here, and there are inherent 
limitations to the ASL MRI technique which should also be acknowledged.  
The signal to noise ratio (SNR) describes how much true physiological signal is measured 
compared to background noise (Dietrich et al., 2007). Increasing the number of acquisitions 
increases SNR, as the contribution of random noise to the MRI signal has the tendency to 
cancel itself out with repeated imaging, such that SNR is proportional to the square root of 
the number of acquisitions. ASL MRI has an inherently low signal to noise ratio, and most 
centres aim to lessen this by acquiring a number of images and producing an average. This 
demands meticulous alignment of images in order to generate an accurate average value of 
each voxel, which necessitates the application of one or more of a number of imaging 
strategies or post processing techniques. In this study, acquisitions were taken during 
exhaled breath holding in order to reduce artefact derived from respiratory motion and post 
processing image registration was performed using in house developed software. Other 
studies have used respiratory gating techniques which use an MR prepulse to identify the 
position of an anatomical landmark such as the diaphragm, in order to synchronise image 
acquisition. Others have trained participants in free light breathing in order to reduce the 
movement which occurs during respiration, acquired dozens of images during an extended 
scan time, and subsequently applied post processing image registration. A number of 
techniques were tested prior to commencement of the VolRASL study, and it was found that 
the breath holding strategy provided the clearest pictures and most accurate image 
registration. Respiratory gating was found to prolong scan time without improving image 
quality, and respiratory training was felt to be impractical in a diverse patient population. 
Future work should seek to formally measure SNR produced by available strategies in order 
to allow standardisation of ASL MRI protocols and allow fair comparisons of measurements 
made in different centres. 
Additionally, in the standard kinetic model used to facilitate quantification of perfusion from 
the ASL signal (Martirosian et al., 2004), a number of assumptions are made which may be 
unfounded especially in a CKD cohort. The principle of ASL MRI is that water is labelled 
with an inversion pulse at an intravascular location proximal to the organ of interest, with 
the labelling then subsequently travelling to the imaging region to exchange with tissue 
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blood, after a period of time in transit. This transit time is the aggregate of arterial transit 
time, meaning the interval from the point of labelling to the tissue microvasculature, and the 
tissue transit time which is the duration of tissue capillary exchange. Image acquisition is 
therefore designed to occur after a fixed time delay following labelling. The standard ASL 
kinetic model assumes a fixed arterial transit time which may not be correct either between 
individuals or in CKD. As a result, image acquisition may be mistimed in relation to 
labelling, leading to an inaccurate measure of perfusion. Furthermore, perfusion quantified 
from the ASL signal is inversely proportional to the T1 longitudinal relaxation time of tissue. 
Given that T1 is longer in patients with CKD, as shown here and in previous studies (Huang 
et al., 2011), it is possible that variation in perfusion measurements in kidney disease may 
relate to differences in T1 than to ASL signal. Further research is needed to clarify how much 
ASL perfusion reflects true changes in microvascular perfusion as opposed to reduction in 
arterial transit time of labelled blood or increased T1 time due to structural changes to the 
interstitium.  
6.3 Future directions 
6.3.1 Oxidative stress in chronic kidney disease 
As has been discussed in chapter 1, ROS and other radicals are not simply harmful by-
products, but signalling molecules involved in a number of normal cellular processes. 
Exogenous antioxidants such as ascorbic acid have effects outwith their antioxidant 
properties, and in certain cases have pro-oxidant effects. As such, it is unsurprising that 
studies investigating the administration of antioxidants have had conflicting results and this 
is reflected in the conflicting results of interventional trials of antioxidant therapy. 
Given these conflicting results and negative outcome of systematic review of antioxidant 
interventions, future studies into the manipulation of redox homeostasis may be more fruitful 
by investigating modulators of endogenous antioxidant pathways. Whilst the recent studies 
using bardoxolone methyl raised concerns regarding cardiovascular safety, specific effects 
relating to activation of endothelin receptors, and electrolyte abnormalities have been 
identified which are potentially modifiable. Novel therapeutics which agonise Nrf-2 without 
these adverse effects are also under investigation. 
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6.3.2 Renal imaging in kidney disease 
Significant differences in kidney perfusion were measured in patients with CKD using ASL 
MRI, and interestingly, there was a weak but significant association with progression of 
renal impairment. At present, evaluation of kidney disease relies on measurement of serum 
creatinine in order to derive the eGFR, and quantification of proteinuria, both of which 
provided prognostic information regarding progression to ESRD and likelihood of 
complications such as CVD. Both are imperfect measures, being insensitive to small changes 
in renal function as well as being confounded by factors such as muscle mass and diet. Novel 
biomarkers which allow more accurate quantification of renal function and prognosis are 
greatly needed in order to guide more aggressive therapy, and to act as outcome measures in 
trials of novel therapeutics aimed at ameliorating progression of CKD.  
MRI has many desirable qualities as an imaging technique, allowing avoidance of ionising 
radiation and potentially nephrotoxic contrast agents, which renders it ideal for repeated, 
longitudinal use in chronic disease, and in clinical studies where avoidance of harm to 
participants is crucial. ASL is one of a number of emerging MRI techniques which may have 
utility in CKD. Many of these techniques, discussed below, also allow conversion of 
“pictures to numbers” by modelling techniques validated in phantom and animal studies 
which allow quantification of anatomical or physiological properties relevant to the 
underlying disease process. 
Blood oxygen level dependent (BOLD) MRI measures tissue oxygenation using the 
principle that deoxyhaemoglobin has paramagnetic properties whilst oxyhaemoglobin does 
not. The paramagnetic effects of deoxyhaemoglobin cause local tissue magnetic field 
inhomogeneity, which results in faster transverse dephasing of photons, represented by a 
shorter T2* relaxation time and a lower signal intensity on T2* weighted images (Logothetis 
and Pfeuffer, 2004). The BOLD MRI measurement is often expressed as the relaxation rate, 
R2*, which is the inverse of T2* such that high signal equates to a low concentration of 
oxyhaemoglobin. The utility of BOLD measurements in renal imaging is still under 
investigation. Chrysochou et al investigated the use of BOLD to identify patients who would 
respond favourably to stenting of an atherosclerotic renal artery stenosis (Chrysochou et al., 
2012). Patients whose eGFR rose following revascularisation had a higher ratio of R2* to 
single kidney GFR at baseline, such that the authors postulated that R2*/GFR represented 
living tissue undergoing cellular respiration and converting oxygenated to deoxygenated 
haemoglobin. Tissue with a lower ratio of R2* to single kidney GFR represented kidneys 
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which had undergone permanent physiological changes which would not benefit from 
revascularisation. In a later study of 342 patients undergoing BOLD MRI however, there 
was no association between R2* and eGFR (Michaely et al., 2012). A criticism of both these 
studies is the use of a single measurement of R2*, given that BOLD measurements are a 
relative, rather than absolute indicator of tissue function, such that change in BOLD signal 
following a challenge with a stimulus which alters tissue oxygenation, such as a loop diuretic 
or intravenous fluid, provides a much more useful measure.  
Another emerging MRI strategy which shows promise in the characterisation of renal disease 
is diffusion weighted imaging (DWI). DWI maps the Brownian motion of water molecules 
of each voxel within a given tissue, such that the signal represents the average rate of 
diffusion within that site (Bammer, 2003). The DWI signal therefore relates to a number of 
complex factors such as the composition of both intra- and extracellular fluid, and the 
diffusion which occurs both within, and between the two compartments. Furthermore, 
diffusion in certain tissues is anisotropic, meaning that the direction of flow is not equal in 
all directions due to the presence of certain tracts within the tissue microstructure. The 
direction of diffusion within a voxel can be represented by a mathematical matrix expressing 
the forces occurring in each direction, and diffusion tensor imaging (DTI) is the technique 
by which this information is represented pictographically in a 2- or 3- dimensional image. 
Anisotropy is higher in some tissues in comparison to others (for example in white, rather 
than grey matter), and may be altered by certain disease states, allowing discrimination of 
anatomical compartments and identification of certain pathologies. For example, in 
neuroimaging DWI is used clinically to diagnose stroke, as a measureable change in 
diffusion develops early in the disease process, visible as a reduction in the DWI signal prior 
to any abnormality becoming visible using other imaging modalities. DTI has been used to 
identify white matter tracts within the cerebral cortex, allowing investigation of connectivity 
between different regions of the brain in neurological research. Patients with CKD have 
significantly lower fractional anisotropy (FA) regardless of eGFR, and there is a correlation 
between eGFR and FA and apparent diffusion coefficient (ADC). There is also a negative 
association between scores of glomerular and tubulointerstitial injury on biopsy with FA in 
patients with CKD (Li et al., 2014). 
In CKD, there is reduction in corticomedullary differentiation (CMD) with progressive renal 
impairment, primarily due to an increase in cortical T1 (Lee et al., 2007). The 
histopathological determinates of the variation in T1 in CKD are yet to be determined, but 
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presumably relate in some way to changes in the extracellular volume or composition which 
reflect and increased fluid content in the region of interest. There are significant differences 
in T1 time in CKD compared to in health, and changes in T1 may be another parameter of 
use in determining prognosis. 
In a small cohort of patients with CKD and healthy volunteers, absolute perfusion measured 
using ASL MRI predicted progression of kidney dysfunction over the preceding year. Future 
work should firstly investigate the histopathological determinates of renal fibrosis which 
predict poor outcome and determine the MRI correlates of this, and which MRI techniques 
are most useful in the investigation of this. It is possible that complementary techniques will 
strengthen the diagnostic power of renal imaging, for example combining measures of 
perfusion such as ASL and BOLD with measures of kidney structure such as DTI and T1.  
6.4 Conclusions 
In patients with hypertension and CKD, parenteral administration of ascorbic acid reduces 
central BP and improves large arterial function, whilst in CKD only, reduces serum ADMA. 
ASL MRI was established as a robust method of measuring renal perfusion in a group of 
healthy volunteers. There are significant differences in ASL MRI measured renal perfusion, 
and in T1 longitudinal relaxation time, in CKD as compared to healthy volunteers, and there 
with correlation between perfusion and progression of CKD over the preceding year.
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Information about the Research: 
Oxidative stress in patients with chronic kidney disease (“Renox”) 
Version 5.0 (10/05/2012) 
Version for patients with chronic kidney disease 
Invitation 
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and discuss it with others if you wish. Ask us if 
there is anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part. 
What is the purpose of the study? 
We already know that the blood vessels in patients with chronic kidney disease (CKD) do 
not function properly, and that this can contribute to a higher blood pressure and to stiffer 
blood vessels. It has been suggested that increased “oxidative stress” is an important cause 
for the impaired function of blood vessels in CKD, but this has not been studied in detail. In 
this context, “oxidative stress” means an increased production of highly reactive oxygen 
molecules that have the potential to impair the function of blood vessels. In this research 
project, we are investigating whether infusing the antioxidant vitamin C, which can reduce 
oxidative stress, improves blood vessel function in CKD patients and in a group of healthy 
volunteers. In future this knowledge could lead to therapies that improve blood vessel 
function and reduce blood pressure in CKD patients. 
Why have I been chosen to take part? 
You have been selected because you have chronic kidney disease (CKD). 
Do I have to take part? 
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No. It is up to you to decide whether or not to take part: participation is completely voluntary. 
If you do decide to take part you will be asked to sign a consent form. If you decide to take 
part you are still free to withdraw at any time and without giving a reason. A decision to 
withdraw at any time, or a decision not to take part, will not affect your current or future 
medical treatment. 
 
 
What will be involved if I decide to take part? 
Study visit 1 will be during one of your regular visits to the renal clinic. We will check 
whether you are eligible for this study, give you information about the study and take some 
blood and urine samples. Visit 2 will be at the Clinical Research Facility for the actual test 
of blood vessel function, including the intravenous infusion of vitamin C. 
 
 
On each occasion, we ask you to come fasted (from midnight for a morning appointment 
and after breakfast for an afternoon appointment) and not to take any caffeine for 12 hours 
beforehand. 
Visit 1 
 After you have read the project information sheet, we will answer any questions that 
you might have about this study. This will take about 15 minutes. 
 We will perform a brief clinical examination, measure height and weight and ask you 
some simple questions about your health and the medication you are taking. 
Visit 1 (Renal clinic) Visit 2 (BHF Research Centre) 
About 160 Minutes 
- Informed consent 
- 2 cannulas 
About 30 Minutes 
- Patient information sheet 
- Clinical examination 
- Blood pressure measurement 
173 
 
 
 We will measure your blood pressure using a machine (similar to the one used at the 
renal clinic and at the GP practice). Clinical examination and blood pressure 
measurement should take no longer than 15 minutes. 
 We will also look at the results of the blood and urine taken at your renal clinic 
appointments (no additional samples are required for visit 1). 
Visit 2 
 We will put two cannulas in the veins of your arms, one for infusions and one for 
drawing bloods.  
 We will first infuse normal saline over duration of 10 minutes. We will wait 10 
minutes and then take a blood sample (about 15 mL, about two teaspoonfuls). The 
blood will be stored in our lab to be analysed at a later date, to look at markers of 
oxidative stress. 
 We will then examine the blood vessels in your wrist. This examination involves 
assessment of your pulse with a pencil-like probe. It is carried out at the artery in 
your wrist and enables us to look at the pulse waveform, which gives us useful 
information about the blood vessels. This will take about 15 minutes. 
 We will then measure changes in the diameter of your main artery of your arm with 
an ultrasound probe. We will apply a jelly-like substance to the skin and the probe 
will be gently pressed against your upper arm to visualise the main artery. A blood 
pressure cuff will be placed around your forearm and inflated for 5 minutes. We can 
then measure the changes in the diameter of the upper arm artery after deflation of 
the blood pressure cuff. The final part of the test involves a spray of a medication 
called GTN spray under the tongue. GTN is a very short acting medication which 
dilates the blood vessel. Overall, this will take about 20 minutes. 
 We will then infuse vitamin C at a dose of 2 grams over 10 minutes. Subsequently, 
we will take another blood sample (about 15 mL, about two teaspoonfuls), and repeat 
the examinations of the blood vessels in your wrist and arm, as described above. We 
will then take a third blood sample (about 15 mL, about two teaspoonfuls). 
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 The total time for these tests will be about 160 minutes (60 minutes for the 
infusions and 70 minutes for the above described tests of blood vessel function, 30 
minutes to take consent, assess basic parameters, and move you through the study 
process). 
Flowchart of Visit 2: 
 
We would also like to look at the renal computer system and in some cases your medical 
case notes to copy some of the information about any other medical conditions which you 
may have. Additionally, we will record on the renal computer system that you are taking 
part in the study to make the other renal doctors looking after you aware. 
What are the risks of taking part in this research? 
We will take blood from the vein in your arm which in rare cases results in a small bruise. 
The amount of blood taken for this research does not place you at any risk. The other tests 
are ‘non-invasive’ – the probes are attached to the skin and no needles are involved. 
Assessment of the pulse waveform has no specific side effects or risks. Inflation of the blood 
pressure cuff during the examination of your main arm artery may lead to some discomfort 
and numbness in the fingers. This will disappear when the cuff is deflated. A small bruise 
on your forearm may result from the cuff but will disappear within a couple of days. Some 
studies have suggested that administration of vitamin C may cause kidney stones. To 
minimize any such risk, you should not take part in this study if you previously had a kidney 
stone or if you are already taking daily vitamin C supplements. GTN spray is very short 
acting. In some people it can cause a headache which is short lived and will disappear within 
a few minutes. 
What are the benefits of taking part? 
Saline 
infusion 
 
Vitamin C 
infusion 
 
20 Minutes 30 Minutes 
Blood sample 
Examination of blood 
vessels in wrist and 
arm 
Examination of blood 
vessels in wrist and 
arm 
35 Minutes 35 Minutes 
Blood sample Blood sample 
Basic 
parameters 
Cannulation 
Exit from 
BHF 
 
30 Minutes 10 Minutes 
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There is no direct benefit to you in taking part in this study. However, the information we 
get from this study may help us in the future to have a better understanding of the role of 
oxidative stress in the function of blood vessels of patients with chronic kidney disease.  
What happens if we discover a previously undiagnosed condition? 
We may discover previously undiagnosed clinical abnormalities/conditions in yourself, e.g. 
during the blood tests. We would notify you and your GP of this. Although potentially this 
could lead to earlier diagnosis and treatment of a condition, this may also lead to further 
investigations which can turn out to have been unnecessary. Further, the discovery of a new 
condition can have implications for insurance matters (e.g. you may be denied life insurance 
or a mortgage because of this newly diagnosed condition). 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements. If you are harmed due to someone's negligence, then you may have grounds 
for a legal action for compensation against NHS Greater Glasgow and Clyde, but you may 
have to pay for it. Regardless of this, if you wish to complain, or have any concerns about 
any aspect of the way you have been approached or treated during the course of this study, 
the normal National Health Service complaints mechanisms will be available to you. 
Will my taking part in this study be kept confidential? 
Your personal information will be kept on a file and stored in a secure place at the BHF 
Glasgow Cardiovascular Research Centre. All samples will be labelled with a code and not 
with any personal details so that all analyses will be carried out anonymously. All 
information which is collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital or the clinical 
research facility will have your name and address removed so that you cannot be recognised 
from it. 
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What will happen to any samples I give? 
You will donate blood and urine samples for research purposes. Some examinations on these 
samples will be done straight away. Other examinations will be done at a later stage when 
we collect more samples from other patients. We will also store some of your samples for 
up to 10 years to perform additional tests if required. The samples are treated as "gift"; this 
means you will not be entitled to any future financial reimbursement related to this study 
and related research. Further tests on stored samples will again require review and approval 
by the Ethics Committee. 
What will happen to the results of the research study? 
The results of the research study will be stored on a computer database and are likely to be 
published in medical journals. Reports or publications resulting from the study will not 
contain any personal details. The research doctor will provide a copy of the results on 
request. 
Will I get any reimbursement for my expenses? 
After you completed the study, we will pay you a lump sum of £15.- to reimburse you for 
your expenses (parking, public transport). 
Contact for Further Information 
Should you have any further questions please feel free to call Dr Patrick Mark at the BHF 
Glasgow Cardiovascular Research Centre by telephone (0141-330-8218).  
If you wish to discuss the study with an independent contact person who is not involved in 
the study, please contact Mr Marc Clancy by telephone (0141-211-1750). 
  
Information about the Research: 
Oxidative stress in patients with chronic kidney disease (“Renox”) 
Version 5.0 (10/05/2012) 
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Version for healthy volunteers 
Invitation 
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and discuss it with others if you wish. Ask us if 
there is anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part. 
What is the purpose of the study? 
We already know that the blood vessels in patients with chronic kidney disease (CKD) do 
not function properly, and that this can contribute to a higher blood pressure and to stiffer 
blood vessels. It has been suggested that increased “oxidative stress” is an important cause 
for the impaired function of blood vessels in CKD, but this has not been studied in detail. In 
this context, “oxidative stress” means an increased production of highly reactive oxygen 
molecules that have the potential to impair the function of blood vessels. In this research 
project, we are investigating whether infusing the antioxidant vitamin C, which can reduce 
oxidative stress, improves blood vessel function in CKD patients and in a group of healthy 
volunteers. In future this knowledge could lead to therapies that improve blood vessel 
function and reduce blood pressure in CKD patients. 
Why have I been chosen to take part? 
You have been selected because you belong to the control group of healthy volunteers for 
this study. 
Do I have to take part? 
No. It is up to you to decide whether or not to take part: participation is completely voluntary. 
If you do decide to take part you will be asked to sign a consent form. If you decide to take 
part you are still free to withdraw at any time and without giving a reason. A decision to 
withdraw at any time, or a decision not to take part, will not affect your current or future 
medical treatment. 
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What will be involved if I decide to take part? 
We would like to invite you to come to our Clinical Research Facility twice. On the first 
occasion we will check whether you are eligible for this study, ask you to sign the consent 
form, and take some blood and urine samples. Visit 2 to the Clinical Research facility will 
be for the actual test of blood vessel function, including the intravenous administration of 
vitamin C.  
 
 
On each occasion, we ask you to come fasted (from midnight for a morning appointment 
and after breakfast for an afternoon appointment) and not to take any caffeine for 12 hours 
beforehand. 
Visit 1 
 After you have read the project information sheet, we will answer any questions that 
you might have about this study. This will take about 15 minutes. 
 We will perform a brief clinical examination, measure height and weight and ask you 
some simple questions about your health and the medication you are taking. 
 We will measure your blood pressure using a machine (similar to the one used at the 
GP practice). Clinical examination and blood pressure measurement should take no 
longer than 15 minutes. 
 We will also take some blood and urine samples. 
Visit 1 (BHF Research Centre) Visit 2 (BHF Research Centre) 
About 160 Minutes 
- 2 cannulas 
- Infusions of saline and vitamin C 
About 30 Minutes 
- Informed Consent 
- Clinical examination 
- Blood pressure measurement 
- Blood and urine samples 
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Visit 2 
 We will put two cannulas in the veins of your arms, one for infusions and one for 
drawing bloods.  
 We will first infuse normal saline over duration of 10 minutes. We will wait 10 
minutes and then take a blood sample (about 15 mL, about two teaspoonfuls). The 
blood will be stored in our lab to be analysed at a later date, to look at markers of 
oxidative stress. 
 We will then examine the blood vessels in your wrist. This examination involves 
assessment of your pulse with a pencil-like probe. It is carried out at the artery in 
your wrist and enables us to look at the pulse waveform, which gives us useful 
information about the blood vessels. This will take about 15 minutes. 
 We will then measure changes in the diameter of your main artery of your arm with 
an ultrasound probe. We will apply a jelly-like substance to the skin and the probe 
will be gently pressed against your upper arm to visualise the main artery. A blood 
pressure cuff will be placed around your forearm and inflated for 5 minutes. We can 
then measure the changes in the diameter of the upper arm artery after deflation of 
the blood pressure cuff. The final part of the test involves a spray of a medication 
called GTN spray under the tongue. GTN is a very short acting medication which 
dilates the blood vessel. Overall, this will take about 20 minutes. 
 We will then infuse vitamin C at a dose of 2 grams over 10 minutes. Subsequently, 
we will take another blood sample (about 15 mL, about two teaspoonfuls), and repeat 
the examinations of the blood vessels in your wrist and arm, as described above. We 
will then take a third blood sample (about 15 mL, about two teaspoonfuls). 
 The total time for these tests will be about 160 minutes (60 minutes for the infusions 
and 70 minutes for the above described tests of blood vessel function, 30 minutes to 
take consent, assess basic parameters, and move you through the study process). 
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  Flowchart of Visit 2: 
 
 
In some cases we may look at your medical case notes to copy some of the information about 
any other medical conditions which you may have. We can inform your GP that you are 
taking part in this study. 
 
What are the risks of taking part in this research? 
We will take blood from the vein in your arm which in rare cases results in a small bruise. 
The amount of blood taken for this research does not place you at any risk. The other tests 
are ‘non-invasive’ – the probes are attached to the skin and no needles are involved. 
Assessment of the pulse waveform has no specific side effects or risks. Inflation of the blood 
pressure cuff during the examination of your main arm artery may lead to some discomfort 
and numbness in the fingers. This will disappear when the cuff is deflated. A small bruise 
on your forearm may result from the cuff but will disappear within a couple of days. Some 
studies have suggested that administration of vitamin C may cause kidney stones. To 
minimize any such risk, you should not take part in this study if you previously had a kidney 
stone or if you are already taking daily vitamin C supplements. GTN spray is very short 
acting. In some people it can cause a headache which is short lived and will disappear within 
a few minutes. 
What are the benefits of taking part? 
There is no direct benefit to you in taking part in this study. However, the information we 
get from this study may help us in the future to have a better understanding of the role of 
oxidative stress in the function of blood vessels of patients with chronic kidney disease.  
Saline 
infusion 
 
Vitamin C 
infusion 
 
20 Minutes 30 Minutes 
Blood sample 
Examination of blood 
vessels in wrist and 
arm 
Examination of blood 
vessels in wrist and 
arm 
35 Minutes 35 Minutes 
Blood sample Blood sample 
Basic 
parameters 
2 cannulas 
Exit from 
BHF 
 
30 Minutes 10 Minutes 
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What happens if we discover a previously undiagnosed condition? 
We may discover previously undiagnosed clinical abnormalities/conditions in yourself, e.g. 
during the blood tests. We would notify you and your GP of this. Although potentially this 
could lead to earlier diagnosis and treatment of a condition, this may also lead to further 
investigations which can turn out to have been unnecessary. Further, the discovery of a new 
condition can have implications for insurance matters (e.g. you may be denied life insurance 
or a mortgage because of this newly diagnosed condition). 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements. If you are harmed due to someone's negligence, then you may have grounds 
for a legal action for compensation against NHS Greater Glasgow and Clyde, but you may 
have to pay for it. Regardless of this, if you wish to complain, or have any concerns about 
any aspect of the way you have been approached or treated during the course of this study, 
the normal National Health Service complaints mechanisms will be available to you. 
 
Will my taking part in this study be kept confidential? 
Your personal information will be kept on a file and stored in a secure place at the BHF 
Glasgow Cardiovascular Research Centre. All samples will be labelled with a code and not 
with any personal details so that all analyses will be carried out anonymously. All 
information which is collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital or the clinical 
research facility will have your name and address removed so that you cannot be recognised 
from it. 
What will happen to any samples I give? 
You will donate blood and urine samples for research purposes. Some examinations on these 
samples will be done straight away. Other examinations will be done at a later stage when 
we collect more samples from other patients. We will also store some of your samples for 
up to 10 years to perform additional tests if required. The samples are treated as "gift"; this 
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means you will not be entitled to any future financial reimbursement related to this study 
and related research. Further tests on stored samples will again require review and approval 
by the Ethics Committee. 
What will happen to the results of the research study? 
The results of the research study will be stored on a computer database and are likely to be 
published in medical journals. Reports or publications resulting from the study will not 
contain any personal details. The research doctor will provide a copy of the results on 
request. 
Will I get any reimbursement for my expenses? 
After you completed the study, we will pay you a lump sum of £15.- to reimburse you for 
your expenses (parking, public transport). 
Contact for Further Information 
Should you have any further questions please feel free to call Dr Patrick Mark at the BHF 
Glasgow Cardiovascular Research Centre by telephone (0141-330-8218).  
If you wish to discuss the study with an independent contact person who is not involved in 
the study, please contact Mr Marc Clancy by telephone (0141-211-1750). 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
 
  
Appendix 2
  
Information about the research 
Renal Arterial Spin Labelling MRI in Healthy Volunteers – “Vol-RASL” 
Version 2.0 17th November 2012 
Version for healthy volunteers 
Invitation 
You are being invited to kindly donate your time to participate in a research study. 
Before you take part it is important for you to understand why the research is being 
carried out and what it will involve for you. Please take time to read the following 
information carefully and discuss it with others if you wish. Ask us if anything is not 
clear or if you would like more information. Take time to decide if you would like to 
take part and remember that your participation is voluntary.  
What is the purpose of the study? 
Magnetic Resonance Imaging – or MRI – is a type of scan which allows us to get 
detailed pictures of internal organs. The advantage of this MRI is that it does not involve 
exposure to harmful radiation, and as far as we know, there are no long term health 
risks. It is often useful to examine the blood supply to internal organs and in these cases 
we have to give the patient a type of dye called ‘contrast’ into a vein around the time 
of the scan. Whilst MRI itself is generally harmless, the contrast given can have 
complications, and certain types of contrast cannot be given to people with kidney 
disease.  
We are developing a type of MRI scan called Arterial Spin Labelling (or ASL) that 
looks at blood flow to the kidneys without giving potentially harmful contrast and 
avoids exposure to radiation. This is cutting edge technology which isn’t carried out in 
clinical practice at the moment. We hope that in the future it will allow us to look at the 
blood flow to the kidneys in people with kidney disease or transplants without exposing 
them to contrast; this would allow us to improve their treatment.  
  
The purpose of this study is to ensure that the way in which we are carrying out the 
scan gives us reliable results.  
 
Why have I been selected to take part? 
You are a healthy person without kidney problems or any other major health problems.  
Do I have to take part? 
No – participation is entirely voluntary. Additionally, if you decide to take part but then 
change your mind you can withdraw at any time.  
 
What will be involved if I decide to take part? 
Participation involves three visits to our clinical research facility. On the first visit one 
of our medical staff will check if you are eligible for the study and after a thorough 
explanation of what is involved, ask you to sign our consent form. We will take some 
screening blood tests and urine samples. On the second visit, again to our clinical 
research facility, you will undergo an MRI scan which will take at the very most, one 
hour. On the third visit, we will carry out the same MRI scan on two different occasions. 
The third visit will also take a maximum of one hour.  
 
Visit 1 
 You will attend the clinical area of our clinical research facility 
 After you have read the Participant Information Sheet we will answer any 
questions you may have 
 A doctor will ask you some simple questions about your past medical history to 
make sure you are suitable for an MRI scan, and if necessary do a quick clinical 
examination of your heart and lungs 
 We will ask you to sign the consent form 
 We will measure your blood pressure and take some samples of blood and urine 
 
Visit 2 
 You will attend the MRI department of our clinical research facility 
 You will be asked to change into a hospital gown and ensure you don’t have any 
metal objects on your person, storing them in a secure locker in the department 
 A trained member of the MRI team will perform an MRI safety questionnaire 
 You will then undergo an MRI scan 
 
  
Visit 3 
 You will attend the MRI department of our clinical research facility 
 You will be asked to change into a hospital gown and ensure you don’t have any 
metal objects on your person, storing them in a secure locker in the department 
 A trained member of the MRI team will perform an MRI safety questionnaire 
 You will undergo the same MRI scan twice 
 
 
What are the risks of taking part in the research? 
We will take blood and urine samples to ensure that your kidneys are working normally 
and that there is no sign of any other health problem of which you are unaware. We will 
take a small amount of blood from the vein in your arm which in some rare cases can 
result in minor bruising. The amount of blood taken does not pose any risks. A blood 
pressure cuff can cause discomfort for the very brief period of time it is inflated, and in 
extremely rare cases cause a bruise.  
 
Are MRI scans dangerous? 
MRI scans are not suitable for people with metal objects in their body such as joint 
replacements, heart valves, surgical clips or metal shrapnel from previous eye injuries. 
We will explore this possibility during medical history taking and via the MRI safety 
questionnaire. The scan takes place in a narrow enclosure, and some people who are 
extremely claustrophobic will find this disconcerting. Lastly, the scan can be quite 
noisy however headphones are used to protect you and can also be used to play music 
for your comfort and relaxation. There are no known health risks associated with MRI 
so long as those individuals who are unsuitable to undergo the investigation are 
identified appropriately.   
 
What are the benefits of taking part? 
Taking part in this study is of no direct benefit to you. We hope to develop a new type 
of MRI scan which is currently unavailable which may improve the care of people with 
kidney problems. If we find that this test gives reliable results in healthy volunteers we 
will progress to using it in people with kidney disease.  
Travel costs can be reimbursed however no other financial incentive will be offered.  
  
 
What happens if we find a previously undiagnosed 
condition? 
If we discover any previously unknown clinical abnormalities during testing then we 
will notify you and your GP with your consent. Although this may potentially lead to 
earlier treatment of a previously unknown condition it may also lead to unnecessary 
tests and cause anxiety. Furthermore any condition that is found can have implications 
for insurance and mortgage purposes. The type of MRI scan used does not examine 
other internal organs aside from the kidneys, and the images that we obtain are not 
examined by an MRI expert, so that this is not an appropriate scan for finding out about 
other underlying health problems. This means that if you are experiencing symptoms 
then this scan will not find out what is causing them. Similarly if you should develop 
symptoms in the future then you should not be reassured by the fact you have had this 
scan to rule out the existence of any problem – you should attend your GP as you would 
have done if you hadn’t taken part in this study.  
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence then you 
may have grounds for legal action for compensation against the University of Glasgow, 
but you may have to pay for it. Regardless, if you wish to complain or have any 
concerns about the way you have been approached or treated during this study then the 
normal complaints procedure will be available to you.  
 
Will my taking part be kept confidential? 
Your personal information will be kept on a file and stored in a secure place at the BHF 
Glasgow Cardiovascular Research Centre. All samples will be labelled with a code and 
with any personal details so that all analyses will be carried out anonymously. All 
information collected about you during the course of the research will be kept strictly 
confidential.  
  
 
What will happen to samples that I give? 
You will donate blood and urine samples for research purposes. Some examinations 
will be done straight away whilst others will be done at a later stage when we collect 
more samples from other participants. We will also store some samples for up to 10 
years to perform additional tests if required. The samples are treated as a “gift”; this 
means you will not be entitled to any future financial imbursement related to this study 
and related research. Further tests on stored samples will again require review and 
approval by the ethics committee.  
 
What will happen to the images obtained by MRI? 
Images taken by the MRI scan will be kept on a computer database and stored 
anonymously. The images from the scan are only able to be seen from a few desktop 
computers in the MRI suite of the Clinical Research Centre, which is secured at all 
times. We will analyse these images in order to determine the circulation to your 
kidneys, and compare this to measurements of healthy kidney blood flow found by 
other studies. We will compare the images from each scan to ensure that they are 
similar, so that we know the scan is reliable.  
 
Contact for further information 
Should you have any further questions please feel free to call Dr Patrick Mark at the 
BHF Glasgow Cardiovascular Research Centre by telephone on 0141-330-8218 
 
 
 
 
  
  
27 July 2016 
 
Dear Dr Keith Gillis 
 
MVLS College Ethics Committee 
 
Project Title: Vol-RASL: Renal Arterial Spin Labelling in Healthy Volunteers  
Project No: 2012098  
 
The College Ethics Committee has reviewed your application and has agreed that 
there is no objection on ethical grounds to the proposed study.  They are happy 
therefore to approve the project, subject to the following conditions 
 The research should be carried out only on the sites, and/or with the groups defined 
in the application. 
 Any proposed changes in the protocol should be submitted for reassessment, 
except when it is necessary to change the protocol to eliminate hazard to the 
subjects or where the change involves only the administrative aspects of the 
project.  The Ethics Committee should be informed of any such changes. 
 If the study does not start within three years of the date of this letter, the project 
should be resubmitted. 
 You should submit a short end of study report to the Ethics Committee within 3 
months of completion. 
 
 
Yours sincerely 
 
 
 
Andrew C Rankin 
College Ethics Officer  
 Professor William Martin 
 Professor of Cardiovascular Pharmacology 
 R507B Level 5 
School of Life Sciences 
West Medical Building 
Glasgow G12 8QQ Tel: 0141 330 4489 
E-mail: William.Martin@glasgow.ac.uk 
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Kid-RASL 
Renal Arterial Spin Labelling in Chronic Kidney Disease 
Information about the research 
Version 2.1 25/04/13 
 
Version for CKD 
Invitation 
You are being invited to kindly donate your time to participate in a research study. 
Before you take part it is important for you to understand why the research is being 
carried out and what it will involve for you. Please take time to read the following 
information carefully and discuss it with others if you wish. Ask us if anything is not 
clear or if you would like more information. Take time to decide if you would like to 
take part and remember that your participation is voluntary.  
 
What is the purpose of the study? 
It has been suggested that increased “oxidative stress” is an important cause of the 
impaired function of blood vessels in chronic kidney disease (CKD), but this has not 
been studied in detail. In this context, “oxidative stress” means an increased production 
of highly reactive oxygen molecules that have the potential to impair the function of 
blood vessels and the flow of blood to the kidneys. In this research project, we are 
investigating whether infusing the antioxidant vitamin C, which can reduce oxidative 
stress, improve blood vessel function, and increase blood flow to the kidneys. 
Magnetic Resonance Imaging – or MRI – is a type of scan which allows us to get 
detailed pictures of internal organs. The advantage of this MRI is that it does not involve 
exposure to harmful radiation, and as far as we know, there are no long term health 
risks. We have developed a type of MRI scan called Arterial Spin Labelling (or ASL) 
that looks at blood flow to the kidneys. This is cutting edge technology which isn’t 
carried out in clinical practice at the moment. We hope that in the future it will allow 
us to look at the blood flow (or “perfusion”) to the kidneys in people with kidney disease 
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or transplants without exposing them to harmful radiation.  The purpose of this study is 
to if the results from the ASL-MRI correlate with markers of kidney function and 
oxidative stress, and if kidney blood flow is improved by vitamin C. 
 
Why have I been selected to take part? 
You have chronic kidney disease and are under follow up at one of the renal clinics.  
 
Do I have to take part? 
No – participation is entirely voluntary. Additionally, if you decide to take part but then 
change your mind you can withdraw at any time.  
What will be involved if I decide to take part? 
Participation involves one visit to our clinical research facility. After having had time 
to read this information sheet you will have a chance to ask questions when you meet 
one of the research team.  
Study visit  
You will attend the Glasgow Cardiovascular Research Centre next to the Western Infirmary Glasgow 
having fasted for around 6 hours. After discussing what the study involves, you will be asked to sign a 
consent form. Your height, weight and blood pressures will be measured and a health questionnaire taken. 
An infusion of 100ml normal saline will be given and blood samples taken. The ASL-MRI scan will then 
be carried out. An infusion of vitamin C will then be given and further blood samples taken. A further 
ASL-MRI scan will then be carried out.  
 
 
 
 
 
Saline 
infusion 
 
20 Minutes 20 Minutes 
Blood sample 
ASL-MRI 
 
ASL-MRI 
 
25 Minutes 25 Minutes 
Blood sample 
Consent 
Clinical assessment 
Exit from 
BHF 
 
20 Minutes 10 Minutes 
Vitamin C infusion 
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What are the risks of taking part in the research? 
We will take blood and urine samples to ensure that your kidneys are working normally 
and that there is no sign of any other health problem of which you are unaware. We will 
take a small amount of blood from the vein in your arm which in some rare cases can 
result in minor bruising. The amount of blood taken does not pose any risks. A blood 
pressure cuff can cause discomfort for the very brief period of time it is inflated, and in 
extremely rare cases cause a bruise.  
Are MRI scans dangerous? 
MRI scans are not suitable for people with metal objects in their body such as joint 
replacements, heart valves, surgical clips or metal shrapnel from previous eye injuries. 
We will explore this possibility during medical history taking and via the MRI safety 
questionnaire. The scan takes place in a narrow enclosure, and some people who are 
extremely claustrophobic will find this unpleasant. Lastly, the scan can be quite noisy 
however headphones are worn for protection and can also be used to play music for 
your comfort and relaxation. There are no known health risks associated with MRI so 
long as those individuals who are unsuitable to undergo the investigation are identified 
appropriately.   
 
Is vitamin C harmful?  
Some studies have suggested that administration of vitamin C may cause kidney stones. 
To minimize any such risk, you should not take part in this study if you previously had 
a kidney stone or if you are already taking daily vitamin C supplements. 
 
What are the benefits of taking part? 
Taking part in this study is of no direct benefit to you. We hope to develop a new type 
of MRI scan which is currently unavailable which may improve the care of people with 
kidney problems. Travel costs can be reimbursed however no other financial incentive 
will be offered.  
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What happens if we find a previously undiagnosed 
condition? 
If we discover any previously unknown clinical abnormalities during testing then we 
will notify you and your GP with your consent. Although this may potentially lead to 
earlier treatment of a previously unknown condition it may also lead to unnecessary 
tests and cause anxiety. Furthermore any condition that is found can have implications 
for insurance and mortgage purposes. The type of MRI scan used does not examine 
other internal organs aside from the kidneys, and the images that we obtain are not 
examined by an MRI expert, so that this is not an appropriate scan for finding out about 
other underlying health problems. This means that if you are experiencing symptoms 
then this scan will not find out what is causing them. Similarly if you should develop 
symptoms in the future then you should not be reassured by the fact you have had this 
scan to rule out the existence of any problem – you should attend your GP as you would 
have done if you hadn’t taken part in this study.  
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone's negligence, then you 
may have grounds for a legal action for compensation against NHS Greater Glasgow 
and Clyde, but you may have to pay for it. Regardless of this, if you wish to complain, 
or have any concerns about any aspect of the way you have been approached or treated 
during the course of this study, the normal National Health Service complaints 
mechanisms will be available to you. 
 
Will my taking part be kept confidential? 
Your personal information will be kept on a file and stored in a secure place at the BHF 
Glasgow Cardiovascular Research Centre. All samples will be labelled with a code and 
with any personal details so that all analyses will be carried out anonymously. All 
information collected about you during the course of the research will be kept strictly 
confidential.  
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What will happen to samples that I give? 
You will donate blood and urine samples for research purposes. Some examinations 
will be done straight away whilst others will be done at a later stage when we collect 
more samples from other participants. We will also store some samples for up to 10 
years to perform additional tests if required. The samples are treated as a “gift”; this 
means you will not be entitled to any future financial imbursement related to this study 
and related research. Further tests on stored samples will again require review and 
approval by the ethics committee.  
 
What will happen to the images obtained by MRI? 
Images taken by the MRI scan will be kept on a computer database and stored 
anonymously. The images from the scan are only able to be seen from a few desktop 
computers in the MRI suite of the Clinical Research Centre, which is secured at all 
times. We will analyse these images in order to determine the circulation to your 
kidneys, and compare this to measurements of healthy kidney blood flow found by 
other studies. We will compare the images from each scan to ensure that they are 
similar, so that we know the scan is reliable.  
 
Contact for further information 
Should you have any further questions please feel free to call Dr Patrick Mark at the 
BHF Glasgow Cardiovascular Research Centre by telephone on 0141-330-8218 
 
Thank you for taking the time to read this Information Sheet 
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Kid-RASL 
Renal Arterial Spin Labelling in Chronic Kidney Disease  
Information about the research 
Version 2.1 25/04/13 
 
Version for LKD 
 
Invitation 
You are being invited to kindly donate your time to participate in a research study. 
Before you take part it is important for you to understand why the research is being 
carried out and what it will involve for you. Please take time to read the following 
information carefully and discuss it with others if you wish. Ask us if anything is not 
clear or if you would like more information. Take time to decide if you would like to 
take part and remember that your participation is voluntary.  
 
What is the purpose of the study? 
Magnetic Resonance Imaging – or MRI – is a type of scan which allows us to get 
detailed pictures of internal organs. The advantage of this MRI is that it does not involve 
exposure to harmful radiation, and as far as we know, there are no long term health 
risks. It is often useful to examine the blood supply to internal organs and in these cases 
we have to give the patient a type of dye called ‘contrast’ into a vein around the time 
of the scan. Whilst MRI itself is generally harmless, the contrast given can have 
complications, and certain types of contrast cannot be given to people with kidney 
disease.  
We have developed a type of MRI scan called Arterial Spin Labelling (or ASL) that 
looks at blood flow to the kidneys without giving potentially harmful contrast and 
avoids exposure to radiation. This is cutting edge technology which isn’t carried out in 
clinical practice at the moment. We hope that in the future it will allow us to look at the 
blood flow to the kidneys in people with kidney disease or transplants without exposing 
them to contrast; this would allow us to improve their treatment.  
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The purpose of this study is to if the results from the ASL-MRI correlate with markers 
of kidney function and damage in the blood and urine.  
 
Why have I been selected to take part? 
You are healthy and have normal kidney function, and we already have a great deal of 
information about your kidneys following your kidney donor assessment.  
 
Do I have to take part? 
No – participation is entirely voluntary. Additionally, if you decide to take part but then 
change your mind you can withdraw at any time.  
 
What will be involved if I decide to take part? 
Participation involves one visit to our clinical research facility. After having had time 
to read this information sheet you will have a chance to ask questions when you meet 
one of the research team.  
 
Study visit  
You will attend the Glasgow Cardiovascular Research Centre next to the Western Infirmary Glasgow 
after having fasted for around 6 hours. After discussing what the study involves, you will be asked to 
sign a consent form. Your height, weight and blood pressures will be measured and a health questionnaire 
taken. Samples of blood and urine will be taken. The ASL-MRI scan will then be carried out. 
 
 
 
 
 
 
20 Minutes 
Blood & urine sample 
ASL-MRI 
 
25 Minutes 
Consent 
Clinical assessment 
Exit from 
BHF 
 
10 Minutes 
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What are the risks of taking part in the research? 
We will take blood and urine samples to ensure that your kidneys are working normally 
and that there is no sign of any other health problem of which you are unaware. We will 
take a small amount of blood from the vein in your arm which in some rare cases can 
result in minor bruising. The amount of blood taken does not pose any risks. A blood 
pressure cuff can cause discomfort for the very brief period of time it is inflated, and in 
extremely rare cases cause a bruise.  
 
Are MRI scans dangerous? 
MRI scans are not suitable for people with metal objects in their body such as joint 
replacements, heart valves, surgical clips or metal shrapnel from previous eye injuries. 
We will explore this possibility during medical history taking and via the MRI safety 
questionnaire. The scan takes place in a narrow enclosure, and some people who are 
extremely claustrophobic will find this unpleasant. Lastly, the scan can be quite noisy 
however headphones are worn for protection and can also be used to play music for 
your comfort and relaxation. There are no known health risks associated with MRI so 
long as those individuals who are unsuitable to undergo the investigation are identified 
appropriately.  
 
What are the benefits of taking part? 
Taking part in this study is of no direct benefit to you. We hope to develop a new type 
of MRI scan which is currently unavailable which may improve the care of people with 
kidney problems. Travel costs can be reimbursed however no other financial incentive 
will be offered.  
 
What happens if we find a previously undiagnosed 
condition? 
If we discover any previously unknown clinical abnormalities during testing then we 
will notify you and your GP with your consent. Although this may potentially lead to 
211 
 
 
earlier treatment of a previously unknown condition it may also lead to unnecessary 
tests and cause anxiety. Furthermore any condition that is found can have implications 
for insurance and mortgage purposes. The type of MRI scan used does not examine 
other internal organs aside from the kidneys, and the images that we obtain are not 
examined by an MRI expert, so that this is not an appropriate scan for finding out about 
other underlying health problems. This means that if you are experiencing symptoms 
then this scan will not find out what is causing them. Similarly if you should develop 
symptoms in the future then you should not be reassured by the fact you have had this 
scan to rule out the existence of any problem – you should attend your GP as you would 
have done if you hadn’t taken part in this study.  
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone's negligence, then you 
may have grounds for a legal action for compensation against NHS Greater Glasgow 
and Clyde, but you may have to pay for it. Regardless of this, if you wish to complain, 
or have any concerns about any aspect of the way you have been approached or treated 
during the course of this study, the normal National Health Service complaints 
mechanisms will be available to you. 
 
Will my taking part be kept confidential? 
Your personal information will be kept on a file and stored in a secure place at the BHF 
Glasgow Cardiovascular Research Centre. All samples will be labelled with a code and 
with any personal details so that all analyses will be carried out anonymously. All 
information collected about you during the course of the research will be kept strictly 
confidential.  
 
What will happen to samples that I give? 
You will donate blood and urine samples for research purposes. Some examinations 
will be done straight away whilst others will be done at a later stage when we collect 
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more samples from other participants. We will also store some samples for up to 10 
years to perform additional tests if required. The samples are treated as a “gift”; this 
means you will not be entitled to any future financial imbursement related to this study 
and related research. Further tests on stored samples will again require review and 
approval by the ethics committee.  
 
What will happen to the images obtained by MRI? 
Images taken by the MRI scan will be kept on a computer database and stored 
anonymously. The images from the scan are only able to be seen from a few desktop 
computers in the MRI suite of the Clinical Research Centre, which is secured at all 
times. We will analyse these images in order to determine the circulation to your 
kidneys, and compare this to measurements of healthy kidney blood flow found by 
other studies. We will compare the images from each scan to ensure that they are 
similar, so that we know the scan is reliable.  
 
Contact for further information 
Should you have any further questions please feel free to call Dr Patrick Mark at the 
BHF Glasgow Cardiovascular Research Centre by telephone on 0141-330-8218. 
 
Thank you for taking the time to read this Information Sheet 
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